

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000846 A1

- (51) International Patent Classification⁷: **C07D 495/04**, A61K 31/44, A61P 29/00, 37/00
- (74) Common Representative: **CELLTECH R & D LIMITED**; Patents Department, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).
- (21) International Application Number: PCT/GB2003/002667
- (22) International Filing Date: 20 June 2003 (20.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0214268.5 20 June 2002 (20.06.2002) GB
- (71) Applicant (for all designated States except US): **CELLTECH R & D LIMITED** [GB/GB]; 208 Bath Road, Slough, Berkshire SL1 3WE (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BROOKINGS, Daniel, Christopher** [GB/GB]; Celltech R & D Limited, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **DAVIS, Jeremy, Martin** [GB/GB]; Celltech R & D Limited, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **LANGHAM, Barry, John** [GB/GB]; Celltech R & D Limited, 208 Bath Road, Slough, Berkshire SL1 3WE (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ARYLAMINE SUBSTITUTED BICYCLIC HETEROAROMATIC COMPOUNDS AS P38 KINASE INHIBITORS



(57) Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(R^a) is present and represents a bond and A is a -N= atom or a -C(R^b)= group, or the dashed line is absent and A is a -N(R^b)-, or -C(R^b)(R^c)- group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O)₂- or -NH-group; Y is a nitrogen or substituted carbon atom or a -CH= group; n is zero or the integer 1; Alk¹ is an optionally substituted aliphatic or heteroaliphatic chain L¹ is a covalent bond or a linker atom or group; Cy¹ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

BICYCLIC HETEROAROMATIC DERIVATIVES

This invention relates to a series of 5-6 fused ring bicyclic heteroaromatic
5 derivatives, to compositions containing them, to processes for their
preparation and to their use in medicine.

Immune and inflammatory responses involve a variety of cell types with
control and co-ordination of the various interactions occurring *via* both cell-
10 cell contacts (e.g integrin interactions with their receptors) and by way of
intercellular signalling molecules. A large number of different signalling
molecules are involved, including cytokines, lymphocytes, chemokines and
growth factors.

15 Cells respond to such intercellular signalling molecules by means of
intracellular signalling mechanisms that include protein kinases,
phosphatases and phospholipases. There are five classes of protein kinase
of which the major ones are the tyrosine kinases and the serine/threonine
kinases [Hunter, T., *Methods in Enzymology (Protein Kinase Classification)*
20 p. 3, Hunter, T. and Sefton, B.M.; eds. Vol. 200, Academic Press; San Diego,
1991].

One sub-class of serine/threonine kinases is the mitogen activating protein
(MAP) kinases of which there are at least three families which differ in the
25 sequence and size of the activation loop [Adams, J. L. *et al*, *Progress in*
Medicinal Chemistry p. 1-60, King, F. D. and Oxford, A. W.; eds. vol 38,
Elsevier Science, 2001]: (i) the extracellular regulated kinases (ERKs), (ii) the
c-Jun NH₂ terminal kinases or stress activated kinases (JNKs or SAP
kinases) and (iii) the p38 kinases which have a threonine-glycine-tyrosine
30 (TGY) activation motif. Both the JNKs and p38 MAP kinases are primarily
activated by stress stimuli including, but not limited to, proinflammatory
cytokines e.g. tumour necrosis factor (TNF) and interleukin-1 (IL-1),
ultraviolet light, endotoxin and chemical or osmotic shock.

Four isoforms of p38 have been described (p38 α /p38 β /p38 γ /p38 δ). The human p38 α enzyme was initially identified as a target of cytokine-suppressive anti-inflammatory drugs (CSAIDs) and the two isoenzymes found were initially
5 termed CSAID binding protein-1 (CSBP-1) and CSBP-2 [Lee, J. C. *et al*, Nature (London) 1994, 372, 739-46]. CSBP-2 is now widely referred to as p38 α and differs from CSBP-1 in an internal sequence of 25 amino acids as a result of differential splicing of two exons that are conserved in both mouse and human [McDonnell, P. C. *et al*, Genomics 1995, 29, 301-2]. CSBP-1 and
10 p38 α are expressed ubiquitously and there is no difference between the two isoforms with respect to tissue distribution, activation profile, substrate preference or CSAID binding. A second isoform is p38 β which has 70% identity with p38 α . A second form of p38 β termed p38 β 2 is also known and of the two this is believed to be the major form. p38 α and p38 β 2 are expressed
15 in many different tissues. However in monocytes and macrophages p38 α is the predominant kinase activity [Lee, J. C., *ibid*; Jing, Y. *et al*, J. Biol. Chem. 1996, 271, 10531-34; Hale, K. K. *et al*, J. Immun. 1999, 162, 4246-52]. p38 γ and p38 δ (also termed SAP kinase-3 and SAP kinase-4 respectively) have ~63% and ~61% homology to p38 α respectively. p38 γ is predominantly
20 expressed in skeletal muscle whilst p38 δ is found in testes, pancreas, prostate, small intestine and in certain endocrine tissues.

All p38 homologues and splice variants contain a 12 amino acid activation loop that includes a Thr-Gly-Tyr motif. Dual phosphorylation of both Thr-180
25 and Tyr-182 in the TGY motif by a dual specificity upstream kinase is essential for the activation of p38 and results in a >1000-fold increase in specific activity of these enzymes [Doza, Y. N. *et al* FEBS Lett., 1995, 364, 7095-8012]. This dual phosphorylation is effected by MKK6 and under certain conditions the related enzyme MKK3 [Enslin, H. *et al* J. Biol. Chem., 1998,
30 273, 1741-48]. MKK3 and MKK6 belong to a family of enzymes termed

MAPKK (mitogen activating protein kinase kinase) which are in turn activated by MAPKKK (mitogen activating kinase kinase kinase) otherwise known as MAP3K.

- 5 Several MAP3Ks have been identified that are activated by a wide variety of stimuli including environmental stress, inflammatory cytokines and other factors. MEKK4/MTK1 (MAP or ERK kinase kinase/MAP three kinase-1), ASK1 (apoptosis stimulated kinase) and TAK1 (TGF- β -activated kinase) are some of the enzymes identified as upstream activators of for MAPKKs.
- 10 MEKK4/MTK1 is thought to be activated by several GADD-45-like genes that are induced in response to environmental stimuli and which eventually lead to p38 activation [Takekawa, M. and Saito, H. Cell, 1998, 95, 521-30]. TAK1 has been shown to activate MKK6 in response to transforming growth factor- β (TGF- β). TNF-stimulated activation of p38 is believed to be mediated by the
- 15 recruitment of TRAF2 [TNF receptor associated factor] and the Fas adaptor protein, Daxx, which results in the activation of ASK1 and subsequently p38.

- Several substrates of p38 have been identified including other kinases [e.g. MAPK activated protein kinase 2/3/5 (MAPKAP 2/3/5), p38
- 20 regulated/activated protein kinase (PRAK), MAP kinase-interacting kinase 1/2 (MNK1/2), mitogen- and stress-activated protein kinase 1 (MSK1/RLPK) and ribosomal S6 kinase-B (RSK-B)]; transcription factors [e.g. activating transcription factor 2/6 (ATF2/6), monocyte-enhancer factor-2A/C (MEF2A/C), C/EBP homologous protein (CHOP), Elk1 and Sap-1a1]; and
- 25 other substrates [e.g. cPLA2, p47phox].

- MAPKAP K2 is activated by p38 in response to environmental stress. Mice engineered to lack MAPKAP K2 do not produce TNF in response to lipopolysaccharide (LPS). Production of several other cytokines such as IL-1,
- 30 IL-6, IFN- γ and IL-10 is also partially inhibited [Kotlyarov, A. *et al* Nature Cell Biol. 1999, 1, 94-7]. Further, MAPKAP K2 from embryonic stem cells from

p38 α null mice was not activated in response to stress and these cells did not produce IL-6 in response to IL-1 [Allen, M. *et al*, J. Exp. Med. 2000, 191, 859-69]. These results indicate that MAPKAP K2 is not only essential for TNF and IL-1 production but also for signalling induced by cytokines. In addition
5 MAPKAP K2/3 phosphorylate and thus regulate heat shock proteins HSP 25 and HSP 27 which are involved in cytoskeletal reorganization.

Several small molecule inhibitors of p38 have been reported which inhibit IL-1 and TNF synthesis in human monocytes at concentrations in the low μ M
10 range [Lee, J. C. *et al*, Int. J. Immunopharm. 1988, 10, 835] and exhibit activity in animal models which are refractory to cyclooxygenase inhibitors [Lee, J. C. *et al*, Annals N. Y. Acad. Sci. 1993, 696, 149]. In addition these small molecule inhibitors are known to decrease the synthesis of a wide variety of pro-inflammatory proteins including IL-6, IL-8,
15 granulocyte/macrophage colony-stimulating factor (GM-CSF) and cyclooxygenase-2 (COX-2). TNF-induced phosphorylation and activation of cytosolic PLA2, TNF-induced expression of VCAM-1 on endothelial cells and IL-1 stimulated synthesis of collagenase and stromelysin are also inhibited by small molecule inhibitors of p38 [Cohen, P. Trends Cell Biol. 1997, 7, 353-
20 61].

A variety of cells including monocytes and macrophages produce TNF and IL-1. Excessive or unregulated TNF production is implicated in a number of disease states including Crohn's disease, ulcerative colitis, pyresis,
25 rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, toxic shock syndrome, endotoxic shock, sepsis, septic shock, gram negative sepsis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejection, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, silicosis, pulmonary
30 sarcoisosis, cerebral malaria, scar tissue formation, keloid formation, fever and myalgias due to infection, such as influenza, cachexia secondary to

acquired immune deficiency syndrome (AIDS), cachexia secondary to infection or malignancy, AIDS or AIDS related complex.

Excessive or unregulated IL-1 production has been implicated in rheumatoid
5 arthritis, osteoarthritis, traumatic arthritis, rubella arthritis, acute synovitis,
psoriatic arthritis, cachexia, Reiter's syndrome, endotoxemia, toxic shock
syndrome, tuberculosis, atherosclerosis, muscle degeneration, and other
acute or chronic inflammatory diseases such as the inflammatory reaction
induced by endotoxin or inflammatory bowel disease. In addition IL-1 has
10 been linked to diabetes and pancreatic β cells [Dinarello, C. A. J. Clinical
Immunology, 1985, 5, 287-97].

IL-8 is a chemotactic factor produced by various cell types including
endothelial cells, mononuclear cells, fibroblasts and keratinocytes. IL-1, TNF
15 and LPS all induce the production of IL-8 by endothelial cells. *In vitro* IL-8 has
been shown to have a number of functions including being a chemoattractant
for neutrophils, T-lymphocytes and basophils. IL-8 has also been shown to
increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils
without *de novo* protein synthesis which may contribute to increased
20 adhesion of neutrophils to vascular endothelial cells. Many diseases are
characterised by massive neutrophil infiltration. Histamine release from
basophils (in both atopic and normal individuals) is induced by IL-8 as is
lysosomal enzyme release and respiratory burst from neutrophils.


25 The central role of IL-1 and TNF together with other leukocyte derived
cytokines as important and critical inflammatory mediators is well
documented. The inhibition of these cytokines has been shown or would be
expected to be of benefit in controlling, alleviating or reducing many of these
disease states.

30

The central position that p38 occupies within the cascade of signalling molecules mediating extracellular to intracellular signalling and its influence over not only IL-1, TNF and IL-8 production but also the synthesis and/or action of other pro-inflammatory proteins (e.g. IL-6, GM-CSF, COX-2, collagenase and stromelysin) make it an attractive target for inhibition by small molecule inhibitors with the expectation that such inhibition would be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. Such an expectation is supported by the potent and diverse anti-inflammatory activities described for p38 kinase inhibitors [Adams, *ibid*; Badger, *et al*, J. Pharm. Exp. Ther. 1996, 279, 1453-61; Griswold, *et al*, Pharmacol. Comm., 1996, 7, 323-29].

We have now found a group of compounds which are potent and selective inhibitors of p38 kinase (p38 α , β , δ and γ) and the isoforms and splice variants thereof, especially p38 α , p38 β and p38 β 2. The compounds are thus of use in medicine, for example in the prophylaxis and treatment of immune or inflammatory disorders as described herein.

Thus according to one aspect of the invention we provide a compound of formula (1):



wherein:

the dashed line joining A and C(R^a) is present and represents a bond and

- A is a $-N=$ atom or a $-C(R^b)=$ group, or the dashed line is absent and A is a $-N(R^b)-$, or $-C(R^b)(R^c)-$ group;
- R^a , R^b and R^c is each independently a hydrogen atom or an optionally substituted C_{1-6} alkyl, $-CN$, $-CO_2H$, $-CO_2R^1$ (where R^1 is an optionally substituted alkyl group), $-CONH_2$, $-CONHR^1$ or $-CONR^1R^2$ group (where R^2 is an optionally substituted alkyl group);
- R is a hydrogen atom or a straight or branched C_{1-6} alkyl group;
- X is an $-O-$, $-S-$ or substituted nitrogen atom or a $-S(O)-$, $-S(O_2)-$ or $-NH-$ group;
- 10 Y is a nitrogen or substituted carbon atom or a $-CH=$ group;
- n is zero or the integer 1;
- Alk^1 is an optionally substituted aliphatic or heteroaliphatic chain
- L^1 is a covalent bond or a linker atom or group;
- Cy^1 is a hydrogen atom or an optionally substituted cycloaliphatic,
- 15 polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;
- Ar is an optionally substituted aromatic or heteroaromatic group;
- and the salts, solvates, hydrates and N-oxides thereof.
- 20 It will be appreciated that compounds of formula (1) may have one or more chiral centres, and exist as enantiomers or diastereomers. The invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof, including racemates. Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless
- 25 stated or shown otherwise. In addition, compounds of formula (1) may exist as tautomers, for example keto ($CH_2C=O$)-enol ($CH=CHOH$) tautomers. Formula (1) and the formulae hereinafter are intended to represent all individual tautomers and mixtures thereof, unless stated otherwise.
- 30 As used in formula (1) the terms "substituted nitrogen atom" and "substituted carbon atom" are intended to include groups such as those in which X is

-N(R¹⁰)- and Y is -C(R¹⁰)= where R¹⁰ is a substituent other than a hydrogen atom as generally or particularly defined hereinafter.

5 The following general terms as used herein in relation to compounds of the invention and intermediates thereto have the stated meaning below unless specifically defined otherwise.

10 Thus as used herein the term "alkyl" whether present as a group or part of a group includes straight or branched C₁₋₆alkyl groups, for example C₁₋₄alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl or t-butyl groups. Similarly, the terms "alkenyl" or "alkynyl" are intended to mean straight or branched C₂₋₆alkenyl or C₂₋₆alkynyl groups such as C₂₋₄alkenyl or C₂₋₄alkynyl groups. Optional substituents which may be present on these groups include those optional substituents mentioned hereinafter in relation
15 to Alk¹ when Alk¹ is an optionally substituted aliphatic chain.

The term halogen is intended to include fluorine, chlorine, bromine or iodine atoms.

20 The term "haloalkyl" is intended to include those alkyl groups just mentioned substituted by one, two or three of the halogen atoms just described. Particular examples of such groups include -CF₃, -CCl₃, -CHF₂, -CHCl₂, -CH₂F and -CH₂Cl groups.

25 The term "alkoxy" as used herein is intended to include straight or branched C₁₋₆alkoxy e.g. C₁₋₄alkoxy such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, i-butoxy and t-butoxy. "Haloalkoxy" as used herein includes any of these alkoxy groups substituted by one, two or three halogen atoms as described above. Particular examples include -OCF₃, -OCCl₃, -OCHF₂, -
30 OCHCl₂, -OCH₂F and -OCH₂Cl groups.

As used herein the term "alkylthio" is intended to include straight or branched C₁₋₆alkylthio, e.g. C₁₋₄alkylthio such as methylthio or ethylthio.

As used herein the term "alkylamino or dialkylamino" is intended to include the groups -NHR^{1a} and -N(R^{1a})(R^{1b}) where R^{1a} and R^{1b} is each independently an optionally substituted straight or branched alkyl group or both together with the N atom to which they are attached form an optionally substituted heterocycloalkyl group which may contain a further heteroatom or heteroatom containing group such as an -O- or -S- atom or -N(R^{1a})- group. Particular examples of such optionally substituted heterocycloalkyl groups include optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and N'-C₁₋₆alkyl-piperazinyl groups. The optional substituents which may be present on such heterocycloalkyl groups include those optional substituents as described hereinafter in relation to aliphatic chains such as Alk¹.

When Alk¹ is present in compounds of formula (1) as an optionally substituted aliphatic chain it may be an optionally substituted C₁₋₁₀aliphatic chain. Particular examples include optionally substituted straight or branched chain C₁₋₆alkylene, C₂₋₆alkenylene, or C₂₋₆alkynylene chains.

Particular examples of aliphatic chains represented by Alk¹ include optionally substituted -CH₂-, -CH₂CH₂-, -CH(CH₃)CH₂-, -(CH₂)₂CH₂-, -(CH₂)₃CH₂-, -CH(CH₃)(CH₂)₂CH₂-, -CH₂CH(CH₃)CH₂-, -C(CH₃)₂CH₂-, -CH₂C(CH₃)₂CH₂-, -(CH₂)₂CH(CH₃)CH₂-, -CH(CH₃)CH₂CH₂-, -CH(CH₃)CH₂CH(CH₃)CH₂-, -CH₂CH(CH₃)CH₂CH₂-, -(CH₂)₂C(CH₃)₂CH₂-, -(CH₂)₄CH₂-, -(CH₂)₅CH₂-, -CHCH-, -CHCHCH₂-, -CH₂CHCH-, -CHCHCH₂CH₂-, -CH₂CHCHCH₂-, -(CH₂)₂CHCH-, -CC-, -CCCH₂-, -CH₂CC-, -CCCH₂CH₂-, -CH₂CCCH₂- or -(CH₂)₂CCH- chains.

Heteroaliphatic chains represented by Alk^1 in the compounds of formula (1) include the aliphatic chains just described but with each additionally containing one, two, three or four heteroatoms or heteroatom-containing groups. Particular heteroatoms or groups include atoms or groups L^2 where L^2 is a linker atom or group. Each L^2 atom or group may interrupt the aliphatic group, or may be positioned at its terminal carbon atom to connect the group to an adjoining atom or group. Particular examples include optionally substituted $-\text{L}^2\text{CH}_2-$, $-\text{CH}_2\text{L}^2-$, $-\text{L}^2\text{CH}(\text{CH}_3)-$, $-\text{CH}(\text{CH}_3)\text{L}^2-$, $-\text{CH}_2\text{L}^2\text{CH}_2-$, $-\text{L}^2\text{CH}_2\text{CH}_2-$, $-\text{L}^2\text{CH}_2\text{CH}(\text{CH}_3)-$, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{L}^2-$, $-\text{CH}_2\text{CH}_2\text{L}^2-$, $-\text{CH}_2\text{L}^2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{L}^2\text{CH}_2\text{CH}_2\text{L}^2-$, $-(\text{CH}_2)_2\text{L}^2\text{CH}_2-$, $-(\text{CH}_2)_3\text{L}^2\text{CH}_2-$, $-\text{L}^2(\text{CH}_2)_2\text{CH}_2-$, $-\text{L}^2\text{CH}_2\text{CHCH}_2-$, $-\text{CHCHCH}_2\text{L}^2-$ and $-(\text{CH}_2)_2\text{L}^2\text{CH}_2\text{CH}_2-$ chains.

When L^2 is present in heteroaliphatic chains as a linker atom or group it may be any divalent linking atom or group. Particular examples include $-\text{O}-$ or $-\text{S}-$ atoms or $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})-$, $-\text{C}(\text{S})-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{N}(\text{R}^3)-$ [where R^3 is a hydrogen atom or a straight or branched alkyl group], $-\text{N}(\text{R}^3)\text{O}-$, $-\text{N}(\text{R}^3)\text{N}-$, $-\text{CON}(\text{R}^3)-$, $-\text{OC}(\text{O})\text{N}(\text{R}^3)-$, $-\text{CSN}(\text{R}^3)-$, $-\text{N}(\text{R}^3)\text{CO}-$, $-\text{N}(\text{R}^3)\text{C}(\text{O})\text{O}-$, $-\text{N}(\text{R}^3)\text{CS}-$, $-\text{S}(\text{O})_2\text{N}(\text{R}^3)-$, $-\text{N}(\text{R}^3)\text{S}(\text{O})_2-$, $-\text{N}(\text{R}^3)\text{CON}(\text{R}^3)-$, $-\text{N}(\text{R}^3)\text{CSN}(\text{R}^3)-$ or $-\text{N}(\text{R}^3)\text{SO}_2\text{N}(\text{R}^3)-$ groups. Where L^2 contains two R^3 groups these may be the same or different.

The optional substituents which may be present on aliphatic or heteroaliphatic chains represented by Alk^1 [and, unless stated otherwise, on alkyl, cycloalkyl heterocycloalkyl and other aliphatic or heteroaliphatic groups where specifically mentioned herein] include one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or $-\text{OH}$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^4$ [where R^4 is an optionally substituted straight or branched C_{1-6} alkyl group, and is in particular a straight or branched C_{1-4} alkyl group], e.g. $-\text{CO}_2\text{CH}_3$ or $-\text{CO}_2\text{C}(\text{CH}_3)_3$, $-\text{CONHR}^4$, e.g. $-\text{CONHCH}_3$, $-\text{CON}(\text{R}^4)_2$, e.g. $-\text{CON}(\text{CH}_3)_2$, $-\text{COR}^4$, e.g. $-\text{COCH}_3$, C_{1-6} alkoxy, e.g. methoxy or ethoxy, halo C_{1-6} alkoxy, e.g.

trifluoromethoxy or difluoromethoxy, thiol (-SH), -S(O)R⁴, e.g. -S(O)CH₃, -S(O)₂R⁴, e.g. -S(O)₂CH₃, C₁₋₆alkylthio e.g. methylthio or ethylthio, amino, -NHR⁴, e.g. -NHCH₃ or -N(R⁴)₂, e.g. -N(CH₃)₂ groups. Where two R⁴ groups are present in any of the above substituents these may be the same or
 5 different.

In addition when two R⁴ alkyl groups are present in any of the optional substituents just described these groups may be joined, together with the N atom to which they are attached, to form a heterocyclic ring. Such
 10 heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom containing group selected from -O-, -S-, -N(R⁴)-, -C(O)- or -C(S)- groups. Particular examples of such heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.

15

When L¹ is present in compounds of formula (1) as a linker atom or group it may be any such atom or group as hereinbefore described in relation to L² linker atoms and groups.

20 Optionally substituted cycloaliphatic groups represented by the group Cy¹ in compounds of the invention include optionally substituted C₃₋₁₀cycloaliphatic groups. Particular examples include optionally substituted C₃₋₁₀cycloalkyl, e.g. C₃₋₇cycloalkyl or C₃₋₁₀cycloalkenyl, e.g. C₃₋₇cycloalkenyl groups.

25 Optionally substituted heterocycloaliphatic groups represented by the group Cy¹ include optionally substituted 3 to 10 membered saturated or partially saturated monocyclic hydrocarbon rings containing one or more heteroatoms or heteroatom containing groups, such as optionally substituted C₃₋₁₀heterocycloaliphatic groups. Particular examples include optionally
 30 substituted C₃₋₁₀heterocycloalkyl, e.g. C₃₋₇heterocycloalkyl or C₃₋₁₀heterocycloalkenyl, e.g. C₃₋₇heterocycloalkenyl groups, each of said groups

containing one, two, three or four heteroatoms or heteroatom containing groups L^4 in place of or in addition to the ring carbon atoms where L^4 is an atom or group as previously defined for L^2 .

- 5 Optionally substituted polycycloaliphatic groups represented by the group Cy^1 include optionally substituted C_{7-10} bi- or tricycloalkyl or C_{7-10} bi- or tricycloalkenyl groups. Optionally substituted heteropolycycloaliphatic groups represented by the group Cy^1 include optionally substituted C_{7-10} bi- or tricycloalkyl or C_{7-10} bi- or tri-cycloalkenyl groups containing one, two, three,
 10 four or more L^4 atoms or groups in place of or in addition to the ring carbon atoms.

- Particular examples of cycloaliphatic, polycycloaliphatic, heterocycloaliphatic and heteropolycycloaliphatic groups represented by the group Cy^1 include
 15 optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, adamantyl, norbornyl, norbornenyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydropyranyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrroline, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, pyrrolidinone, oxazolidinyl, oxazolidinone,
 20 dioxolanyl, e.g. 1,3-dioxolanyl, imidazolanyl, e.g. 2-imidazolanyl, imidazolidinyl, pyrazolanyl, e.g. 2-pyrazolanyl, pyrazolidinyl, 5,6-dihydro-2(1H)-pyrazinone, tetrahydropyrimidinyl, thiazolanyl, thiazolidinyl, pyranal, e.g. 2- or 4-pyranal, piperidinyl, homopiperidinyl, heptamethyleneiminyl, piperidinone, 1,4-dioxanyl, morpholanyl, morpholinone, 1,4-dithianyl, thiomorpholanyl,
 25 piperazinyl, homopiperazinyl, 1,3,5-trithianyl, oxazinyl, e.g. 2H-1,3-, 6H-1,3-, 6H-1,2-, 2H-1,2- or 4H-1,4-oxazinyl, 1,2,5-oxathiazinyl, isoxazinyl, e.g. o- or p-isoxazinyl, oxathiazinyl, e.g. 1,2,5 or 1,2,6-oxathiazinyl, 1,3,5-oxadiazinyl, dihydroisothiazolyl, dihydroisothiazole 1,1-dioxide, e.g. 2,3-dihydroisothiazole 1,1-dioxide, dihydropyrazinyl and tetrahydropyrazinyl
 30 groups.

The optional substituents which may be present on the cycloaliphatic, polycycloaliphatic, heterocycloaliphatic or heteropolycycloaliphatic groups represented by the group Cy¹ include one, two, three or more substituents selected from halogen atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, haloC₁₋₆alkyl, e.g. halomethyl or haloethyl such as difluoromethyl or trifluoromethyl, optionally substituted by hydroxyl, e.g. -C(OH)(CF₃)₂, C₁₋₆alkoxy, e.g. methoxy or ethoxy, haloC₁₋₆alkoxy, eg. halomethoxy or haloethoxy such as difluoromethoxy or trifluoromethoxy, thiol, C₁₋₆alkylthiol, e.g. methylthiol or ethylthiol, carbonyl (=O), thiocarbonyl (=S), imino (=NR^{4a}) [where R^{4a} is an -OH group or a C₁₋₆alkyl group], or -(Alk³)_vR⁵ groups in which Alk³ is a straight or branched C₁₋₃alkylene chain, v is zero or the integer 1 and R⁵ is a C₃₋₈cycloalkyl, -OH, -SH, -N(R⁶)(R⁷) [in which R⁶ and R⁷ is each independently selected from a hydrogen atom or an optionally substituted alkyl or C₃₋₈cycloalkyl group], -OR⁶, -SR⁶, -CN, -NO₂, -CO₂R⁶, -SOR⁶, -SO₂R⁶, -SO₃R⁶, -OCO₂R⁶, -C(O)R⁶, -OC(O)R⁶, -C(S)R⁶, -C(O)N(R⁶)(R⁷), -OC(O)N(R⁶)(R⁷), -N(R⁶)C(O)R⁷, -C(S)N(R⁶)(R⁷), -N(R⁶)C(S)R⁷, -SO₂N(R⁶)(R⁷), -N(R⁶)SO₂R⁷, -N(R⁶)C(O)N(R⁷)(R⁸) [where R⁸ is as defined for R⁶], -N(R⁶)C(S)N(R⁷)(R⁸), -N(R⁶)SO₂N(R⁷)(R⁸) or an optionally substituted aromatic or heteroaromatic group.

20

Particular examples of Alk³ chains include -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂- and -CH(CH₃)CH₂- chains.

When R⁵, R⁶, R⁷ and/or R⁸ is present as a C₃₋₈cycloalkyl group it may be for example a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group. Optional substituents which may be present on such groups include for example one, two or three substituents which may be the same or different selected from halogen atoms, for example fluorine, chlorine, bromine or iodine atoms, or hydroxy or C₁₋₆alkoxy, e.g. methoxy, ethoxy or *i*-propoxy groups.

30

When the groups R^6 and R^7 or R^7 and R^8 are both alkyl groups these groups may be joined, together with the N atom to which they are attached, to form a heterocyclic ring. Such heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom containing group selected from -O-, -S-, -N(R^7)-, -C(O)- or -C(S)- groups. Particular examples of such heterocyclic rings include piperidiny, pyrazolidiny, morpholinyl, thiomorpholinyl, pyrrolidiny, imidazolidiny and piperaziny rings.

When R^6 is an optionally substituted aromatic or heteroaromatic group it may be any such group as described hereinafter in relation to Cy^1 .

Additionally, when the group Cy^1 is a heterocycloaliphatic or heteropolycycloaliphatic group containing one or more nitrogen atoms each nitrogen atom may be optionally substituted by a group $-(L^5)_p(Alk^4)_qR^9$ in which L^5 is a -C(O)-, -C(O)O-, -C(S)-, -S(O)₂-, -CON(R^6)- or -SO₂N(R^6)-group; p is zero or the integer 1; Alk^4 is an optionally substituted aliphatic or heteroaliphatic chain; q is zero or the integer 1; and R^9 is a hydrogen atom or an optionally substituted cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaliphatic, aromatic or heteroaromatic group as herein described in relation to Cy^1 . Optional substituents include those described previously in relation to heterocycloaliphatic groups.

When Alk^4 is present as an aliphatic or heteroaliphatic chain it may be for example any aliphatic or heteroaliphatic chain as hereinbefore described for Alk^1 .

In general, optionally substituted aromatic groups represented by the groups Cy^1 include for example monocyclic or bicyclic fused ring C₆₋₁₂aromatic groups, such as phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups.

Heteroaromatic groups represented by the groups Cy¹ include for example C₁₋₉heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example monocyclic or bicyclic fused ring

5 heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example eight- to thirteen-membered fused ring heteroaromatic groups containing one, two or more

10 heteroatoms selected from oxygen, sulphur or nitrogen atoms.

Particular examples of heteroaromatic groups of these types include pyrrolyl, furyl, thienyl, imidazolyl, N-C₁₋₆alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,5-

15 oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, benzothieryl, [2,3-dihydro]benzothieryl, benzotriazolyl, indolyl, indolinyl, indazolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzopyranyl, [3,4-

20 dihydro]benzopyranyl, quinazolinyl, quinoxalinyl, naphthyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,5-a]pyrazinyl, imidazo[1,5-c]pyrimidinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, phthalazinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, imidyl, e.g. succinimidyl, phthalimidyl or

25 naphthalimidyl such as 1,8-naphthalimidyl, pyrazolo[4,3-d]pyrimidinyl, furo[3,2-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, pyrrolo[3,2-d]pyrimidinyl, pyrazolo[3,2-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, thiazolo[3,2-a]pyridinyl, pyrido[1,2-a]pyrimidinyl, tetrahydroimidazo[1,2-a]pyrimidinyl and dihydroimidazo[1,2-a]pyrimidinyl

30 groups.

- Optional substituents which may be present on aromatic or heteroaromatic groups represented by the group Cy^1 include one, two, three or more substituents, each selected from an atom or group R^{10} in which R^{10} is R^{10a} or $-L^6Alk^5(R^{10a})_r$, where R^{10a} is a halogen atom, or an amino ($-NH_2$), substituted
- 5 amino, nitro, cyano, hydroxyl ($-OH$), substituted hydroxyl, formyl, carboxyl ($-CO_2H$), esterified carboxyl, thiol ($-SH$), substituted thiol, $-COR^{11}$ [where R^{11} is an $-L^6Alk^3(R^{10a})_r$, aryl or heteroaryl group], $-CSR^{11}$, $-SO_3H$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-SO_2NH_2$, $-SO_2NHR^{11}$, $-SO_2N(R^{11})_2$, $-CONH_2$, $-CSNH_2$, $-CONHR^{11}$, $-CSNHR^{11}$, $-CON(R^{11})_2$, $-CSN(R^{11})_2$, $-N(R^{12})SO_2R^{11}$ [where R^{12} is a hydrogen
- 10 atom or a straight or branched alkyl group], $-N(SO_2R^{11})_2$, $-N(R^{12})SO_2NH_2$, $-N(R^{12})SO_2NHR^{11}$, $-N(R^{12})SO_2N(R^{11})_2$, $-N(R^{12})COR^{11}$, $-N(R^{12})CONH_2$, $-N(R^{12})CONHR^{11}$, $-N(R^{12})CON(R^{11})_2$, $-N(R^{12})CSNH_2$, $-N(R^{12})CSNHR^{11}$, $-N(R^{12})CSN(R^{11})_2$, $-N(R^{12})CSR^{11}$, $-N(R^{12})C(O)OR^{11}$, $-C=NR^{12}(NR^{12})$, $-SO_2NHet^1$ [where $-NHet^1$ is an optionally substituted C_{3-7} cyclicamino group
- 15 optionally containing one or more other $-O-$ or $-S-$ atoms or $-N(R^{12})-$, $-C(O)-$ or $-C(S)-$ groups], $-CONHet^1$, $-CSNHet^1$, $-N(R^{12})SO_2NHet^1$, $-N(R^{12})CONHet^1$, $-N(R^{12})CSNHet^1$, $-SO_2N(R^{12})Het$ [where $-Het$ is an optionally substituted monocyclic C_{3-7} carbocyclic group optionally containing one or more other $-O-$ or $-S-$ atoms or $-N(R^{12})-$, $-C(O)-$, $-S(O)-$ or $-S(O)_2-$ groups], $-Het$, $-CON(R^{12})Het$, $-CSN(R^{12})Het$, $-N(R^{12})CON(R^{12})Het$, $-N(R^{12})CSN(R^{12})Het$, $-N(R^{12})SO_2N(R^{12})Het$, aryl or heteroaryl groups; L^6 is a covalent bond or a linker atom or group as hereinbefore defined for L^2 ; Alk^5 is an optionally substituted straight or branched C_{1-6} alkylene, C_{2-6} alkenylene or C_{2-6} alkynylene chain, optionally interrupted by one, two or three $-O-$ or $-S-$
- 20 atoms or $-S(O)_n-$ [where n is an integer 1 or 2] or $-N(R^{12})-$ e.g. $-N(CH_3)-$ groups; and r is zero or the integer 1, 2, or 3. It will be appreciated that when two R^{11} or R^{12} groups are present in one of the above substituents the R^{11} and R^{12} groups may be the same or different.
- 30 When in the group $-L^6Alk^5(R^{10a})_r$, r is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R^{10a} may be present on any suitable carbon

atom in $-Alk^5$. Where more than one R^{10a} substituent is present these may be the same or different and may be present on the same or different atom in $-Alk^5$. Clearly, when r is zero and no substituent R^{10a} is present the alkylene, alkenylene or alkynylene chain represented by Alk^5 becomes an alkyl, alkenyl or alkynyl group.

When R^{10a} is a substituted amino group it may be for example a group $-NHR^{11}$ [where R^{11} is as defined above] or a group $-N(R^{11})_2$ wherein each R^{11} group is the same or different.

When R^{10a} is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

When R^{10a} is a substituted hydroxyl or substituted thiol group it may be for example a group $-OR^{11}$ or a $-SR^{12}$ group respectively.

Esterified carboxyl groups represented by the group R^{10a} include groups of formula $-CO_2Alk^6$ wherein Alk^6 is a straight or branched, optionally substituted C_{1-8} alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C_{6-12} aryl C_{1-8} alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C_{6-12} aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C_{6-12} aryloxy C_{1-8} alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C_{1-8} alkanoyloxy C_{1-8} alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C_{6-12} aroyloxy C_{1-8} alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk^6 group include R^{10a} atoms and groups as described above.

When Alk^5 is present in or as a substituent it may be for example a $-\text{CH}_2-$, $-\text{CH}(\text{CH}_3)-$, $-\text{C}(\text{CH}_3)_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2-$, $-\text{C}(\text{CH}_3)_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CCH}_2-$, $-\text{CH}_2\text{C}=\text{CH}-$, $-\text{CH}=\text{CHCH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}=\text{CHCH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}=\text{CH}_2-$, $-\text{CC}-$, $-\text{CCCH}_2-$, $-\text{CH}_2\text{CC}-$, $-\text{CCCH}_2\text{CH}_2-$, $-\text{CH}_2\text{CCCH}_2-$ or $-\text{CH}_2\text{CH}_2\text{CC}-$ chain, optionally interrupted by one, two, or three $-\text{O}-$ or $-\text{S}-$, atoms or $-\text{S}(\text{O})-$, $-\text{S}(\text{O})_2-$ or $-\text{N}(\text{R}^{12})-$, e.g. $-\text{N}(\text{CH}_3)-$ groups. The aliphatic chains represented by Alk^5 may be optionally substituted by one, two or three halogen atoms in addition to any R^{10a} groups that may be present.

10

Aryl or heteroaryl groups represented by the groups R^{10a} or R^{11} include mono- or bicyclic optionally substituted C_{6-12} aromatic or C_{1-9} heteroaromatic groups as described above for the group Cy^1 . The aromatic and heteroaromatic groups may be attached to the group Cy^1 in compounds of formula (1) by any carbon or hetero e.g. nitrogen atom as appropriate.

15

It will be appreciated that when $-\text{NHet}^1$ or $-\text{Het}$ forms part of a substituent R^{10} the heteroatoms or heteroatom containing groups that may be present within the ring $-\text{NHet}^1$ or $-\text{Het}$ take the place of carbon atoms within the parent carbocyclic ring.

20

Thus when $-\text{NHet}^1$ or $-\text{Het}$ forms part of a substituent R^{10} each may be for example an optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl group. Additionally Het may represent for example, an optionally substituted cyclopentyl or cyclohexyl group. Optional substituents which may be present on $-\text{NHet}^1$ include those substituents described above when Cy^1 is a heterocycloaliphatic group.

25

Particularly useful atoms or groups represented by R^{10} include fluorine, chlorine, bromine or iodine atoms, or C_{1-6} alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-

- butyl or t-butyl, optionally substituted phenyl, pyridyl, pyrimidinyl, pyrrolyl, furyl, thiazolyl, or thienyl, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC₁₋₆alkyl, e.g. carboxyethyl, C₁₋₆alkylthio e.g. methylthio or ethylthio, carboxyC₁₋₆alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxypropylthio, C₁₋₆alkoxy, e.g. methoxy or ethoxy, hydroxyC₁₋₆alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy, pyridyloxy, thiazolyloxy, phenylthio or pyridylthio, C₃₋₇cycloalkyl, e.g. cyclobutyl, cyclopentyl, C₅₋₇cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₁₋₆alkylamino, e.g. methylamino, ethylamino, –
- 10 CH(CH₃)NH₂ or –C(CH₃)₂NH₂, haloC₁₋₆alkylamino, e.g. fluoroC₁₋₆alkylamino, e.g. –CH(CF₃)NH₂ or –C(CF₃)₂NH₂, amino (–NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, C₁₋₆alkylaminoC₁₋₆alkyl, e.g. ethylaminoethyl, C₁₋₆dialkylaminoC₁₋₆alkyl, e.g. diethylaminoethyl, aminoC₁₋₆alkoxy, e.g. aminoethoxy, C₁₋₆alkylaminoC₁₋₆alkoxy,
- 15 e.g. methylaminoethoxy, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, diisopropylaminoethoxy, or dimethylaminopropoxy, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, nitro, cyano, hydroxyl (–OH), formyl [HC(O)–], carboxyl (–CO₂H), –CO₂Alk⁶ [where Alk⁶ is as defined above], C₁₋₆alkanoyl e.g. acetyl, optionally substituted benzoyl, thiol (–
- 20 SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, sulphonyl (–SO₃H), C₁₋₆alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (–SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (–CONH₂), C₁₋₆alkylaminocarbonyl, e.g.
- 25 methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl, e.g. aminoethylamino-carbonyl, C₁₋₆dialkylaminoC₁₋₆alkylaminocarbonyl, e.g. diethylaminoethyl-aminocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or
- 30 ethylaminocarbonylamino, C₁₋₆dialkylamino-carbonylamino, e.g. dimethylaminocarbonylamino or diethylamino-carbonylamino, C₁₋

C_{1-6} alkylaminocarbonyl C_{1-6} alkylamino, e.g. methylamino-carbonylmethylamino,
 aminothiocarbonylamino, C_{1-6} alkylaminothiocarbonyl-amino, e.g.
 methylaminothiocarbonylamino or ethylaminothiocarbonylamino, C_{1-6}
 dialkylaminothiocarbonylamino, e.g. dimethylaminothiocarbonylamino or
 5 diethylaminothiocarbonylamino, C_{1-6} alkylaminothiocarbonyl C_{1-6} alkylamino, e.g.
 ethylaminothiocarbonylmethylamino, $-\text{CONHC}(=\text{NH})\text{NH}_2$, C_{1-6} alkylsulphonyl-
 amino, e.g. methylsulphonylamino or ethylsulphonylamino, C_{1-6} dialkyl-
 sulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino,
 optionally substituted phenylsulphonylamino, aminosulphonylamino ($-\text{NHSO}_2\text{NH}_2$),
 10 C_{1-6} alkylaminosulphonylamino, e.g. methylaminosulphonylamino
 or ethylaminosulphonylamino, C_{1-6} dialkylaminosulphonylamino, e.g. dimethyl-
 aminosulphonylamino or diethylaminosulphonylamino, optionally substituted
 morpholinesulphonylamino or morpholinesulphonyl C_{1-6} alkylamino, optionally
 substituted phenylaminosulphonylamino, C_{1-6} alkanoylamino, e.g. acetylamino,
 15 amino C_{1-6} alkanoylamino e.g. aminoacetylamino, C_{1-6} dialkylamino C_{1-6} alkanoyl-
 amino, e.g. dimethylaminoacetylamino, C_{1-6} alkanoylamino C_{1-6} alkyl, e.g.
 acetylaminomethyl, C_{1-6} alkanoylamino C_{1-6} alkylamino, e.g. acetamidoethyl-
 amino, C_{1-6} alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonyl-
 amino or t-butoxycarbonylamino or optionally substituted benzyloxy,
 20 pyridylmethoxy, thiazolylmethoxy, benzyloxycarbonylamino, benzyloxy-
 carbonylamino C_{1-6} alkyl e.g. benzyloxycarbonylaminoethyl, benzothio, pyridyl-
 methylthio or thiazolylmethylthio groups.

A further particularly useful group of substituents represented by R^{10} when
 25 present on aromatic or heteroaromatic groups includes substituents of formula $-\text{L}^6\text{Alk}^5\text{R}^{10a}$ where L^6 is preferably a covalent bond or an $-\text{O}-$ or $-\text{S}-$ atom or $-\text{N}(\text{R}^3)-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{N}(\text{R}^3)\text{CO}-$, $-\text{CON}(\text{R}^3)-$ or $-\text{N}(\text{R}^3)\text{S}(\text{O})_2-$
 group, Alk^5 is an optionally substituted C_{1-6} alkyl group optionally interrupted by
 one or two $-\text{O}-$ or $-\text{S}-$ atoms or $-\text{N}(\text{R}^{12})-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{S})-$, $-\text{CON}(\text{R}^{12})-$ or $-\text{N}(\text{R}^{12})\text{CO}-$ groups and R^{10a} is an optionally substituted Het group as herein
 30

defined or an optionally substituted heteroaromatic group as hereinbefore described in relation to Cy¹.

Where desired, two R¹⁰ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₁₋₆alkylenedioxy group such as methylenedioxy or ethylenedioxy.

It will be appreciated that where two or more R¹⁰ substituents are present, these need not necessarily be the same atoms and/or groups. In general, the substituent(s) may be present at any available ring position on the aromatic or heteroaromatic group represented by the group Cy¹.

The substituted aromatic or heteroaromatic group represented by Ar in compounds of the invention may be any aromatic or heteroaromatic group as hereinbefore described for Cy¹. Optional substituents which may be present include those R¹⁰ atoms and groups as generally or particularly described in relation to Cy¹ aromatic and heteroaromatic groups.

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulfonates, e.g. methanesulfonates, ethanesulfonates, or isothionates, arylsulfonates, e.g. *p*-toluenesulfonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

5

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

10 In compounds of formula (1) R is preferably a hydrogen atom.

In compounds of this type and in general in compounds of formula (1) X is preferably an -O- or -S- atom, and is especially a -S- atom.

15 In general in compounds of formula (1) R^a is preferably a hydrogen atom or a C₁₋₄alkyl group, especially a methyl, ethyl, n-propyl or i-propyl group. In particular R^a is a methyl group or more especially a hydrogen atom.

20 In another particular class of compounds of formula (1) the bond represented by the dashed line is present and A is a -C(R^b)= group. In these compounds R^b is preferably a hydrogen atom or a C₁₋₄alkyl group, especially a methyl, ethyl, n-propyl or i-propyl group. More particularly R^b is a methyl group or more especially a hydrogen atom.

25 When in compounds of formula (1) n is the integer 1, Alk¹ is preferably an optionally substituted C₁₋₆alkylene chain, especially an optionally substituted -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH(CH₃)CH₂- or -CH₂CH(CH₃)- chain, most especially a -CH₂- or -CH₂CH₂- chain.

30 In one class of compounds of formula (1) n is zero.

The group L^1 in compounds of formula (1) is preferably a covalent bond or an $-O-$ or $-S-$ atom or an $-N(R^3)-$, especially $-NH-$ or $-N(CH_3)-$, $-C(O)-$, $-C(S)-$, $-S(O)-$ or $-S(O)_2-$ group. More particularly L^1 is a covalent bond or an $-O-$ or $-S-$ atom or $-NH-$ group. L^1 is more especially preferably is a covalent bond.

5

Cy^1 in compounds of formula (1) is preferably an optionally substituted cycloaliphatic, aromatic or heteroaromatic group as hereinbefore generally and particularly defined.

- 10 Particularly preferred Cy^1 optionally substituted cycloaliphatic groups include optionally substituted C_{3-7} cycloalkyl groups, especially cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl groups. Cy^1 is in particular a cyclopropyl group.
- 15 Each of these preferred Cy^1 cycloalkyl groups may be unsubstituted. When substituents are present these may in particular include halogen atoms, especially fluorine, chlorine or bromine atoms, or C_{1-6} alkyl groups, especially C_{1-3} alkyl groups, most especially a methyl group, or a halo C_{1-6} alkyl group, especially a fluoro C_{1-6} alkyl group, most especially a $-CF_3$ group, or a C_{1-6} alkoxy, especially methoxy, ethoxy, propoxy or i-propoxy group, or a halo C_{1-6} alkoxy, especially a fluoro C_{1-6} alkoxy, most especially a $-OCF_3$ group, or a cyano ($-CN$), esterified carboxyl, especially $-CO_2CH_3$ or $-CO_2C(CH_3)_3$, nitro ($-NO_2$), amino ($-NH_2$), substituted amino, especially $-NHCH_3$ or $-N(CH_3)_2$, $-C(O)R^6$, especially $-C(O)CH_3$, or $-N(R^6)C(O)R^7$, especially $-NHCOCH_3$
- 20
- 25 group.

- Particularly preferred Cy^1 aromatic groups include optionally substituted phenyl groups. Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially
- 30 optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur

or nitrogen atoms. Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl or triazinyl group. In a further preference, the heteroaromatic group may be an eight- to thirteen-membered
 5 bicyclic fused ring containing one or two oxygen, sulphur or nitrogen atoms. Particularly useful groups of this type include optionally substituted indolyl groups.

Particularly preferred optional substituents which may be present on Cy¹
 10 aromatic or heteroaromatic groups include one, two or three atoms or groups –R^{10a} or –L⁶Alk⁵(R^{10a})_r as hereinbefore defined. Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C₁₋₆alkyl groups, especially C₁₋₃alkyl groups, most especially a methyl group, or a haloC₁₋₆alkyl group, especially a fluoroC₁₋₆alkyl group,
 15 most especially a –CF₃ group, or a C₁₋₆alkoxy, especially methoxy, ethoxy, propoxy or i-propoxy group, or a haloC₁₋₆alkoxy, especially a fluoroC₁₋₆alkoxy, most especially a –OCF₃ group, or a cyano (–CN), carboxyl (–CO₂H), esterified carboxyl (–CO₂Alk⁶), especially –CO₂CH₃, –CO₂CH₂CH₃, or –CO₂C(CH₃)₃, nitro (–NO₂), amino (–NH₂), substituted amino, especially –
 20 NHCH₃ or –N(CH₃)₂, –COR¹¹, especially –COCH₃, or –N(R¹²)COR¹¹, especially –NHCOCH₃ group.

Further preferred optional substituents which may be present on Cy¹
 aromatic or heteroaromatic groups include groups of formula –L⁶Alk⁵(R^{10a})_r,
 25 in which r is the integer 1 or 2, L⁶ is a covalent bond or an –O- or –S- atom or a –N(R³)-, especially –NH- or –N(CH₃)-, –C(O)-, –C(S)-, –C(O)O-, –OC(O)-, –N(R³)CO-, especially –NHCO-, or –CON(R³)-, especially –CHNH-group, Alk⁵ is a C₁₋₆alkyl chain, especially a –CH₂-, –CH₂CH₂-, –CH₂CH₂CH₂- or –CH₂CH₂CH₂CH₂- chain and R^{10a} is a hydroxyl or substituted hydroxyl group,
 30 especially a –OCH₃, –OCH₂CH₃ or –OCH(CH₃)₂ group or a –NH₂ or substituted amino group, especially a –N(CH₃)₂ or –N(CH₂CH₃)₂ group or a –

- Het group, especially an optionally substituted monocyclic C₅₋₇carbocyclic group containing one, two or three -O-, -S-, -N(R¹²)-, especially -NH- or -N(CH₃)- or -C(O)- groups within the ring structure as previously described, most especially an optionally substituted pyrrolidinyl, imidazolidinyl, 5 piperidinyl, e.g. N-methylpiperidinyl, morpholinyl, thiomorpholinyl or piperazinyl group or R^{10a} is an optionally substituted heteroaromatic group, especially a five- or six-membered monocyclic heteroaromatic group containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms, such as optionally substituted pyrrolyl, furyl, thienyl, 10 imidazolyl, triazolyl, pyridyl, pyrimidinyl, triazinyl, pyridazinyl, or pyrazinyl group. Particularly preferred optional substituents on the -Het groups just described include hydroxyl (-OH) and carboxyl (-CO₂H) groups or those preferred optional substituents just described in relation to the group Cy¹, especially when Cy¹ is a cycloalkyl group.
- 15 In one particularly preferred group of compounds of formula (1) Cy¹ is an optionally substituted phenyl group, especially a phenyl group optionally substituted by one, two or three substituents where at least one, and preferably two substituents are located *ortho* to the bond joining Cy¹ to the remainder of the compound of formula (1). Particularly preferred *ortho* 20 substituents include halogen atoms, especially fluorine or chlorine atoms, or C₁₋₃alkyl groups, especially methyl groups, C₁₋₃alkoxy groups, especially methoxy, haloC₁₋₃alkyl groups, especially -CF₃, haloC₁₋₃alkoxy groups, especially -OCF₃, or cyano (-CN), groups. In this class of compounds a second or third optional substituent when present in a position other than the 25 *ortho* positions of the ring Cy¹ may be preferably an atom or group -R^{10a} or -L⁶Alk⁵(R^{10a}), as herein generally and particularly described. In another preference, the Cy¹ phenyl group may have a substituent *para* to the bond joining Cy¹ to the remainder of the compound of formula (1). Particular *para* substituents include those particularly preferred *ortho* substituents just

described. Where desired, the *para* substituent may be present with other *ortho* or *meta* substituents as just mentioned.

The group Y in compounds of formula (1) is preferably a $-\text{CH}=\text{}$ group or a substituted carbon atom. Particular substituted carbon atoms include those where Y is $-\text{C}(\text{R}^{10})=$ wherein R^{10} is as generally or particularly described above, especially those $-\text{R}^{10a}$ and $-\text{L}^6\text{Alk}^5(\text{R}^{10a})_r$ substituents just described with respect to those preferred optional substituents present on Cy^1 aromatic or heteroaromatic groups. Particularly useful R^{10} groups include $-\text{CN}$, $-\text{X}^1\text{NH}_2$, (where X^1 is a $-\text{C}(\text{O})-$ or $-\text{S}(\text{O})_2-$ group), $-\text{X}^1\text{NHR}^{11}$, $-\text{X}^1\text{N}(\text{R}^{11})_2$, $-\text{X}^1\text{NHet}^1$, $-\text{X}^1\text{N}(\text{R}^{12})\text{Het}$, $-\text{X}^1\text{N}(\text{R}^{12})\text{Alk}^5\text{Het}$, $-\text{COR}^{11}$, $-\text{C}=\text{NR}^{12}(\text{NR}^{12})$ or esterified carboxyl groups as described previously in relation to Cy^1 aromatic or heteroaromatic groups. Particularly useful compounds of formula (1) are those compounds wherein Y is $-\text{CH}=\text{}$ or $-\text{C}(\text{R}^{10})=$ in which R^{10} is a $-\text{CN}$, $-\text{CONH}_2$, $-\text{CONHR}^{11}$, $-\text{CON}(\text{R}^{11})_2$, $-\text{CONHet}^1$, $-\text{CON}(\text{R}^{12})\text{Het}$, $-\text{CON}(\text{R}^{12})\text{Alk}^5\text{Het}$, or esterified carboxyl, particularly $-\text{CO}_2\text{Alk}^6$ group as generally or particularly described herein.

Particularly preferred Ar aromatic groups in compounds of formula (1) include optionally substituted phenyl groups. Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl or triazinyl group.

Particularly preferred optional substituents which may be present on Ar aromatic or heteroaromatic groups include atoms or groups $-\text{R}^{10a}$ or $-\text{L}^6\text{Alk}^5(\text{R}^{10a})_r$ as hereinbefore defined. Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C_1 .

- alkyl groups, especially C₁₋₃alkyl groups, most especially a methyl group, or a haloC₁₋₆alkyl group, especially a fluoroC₁₋₆alkyl group, most especially a –CF₃ group, or a C₁₋₆alkoxy, especially methoxy, ethoxy, propoxy or i-propoxy group, or a haloC₁₋₆alkoxy, especially a fluoroC₁₋₆alkoxy, most especially a –
- 5 OCF₃ group, or a cyano (–CN), esterified carboxyl, especially –CO₂CH₃ or –CO₂C(CH₃)₃, nitro (–NO₂), amino (–NH₂), substituted amino, especially –NHCH₃ or –N(CH₃)₂, –COR¹¹, especially –COCH₃, or –N(R¹²)COR¹¹, especially –NHCOCH₃ group.
 - 10 Particularly useful Ar groups in compounds of formula (1) include phenyl and mono- or disubstituted phenyl groups in which each substituent is in particular a –R^{10a} or –L⁶Alk⁵(R^{10a})_r atom or group as just defined and is especially a halogen atom or a C₁₋₃alkyl, C₁₋₃alkoxy or –CN group
 - 15 Particularly useful compounds of the invention include each of the compounds described in the Examples hereinafter, and the salts, solvates, hydrates and N-oxides thereof.
- Compounds according to the invention are potent and selective inhibitors of
- 20 p38 kinases, including all isoforms and splice variants thereof. More specifically the compounds of the invention are inhibitors of p38 α , p38 β and p38 β 2. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.
 - 25 The compounds of formula (1) are of use in modulating the activity of p38 kinases and in particular are of use in the prophylaxis and treatment of any p38 kinase mediated diseases or disorders in a human, or other mammal. The invention extends to such a use and to the use of the compounds for the
 - 30 manufacture of a medicament for treating such diseases or disorders. Further

the invention extends to the administration to a human an effective amount of a p38 inhibitor for treating any such disease or disorder.

5 The invention also extends to the prophylaxis or treatment of any disease or disorder in which p38 kinase plays a role including conditions caused by excessive or unregulated pro-inflammatory cytokine production including for example excessive or unregulated TNF, IL-1, IL-6 and IL-8 production in a human, or other mammal. The invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such
10 cytokine-mediated diseases or disorders. Further the invention extends to the administration to a human an effective amount of a p38 inhibitor for treating any such disease or disorder.

15 Diseases or disorders in which p38 kinase plays a role either directly or via pro-inflammatory cytokines including the cytokines TNF, IL-1, IL-6 and IL-8 include without limitation autoimmune diseases, inflammatory diseases, destructive-bone disorders, proliferative disorders, neurodegenerative disorders, viral diseases, allergies, infectious diseases, heart attacks, angiogenic disorders, reperfusion/ischemia in stroke, vascular hyperplasia,
20 organ hypoxia, cardiac hypertrophy, thrombin-induced platelet aggregation and conditions associated with prostaglandin endoperoxidase synthetase-2 (COX-2).

Autoimmune diseases which may be prevented or treated include but are not
25 limited to rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, multiple sclerosis, diabetes, glomerulonephritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, hemolytic anemia, autoimmune gastritis, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, atopic
30 dermatitis, graft vs, host disease or psoriasis.

The invention further extends to the particular autoimmune disease rheumatoid arthritis.

Inflammatory diseases which may be prevented or treated include but are not
5 limited to asthma, allergies, respiratory distress syndrome or acute or chronic pancreatitis.

Destructive bone disorders which may be prevented or treated include but are not limited to osteoporosis, osteoarthritis and multiple myeloma-related
10 bone disorder.

Proliferative diseases which may be prevented or treated include but are not limited to acute or chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma and multiple myeloma.
15

Neurodegenerative diseases which may be prevented or treated include but are not limited to Parkinson's disease, Alzheimer's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury.

20 Viral diseases which may be prevented or treated include but are not limited to acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.

Infectious diseases which may be prevented or treated include but are not
25 limited to septic shock, sepsis and Shigellosis.

In addition, p38 inhibitors of this invention also exhibit inhibition of expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxidase synthetase-2, otherwise known as cyclooxygenase-2 (COX-2) and are
30 therefore of use in therapy. Pro-inflammatory mediators of the cyclooxygenase pathway derived from arachidonic acid are produced by

inducible COX-2 enzyme. Regulation of COX-2 would regulate these pro-inflammatory mediators such as prostaglandins, which affect a wide variety of cells and are important and critical inflammatory mediators of a wide variety of disease states and conditions. In particular these inflammatory mediators
5 have been implicated in pain, such as in the sensitization of pain receptors, or edema. Accordingly additional p38 mediated conditions which may be prevented or treated include edema, analgesia, fever and pain such as neuromuscular pain, headache, dental pain, arthritis pain and pain caused by cancer.

10

As a result of their p38 inhibitory activity, compounds of the invention have utility in the prevention and treatment of diseases associated with cytokine production including but not limited to those diseases associated with TNF, IL-1, IL-6 and IL-8 production.

15

Thus TNF mediated diseases or conditions include for example rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease,
20 silicosis, pulmonary sarcoiiosis, bone resorption disease, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, AIDS, ARC or malignancy, keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, pyresis, viral infections such as HIV, CMV, influenza and herpes; and veterinary viral
25 infections, such as lentivirus infections, including but not limited to equine infectious anemia virus, caprine arthritis virus, visna virus or maedi virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus or canine immunodeficiency virus.

30 Compounds of the invention may also be used in the treatment of viral infections, where such viruses elicit TNF production *in vivo* or are sensitive to

upregulation by TNF. Such viruses include those that produce TNF as a result of infection and those that are sensitive to inhibition, for instance as a result of decreased replication, directly or indirectly by the TNF inhibiting compounds of the invention. Such viruses include, but are not limited to, HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses such as Herpes Zoster and Herpes Simplex.

IL-1 mediated diseases or conditions include for example rheumatoid arthritis, osteoarthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, inflammatory bowel disease, stroke, endotoxemia and/or toxic shock syndrome, inflammatory reaction induced by endotoxin, diabetes, pancreatic β -cell disease, Alzheimer's disease, tuberculosis, atherosclerosis, muscle degeneration and cachexia.

IL-8 mediated diseases and conditions include for example those characterized by massive neutrophil infiltration such as psoriasis, inflammatory bowel disease, asthma, cardiac, brain and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. The increased IL-8 production associated with each of these diseases is responsible for the chemotaxis of neutrophils into inflammatory sites. This is due to the unique property of IL-8 (in comparison to TNF, IL-1 and IL-6) of promoting neutrophil chemotaxis and activation. Therefore, inhibition of IL-8 production would lead to a direct reduction in neutrophil infiltration.

25

It is also known that both IL-6 and IL-8 are produced during rhinovirus (HRV) infections and contribute to the pathogenesis of the common cold and exacerbation of asthma associated with HRV infection [Turner *et al*, Clin. Infect. Dis., 1997, 26, 840; Grunberg *et al*, Am. J. Crit. Care Med. 1997, 155, 1362; Zhu *et al*, J. Clin. Invest. 1996, 97, 421]. It has also been demonstrated *in vitro* that infection of pulmonary epithelial cells (which represent the

primary site of infection by HRV) with HRV results in production of IL-6 and IL-8 [Sabauste *et al*, J. Clin. Invest. 1995, 96, 549]. Therefore, p38 inhibitors of the invention may be used for the treatment or prophylaxis of the common cold or respiratory viral infection caused by human rhinovirus infection (HRV),
5 other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus or adenovirus infection.

For the prophylaxis or treatment of a p38 or pro-inflammatory cytokine mediated disease the compounds according to the invention may be
10 administered to a human or mammal as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

15 Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.

20 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium
25 hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a
30 dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with

pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

5

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or
10 lozenges formulated in conventional manner.

The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or
15 multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g.
20 sterile pyrogen-free water, before use.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular
25 injection.

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with
30 the use of suitable propellant, e.g. dichlorodifluoromethane, trichloro-

fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device
5 which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

For topical administration the compounds for use according to the present
10 invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water. Alternatively the compounds
15 for use according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.

20

For ophthalmic administration the compounds for use according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH adjusted sterile saline, either with or without a preservative such as bactericidal or fungicidal agent, for example
25 phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate. Alternatively for ophthalmic administration compounds may be formulated in an ointment such as petrolatum.

For rectal administration the compounds for use according to the present
30 invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating

excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component. Such materials include for example cocoa butter, beeswax and polyethylene glycols.

5

The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around
10 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

15 The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols Ar, Cy¹, Alk¹, n, L¹, R, R^a, R^b, R^c, A, X and Y when used in the formulae depicted are to be understood to represent those groups described above in relation to formulae
20 (1a) and (1b) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example,
25 Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1999]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.

30


Thus according to a further aspect of the invention a compound of formula (1) in which A is a $-C(R^b)=$ group, X is a $-O-$ or $-S-$ atom or $-NH-$ group and Y is a substituted carbon atom in which the substituent is an esterified carboxyl group, for example a $-CO_2Alk^6$ group, may be prepared according to the reactions set out in Scheme 1 below. In the Scheme the preparation of an ethyl ester is specifically shown, but it will be appreciated that other esters may be obtained by simply varying the ester starting material and if appropriate any reaction conditions:

10

15

20

Scheme 1



Thus in Scheme 1 a compound of formula (1) may be prepared by reaction of a compound of formulae (2) or (3) with an amine ArNH_2 in the presence of a palladium catalyst. The reaction may be conveniently carried out in a solvent such as toluene at an elevated temperature, eg the reflux temperature, using a catalyst such as tris(dibenzylideneacetone)dipalladium(0), a phosphine ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and a base such as caesium carbonate. Where desired, alternative reaction conditions may be used, for example as described in the literature [Luker et al. Tet. Lett. (2001) 41, 7731; Buchwald S.L. J.Org.Chem. (2000) 65 1144; Hartwig J.F. Angew. Chem. Int. Ed. Engl. (1998) 37, 2046].

Intermediates of formula (2) may be prepared by reaction of a compound of formula (4) with an alkylating agent of formula $\text{Cy}^1\text{L}^1(\text{Alk}^1)_n\text{Z}$, where Z is a

leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom or a sulphonyloxy group such as an alkylsulphonyloxy e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy e.g. phenylsulphonyloxy group.

5

The reaction may be performed in the presence of a solvent, for example a substituted amide such as dimethylformamide, optionally in the presence of a base, for example an inorganic base such as sodium hydride, or an organic base such as an organic amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene or a resin bound organic amine such as resin bound 2-*tert*-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine (PS-BEMP), at an elevated temperature, for example 80 to 100°C.

15 Intermediates of formula (3) may be prepared by the reaction of a compound of formula (4) with a boronic acid of formula $Cy^1B(OH)_2$ in which Cy^1 is an aryl or heteroaryl group. The reaction may be performed in an organic solvent, for example a halogenated hydrocarbon such as dichloromethane or dichloroethane in the presence of a copper reagent, for example a copper (I) salt such as CuI or for example a copper (II) reagent such as copper (II) acetate, optionally in the presence of an oxidant, for example 2,2,6,6-tetramethylpiperidine-1-oxide or pyridine-N-oxide, optionally in the presence of a base, for example an organic amine such as an alkylamine, e.g. triethylamine or an aromatic amine, e.g. pyridine at a temperature from around ambient to the reflux temperature [see for example Chan, D.T. *et al* Tetrahedron Letters, 1998, 2933; Lam, P.Y.S. *et al*, Tetrahedron Letters, 2001, 3415]


30 Intermediates of formula (3) where Cy^1 is an aryl or heteroaryl group may also be prepared by nucleophilic aromatic substitution of a suitably activated aryl or heteroaryl halide with a compound of formula (4). The reaction may be

performed in a dialkylamide solvent such as dimethylformamide in the presence of a base such as a metal hydride e.g. sodium hydride at a temperature from around ambient to 100°C. Suitably activated aryl or heteroaryl halides are those with an electron withdrawing substituent such as a nitro, cyano or ester group e.g. a chloro- or fluoro-nitrobenzene or 2-chloro-5-nitropyridine. Alternatively a nitrogen containing heteroaryl halide can be activated to nucleophilic substitution by N-oxidation for example a halopyridine N-oxide such as a chloropyridine N-oxide e.g. 2-chloropyridine N-oxide.

10

It will be appreciated that if desired the reactions just described may be carried out in the reverse order so that the amination using ArNH_2 is performed first with the intermediate of formula (4) followed by alkylation/arylation to yield the compound of formula (1). It may be necessary to protect the nitrogen function of compounds of formula (4) during the course of these reactions. Such protection may be achieved by O-alkylation with an alkyl halide e.g. cyclopropylmethyl bromide or an arylalkyl bromide e.g. benzyl bromide as shown in Scheme 1a.

Scheme 1a



20

The O-alkylation reaction may be performed in an organic solvent such as dimethylformamide in the presence of a base, for example an inorganic base

such as Cs_2CO_3 or an organic base such as an amine e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene at an elevated temperature e.g. 80°C to 100°C to give a compound of formula (13). Reaction of the protected compound (13) with ArNH_2 under palladium catalysis can then be performed
5 as previously described to give a compound of formula (14). Deprotection can then be achieved by treating a solution of this compound in an alcohol e.g. methanol with a mineral acid such as concentrated HCl at an elevated temperature e.g. the reflux temperature to give a compound of formula (15). Alternatively when benzyl protection is employed then this group may be
10 removed reductively by treating a solution of compound (14) in a solvent e.g. water or an organic solvent such as ethanol using a palladium or platinum catalyst e.g. palladium on carbon or PtO_2 under an elevated pressure of hydrogen at a temperature from around ambient to 60°C . Compounds of formula (15) can then undergo alkylation/arylation reactions as previously
15 described to give compounds of formula (1).

Intermediate pyridinones of formula (4) may be prepared from pyridine N-oxides of formula (5) by sequential reaction with an anhydride, for example acetic anhydride at an elevated temperature, for example the reflux
20 temperature followed by reaction with an inorganic base, for example a carbonate such as aqueous potassium carbonate in a solvent such as an ether for example a cyclic ether e.g. tetrahydrofuran at around ambient temperature. Alternatively the reaction may be performed using trifluoroacetic anhydride in dimethylformamide from 0°C to ambient temperature conditions
25 [see for example Konno et al., *Heterocycles* (1986) 24, 2169].

Pyridine N-oxides of formula (5) may be formed by oxidation of pyridines of formula (6) using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for
30 example around 70°C to 80°C , or alternatively by reaction with a peracid such as peracetic acid or *m*-chloroperoxybenzoic acid in a solvent, such as a

halogenated hydrocarbon e.g. dichloromethane or an alcohol e.g. tert-butanol at a temperature from the ambient temperature to the reflux temperature.


Intermediate pyridines of formula (6) in Scheme 1 may be obtained by standard methods such as for example by the Sandmeyer reaction. Thus for example a bromide of formula (6) may be prepared by treatment of an aryl amine of formula (7) with an alkyl nitrite, for example t-butyl nitrite and a copper salt, for example copper (II) bromide in the presence of a solvent, for example a nitrile such as acetonitrile at a temperature from about 0° to around 65°C.

Amines of formula (7) may be formed from 2-halopyridine-3-carbonitriles of formula (8) by reaction with a reagent of formula $HXCH_2CO_2Et$ [where Et is an ethyl group and X is a -O- or -S- atom or -NH- group]. The reaction may be performed in the presence of a solvent such as a substituted amide for example dimethylformamide or an ether e.g. a cyclic ether such as tetrahydrofuran or alcohol such as ethanol in the presence of a base, for example an inorganic base such as sodium carbonate or a hydride e.g. sodium hydride or an organic base such as 1,5-diazabicyclo[4.3.0]non-5-ene or a trialkylamine such as triethylamine at a temperature between about 0°C and 100°C. The carbonitrile starting materials are readily available or may be obtained from known compounds using standard procedures.

In another process according to the invention, a compound of formula (1) in which A is a $-C(R^b)=$ group, X is a -O- or -S- atom or -NH- group and Y is a $-C(CN)=$ group may be prepared using the reactions set out in Scheme 2 below:


Scheme 2

30




- Thus in Scheme 2, a 2-cyano intermediate of formula (9) may be aminated and alkylated or arylated in a final step to yield a compound of the invention
- 5 using the reactions and reagents described above in relation to the amination, alkylation and arylation of intermediates of formula (4). Nitriles of formula (9) may be obtained by dehydration of the corresponding amide of formula (10) using a dehydrating agent such as trifluoroacetic anhydride in the presence of a base such as pyridine in a solvent, for example a
- 10 halogenated hydrocarbon such as dichloromethane at around ambient temperature. Alternatively, cyanuric chloride may be used in a solvent such as dimethylformamide at a temperature from around 0°C to 110°C. Amides of formula (10) may be obtained from the corresponding acids of formula (11) using conventional procedures, for example by reaction with 1,1'-
- 15 carbonyldiimidazole and aqueous ammonia in a solvent such as dimethyl formamide at ambient temperature. The intermediate acids of formula (11) may be prepared by hydrolysis of esters of formula (4) using a base such as lithium hydroxide in water and a solvent such as tetrahydrofuran.
- 20 In another process according to the invention, a compound of formula (1) in which A is a $-\text{C}(\text{R}^b)=$ group, X is a $-\text{O}-$ or $-\text{S}-$ atom, Y is a $-\text{C}(\text{CN})=$ group,

Ar is a heteroaromatic group and Alk¹, L, n and Cy¹ are as previously defined, may be prepared by nucleophilic aromatic substitution of a suitably activated heteroaryl halide with a compound of formula (16). This reaction can be performed in an organic solvent such as an ether, e.g. tetrahydrofuran or dialkylamide e.g. dimethylformamide or a solvent such as dimethylsulphoxide in the presence of an inorganic base such as sodium hydride at an elevated temperature from 50-80°C. Suitably activated heteroaryl halides include halopyridines e.g. a chloropyridine such as 2,6-dichloropyridine or halopyridine N-oxides e.g. a chloropyridine N-oxide such as 2-chloro-6-methylpyridine N-oxide.



Amides of formula (1a) may be obtained from acids of formula (17) using conventional procedures such as those described in Scheme (4).


15 Scheme 4



Thus amides may be formed by reaction of the acid (17) with 1,1'-carbonyldiimidazole and an amine of formula HNR¹⁵R¹⁵ (where each R¹⁵ is independently H or R¹¹ as previously described) or aqueous ammonia in a solvent e.g. an amide solvent such as dimethylformamide at around ambient

- temperature to 60°C. Alternatively the acid may be reacted with an activating agent such as a carbodiimide e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N,N'-dicyclohexylcarbodiimide and the amine $\text{HNR}^{15}\text{R}^{15}$ optionally in the presence of a base such as an amine e.g. triethylamine or N-methylmorpholine in a solvent such as dimethylformamide or an ether e.g. tetrahydrofuran or a halogenated hydrocarbon, e.g. dichloromethane at around ambient temperature to the reflux temperature. In another procedure reaction of an acid of formula (17) with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and pentafluorophenol in a solvent such as an amide solvent e.g. DMF at around ambient temperature affords a pentafluorophenyl ester of formula (18). Amides of formula (1a) can then be prepared by reaction of this ester with amines of formula $\text{HNR}^{15}\text{R}^{15}$ or aqueous ammonia in a solvent such as a halogenated hydrocarbon e.g. dichloromethane at around ambient temperature. The intermediate acids of formula (17) may be prepared by hydrolysis of esters of formula (1) described in Scheme 1 using a base such as an alkali metal hydroxide e.g. sodium hydroxide or lithium hydroxide in water and a solvent such as tetrahydrofuran or alcohol such as ethanol from around ambient temperature to the reflux temperature.
- Amides of formula (1a) can also be prepared directly from esters of formula (1) described in Scheme 1 by heating with an amine of formula $\text{HNR}^{15}\text{R}^{15}$ up to the reflux temperature of that amine either at atmospheric pressure or under pressure in a sealed tube. Carboxamides of formula (1b) in which X is a -O- or -S- atom and Y is a $-\text{C}(\text{CONH}_2)=$ group, and where A, Ar, Alk^1 , L, n and Cy^1 are as previously defined may also be prepared by reaction of an ester of formula (1) with liquid ammonia in a solvent such as 2-ethoxyethanol at elevated pressure (200-400 psi) in a Parr pressure vessel and temperature between 60-120°C. In another process carboxamides of formula (1b) as described above could also be prepared by hydrolysis of a nitrile of formula (1c) with a base such as an alkali metal hydroxide e.g. sodium hydroxide or

potassium hydroxide in water with a solvent such as an alcohol e.g. ethanol at a temperature from around ambient up to the reflux temperature.




5

In another process compounds of formula (1) in which A is a $-\text{C}(\text{H})=$ group, R^a is H, X is a $-\text{S}-$ atom, Y is a $-\text{C}(\text{CR}^{10a})=$ group where R^{10a} is a $-\text{CN}$, $-\text{NO}_2$, $-\text{CONH}_2$, $-\text{CONHR}^{11}$, $-\text{CON}(\text{R}^{11})_2$, $-\text{COR}^{11}$ or $-\text{CO}_2\text{Alk}^6$ group, L is a covalent bond, $n=0$ and Cy^1 , R^{11} , Alk^6 and Ar are as previously defined may be

10 prepared by the reactions set out in Scheme 5.

Scheme 5



Thus in step (A) of the reaction scheme a compound of formulae (19) or (20), where Rx is an optionally substituted alkyl group e.g. methyl and W is a
 15 hydrogen atom metal ion or amine salt, may be reacted with a thioamide of formula (21). The reaction may be performed in the presence of a base. Appropriate bases may include, but are not limited to, lithium bases such as n-butyl or t-butyl lithium or lithium diisopropylamide (LDA), or silazanes e.g. lithium hexamethyldisilazane (LiHMDS) or sodium hexamethyldisilazane
 20 (NaHMDS), or a carbonate, e.g. potassium carbonate, an alkoxide, e.g. sodium ethoxide, sodium methoxide, potassium t-butoxide, a hydroxide e.g.

NaOH or a hydride, e.g. sodium hydride, or an organic amine e.g. triethylamine or N,N-diisopropylethylamine or a cyclic amine, such as N-methylmorpholine or pyridine. The reaction may be performed in an organic solvent such as an amide e.g. a substituted amide such as
5 dimethylformamide, an ether e.g. a cyclic ether such as tetrahydrofuran or dioxane or an alcohol e.g. methanol, ethanol or propanol or acetonitrile, at a temperature from ambient to the reflux temperature. In one particular aspect of the process the reaction is achieved using an alkoxide base, especially sodium ethoxide or sodium methoxide in an alcoholic solvent, especially
10 ethanol at reflux temperature.

Intermediates of formula (19), where not commercially available, may be prepared using standard methodology. (See, for example, Mir Hedayatullah, J. Heterocyclic Chem., 18, 339, (1981)). Similarly, intermediates of formula
15 (20) where not commercially available, may be prepared using standard methodology. For example they may be prepared *in-situ* by reaction of an acetate e.g. ethyl acetate with a base such as sodium methoxide followed by addition of a formate e.g. methyl formate.

20 In a similar manner, Intermediates of formula (21), if not commercially available, may be prepared using methods known to those skilled in the art (see, for example Adhikari et al, Aust. J. Chem., 52, 63-67, (1999)). For example, an isothiocyanate of formula Cy^1NCS may be reacted with acetonitrile in the presence of a base e.g. NaHMDS in a suitable solvent e.g.
25 tetrahydrofuran, optionally at a low temperature, e.g. around $-78^{\circ}C$. According to the nature of the group Cy^1 , the Intermediate of formula (21) may be prepared *in situ*, for example, using the methods as described herein, followed by subsequent addition of a compound of formulae (19) or (20).

30 During the course of this process an intermediate of formula (22) may be formed. If desired the intermediate may be isolated at the end of step (A) and

subsequently reacted with intermediate (23) to form the desired amine (24). In some instances however it may be advantageous not to isolate the intermediate of formula (22) and reaction (B) may be carried out directly with the reaction mixture of step (A).


5

If a different solvent is used during the second stage of the process, it may be necessary to evaporate the solvent, *in vacuo*, from the first stage of the process before proceeding with the second stage. Once evaporated, the crude solids from step (A) may be used in the next stage or they may be purified, for example, by crystallisation, to yield an isolated intermediate, such as a compound of formula (22).

During step (B) of the process an intermediate of formula (23) may then be added to the reaction mixture or to the crude solids or purified product from step (A) in a suitable solvent. Suitable solvents include, but are not limited to, amides e.g. a substituted amide such as dimethylformamide, alcohols e.g. ethanol, methanol or isopropyl alcohol, ethers e.g. a cyclic ether such as tetrahydrofuran or dioxane or acetonitrile. The reaction may be performed at a temperature from ambient up to the reflux temperature.

20

During the course of step (B) an intermediate of formula (26):



may be observed or even isolated, depending upon the nature of the group R. The intermediate of formula (26) may be converted to a compound of formula (24) using the methods described above. In this situation it may be necessary to add a base, in order for the reaction to proceed to completion. Appropriate bases include carbonates e.g. caesium or potassium carbonate,

25

or alkoxides e.g. potassium *t*-butoxide, or hydrides e.g. sodium hydride or organic amines e.g. triethylamine or *N,N*-diisopropylethylamine or cyclic amines, such as *N*-methylmorpholine or pyridine.

- 5 Amines of formula (24) can be converted to bromides of formula (25) by standard methods such as for example by the Sandmeyer reaction as previously described for compounds of formula (7). Compounds of formula (1) can then be prepared from these bromides by the palladium catalysed amination reactions already described.

10


- It will be appreciated that Intermediates of formula (23) where not commercially available may be prepared using standard methods known to those skilled in the art. For example, alcohol groups may be converted into leaving groups, such as halogen atoms or sulfonyloxy groups using conditions
15 known to the skilled artisan. For example, an alcohol may be reacted with thionyl chloride in a halogenated hydrocarbon e.g., dichloromethane to yield the corresponding chloride. A base e.g., triethylamine may also be used in the reaction.

- 20 It will be appreciated that intermediates, such as intermediates (19), (20), (21) or (23), if not available commercially, may also be prepared by methods known to those skilled in the art following procedures set forth in references such as Rodd's Chemistry of Carbon Compounds, Volumes 1-15 and Supplementals (Elsevier Science Publishers, 1989), Fieser and Fieser's
25 Reagents for Organic Synthesis, Volumes 1-19 (John Wiley and Sons, 1999), Comprehensive Heterocyclic Chemistry, Ed. Katritzky et al, Volumes 1-8, 1984 and Volumes 1-11, 1994 (Pergamon), Comprehensive Organic Functional Group Transformations, Ed. Katritzky et al, Volumes 1-7, 1995 Pergamon), Comprehensive Organic Synthesis, Ed. Trost and Fleming,
30 Volumes 1-9, (Pergamon, 1991), Encyclopedia of Reagents for Organic Synthesis Ed. Paquette, Volumes 1-8 (John Wiley and Sons, 1995), Larock's

Comprehensive Organic Transformations (VCH Publishers Inc., 1989) and March's Advanced Organic Chemistry (John Wiley and Sons, 1992).

- According to a further aspect of the invention a compound of formula (1) in which X is an -S- atom and Y is a -C(S(O)₂NR¹⁶R¹⁶)= group (where each R¹⁶ substituent is independently H or R¹¹ as previously defined) may be prepared by the route set out in Scheme 6.


Scheme 6



- Thus a compound of formula (28) can be obtained by reaction of a compound of formula (27) with a metal amide base such as sodium bis(trimethylsilyl)amide in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran at a temperature of around 0°C and then adding di-*tert*-butyl dicarbonate in a solvent such as tetrahydrofuran and stirring at ambient temperature. A compound of formula (1) can then be prepared by the following reaction sequence. A compound of formula (28) is treated with a base such as an alkyl lithium, e.g. n-butyl lithium in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran at a temperature of around -78°C. Sulfur dioxide gas is bubbled through the reaction mixture before allowing the reaction to warm to room temperature. Solvents are removed *in vacuo* and the crude material dissolved in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane and the mixture treated with a chlorinating reagent such as N-chlorosuccinimide at around ambient temperature. An amine of formula HNR¹⁶R¹⁶ or ammonia can then be added to the reaction mixture to produce a compound of formula (29), where R = *t*-butoxycarbonyl. A sulphonamide of formula (1) can then be prepared by

treating a compound of formula (29) with an acid e.g. a mineral acid such as HCl or an organic acid such as trifluoroacetic acid in a solvent such as a halogenated hydrocarbon e.g. dichloromethane. Intermediates of formula (27) may be obtained by decarboxylation of compounds of formula (17) with an acid such as a mineral acid e.g. HCl in a solvent such as an ether e.g. a cyclic ether e.g. tetrahydrofuran or 1,4-dioxane at a temperature from 50°C up to the reflux temperature.

- 10 Compounds of formula (1) in which A is a $-N=$ atom may be obtained using the synthetic routes in Schemes (1) and (2) with a pyrimidine starting material of formula (12):



- wherein Hal is a halogen atom such as a chlorine atom and LG is a halogen such as chlorine or group such as a methylsulfanyl or methylsulfonyl. Compound (30) and analogues, where LG is a methylsulfanyl group, are known [Santilli et al, J. Heterocycl. Chem. 8, 445-453 (1971)]. A compound of formula (30) can undergo a reaction such as the Sandmeyer reaction as described for compounds of formula (7) to afford a bromide of formula (31). In subsequent steps the methylsulfanyl group or other leaving group LG present in compounds such as (31) may be hydrolysed using a base such as sodium or potassium hydroxide in a solvent such as an alcohol e.g. methanol or ethanol at an elevated temperature, e.g. the reflux temperature. Alternatively, the LG group may first be converted to an ether by reaction with an alkoxide such as sodium methoxide or sodium phenyl methanolate in a solvent, e.g. an alcohol such as methanol or ethanol at a temperature between 0°C and the reflux, and the ether then cleaved using standard procedures such as by reduction with hydrogen gas in the presence of a catalyst such as a palladium catalyst, e.g. palladium on charcoal, or where

the ether is an alkyl ether, by reaction with a trialkylsilyl halide such as trimethylsilyl chloride, in the presence of an inorganic halide such as sodium iodide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or in a nitrile e.g. acetonitrile. This will reveal the pyrimidinone functionality
5 which can be either alkylated or arylated as described for compounds of formula (4) and can be converted to compounds of formula (1) as previously described.

Compounds of the invention and intermediates thereto where A represents a
10 $-N(R^b)-$ or $-C(R^b)(R^c)-$ group may be generated from corresponding compounds of the invention or intermediates thereto where A represents a $-N=$ or $-C(R^b)=$ group by reduction, for instance by catalytic hydrogenation using a metal catalyst such as palladium on charcoal in the presence of hydrogen gas at an elevated pressure in a solvent such as an alcohol, e.g.
15 ethanol optionally at an elevated temperature e.g. between 40°C and 60°C.

Where in the general processes described above intermediates such as alkylating agents of formula $Cy^1L^1(Alk^1)_nZ$, reagents of formula $HXCH_2CO_2Et$ and any other intermediates required in the synthesis of compounds of the
20 invention are not available commercially or known in the literature, they may be readily obtained from simpler known compounds by one or more standard synthetic methods employing substitution, oxidation, reduction or cleavage reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, thioacylation, halogenation,
25 sulphonylation, nitration, formylation and coupling procedures. It will be appreciated that these methods may also be used to obtain or modify other intermediates and in particular compounds of formula (1) where appropriate functional groups exist in these compounds. Particular examples of such methods are given in the Examples hereinafter.

30

Thus for example aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange with a base, for example a lithium base such as n-butyl or t-butyl lithium, optionally at a low temperature, e.g. around -78°C, in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent. Thus, for example, a formyl group may be introduced by using dimethylformamide as the electrophile, a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile, an alcohol group may be introduced by using an aldehyde as electrophile and an acid may be introduced by using carbon dioxide as electrophile. Aromatic acids of formula ArCO_2H may also be generated by quenching Grignard reagents of formula ArMgHal with carbon dioxide.

Aromatic acids of formula ArCO_2H generated by this method and acid containing compounds in general may be converted to activated derivatives, e.g. acid halides by reaction with a halogenating agent such as a thionyl halide e.g. thionyl chloride, a phosphorous trihalide such as phosphorous trichloride or a phosphorous pentahalide such as phosphorous pentachloride optionally in an inert solvent such as an aromatic hydrocarbon e.g. toluene or a chlorinated hydrocarbon e.g. dichloromethane at a temperature from about 0°C to the reflux temperature, or may be converted into Weinreb amides of formula ArC(O)N(OMe)Me by conversion to the acid halide as just described and subsequent reaction with an amine of formula HN(OMe)Me or a salt thereof, optionally in the presence of a base such as an organic amine, e.g. triethylamine in an inert solvent such as an aromatic hydrocarbon e.g. toluene or a chlorinated hydrocarbon e.g. dichloromethane at a temperature from about 0°C to ambient temperature.

Compounds of the invention and intermediates thereto may be prepared by alkylation, arylation or heteroarylation. For example, compounds containing a $-\text{L}^1\text{H}$ group (where L^1 is a linker atom or group) may be treated with an alkylating agent Cy^1Z^2 in which Z^2 is a leaving atom or group such as a

halogen atom, e.g. a fluorine, chlorine, bromine or iodine atom or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy, e.g. p-toluenesulphonyloxy group.

5

The reaction may be carried out in the presence of a base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an
10 ether, e.g. a cyclic ether such as tetrahydrofuran.

In another example, compounds containing a $-L^2H$ group as defined above may be functionalised by acylation or thioacylation, for example by reaction with the alkylating agents just described but in which Z^2 is replaced by a -
15 $C(O)Z^3$, $C(S)Z^3$, $-N(R^2)COZ^3$ or $-N(R^2)C(S)Z^3$ group in which Z^3 is a leaving atom or group as described for Z^2 . The reaction may be performed in the presence of a base, such as a hydride, e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g.
20 dimethylformamide, at for example ambient temperature. Alternatively, the acylation may be carried out under the same conditions with an acid (for example one of the alkylating agents described above in which Z^2 is replaced by a $-CO_2H$ group) in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N,N'-dicyclohexylcarbodiimide, or a benzotriazole such as [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophosphate advantageously in the
25 presence of a catalyst such as a N-hydroxy compound e.g. a N-hydroxytriazole such as 1-hydroxybenzotriazole. Alternatively the acid may be reacted with a chloroformate, for example ethylchloroformate, prior to the
30 desired acylation reaction

In a further example compounds may be obtained by sulphonylation of a compound containing an -OH group by reaction with one of the above alkylating agents but in which Z² is replaced by a -S(O)Hal or -SO₂Hal group [in which Hal is a halogen atom such as chlorine atom] in the presence of a
5 base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature.

In another example, compounds containing a -L²H group as defined above
10 may be coupled with one of the alkylation agents just described but in which Z² is replaced by an -OH group in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl, diisopropyl- or dimethylazodicarboxylate.

15 Ester groups such as -CO₂Alk⁶ and -CO₂R⁴ in the compound of formula (1) and intermediates thereto may be converted to the corresponding acid [-CO₂H] by acid- or base-catalysed hydrolysis depending on the nature of the group Alk⁶ or R⁴. Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic
20 acid in an organic solvent e.g. dichloromethane or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol.

In a further example, -OR⁶ [where R⁶ represents an alkyl group such as
25 methyl group] in compounds of formula (1) and intermediates thereto may be cleaved to the corresponding alcohol -OH by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C.

30 Alcohol [-OH] groups may also be obtained by hydrogenation of a corresponding -OCH₂R³¹ group (where R³¹ is an aryl group) using a metal

catalyst, for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature. In another example, -OH groups may be generated from the corresponding ester [e.g. -
5 CO₂Alk⁶] or aldehyde [-CHO] by reduction, using for example a complex metal hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol.

In another example, alcohol -OH groups in the compounds may be converted
10 to a corresponding -OR⁶ group by coupling with a reagent R⁶OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.

15 Aminosulphonylamino [-NHSO₂NH₂] groups in the compounds may be obtained, in another example, by reaction of a corresponding amine [-NH₂] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.

20 In another example compounds containing a -NHCSR⁷ or -CSNHR⁷ group may be prepared by treating a corresponding compound containing a -NHCOR⁷ or -CONHR⁷ group with a thiation reagent, such as Lawesson's Reagent or P₂S₅, in an anhydrous solvent, for example a cyclic ether such as tetrahydrofuran, at an elevated temperature such as the reflux temperature.

25

In a further example amine (-NH₂) groups may be alkylated using a reductive alkylation process employing an aldehyde and a reducing agent. Suitable reducing agents include borohydrides for example sodium triacetoxyborohydride or sodium cyanoborohydride. The reduction may be
30 carried out in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol,

where necessary in the presence of an acid such as acetic acid at around ambient temperature. Alternatively, the amine and aldehyde may be initially reacted in a solvent such as an aromatic hydrocarbon e.g. toluene and then subjected to hydrogenation in the presence of a metal catalyst, for example
5 palladium on a support such as carbon, in a solvent such as an alcohol, e.g. ethanol.

In a further example, amine [-NH₂] groups in compounds of formula (1) and intermediates thereto may be obtained by hydrolysis from a corresponding
10 imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

In another example, a nitro [-NO₂] group may be reduced to an amine [-NH₂], for example by catalytic hydrogenation using for example hydrogen in the
15 presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol e.g. methanol, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

20 In a further example amine (-CH₂NH₂) groups in compounds of formula (1) and intermediates thereto may be obtained by reduction of nitriles (-CN), for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon, or Raney[®] nickel, in a solvent such as an ether e.g. a cyclic ether
25 such as tetrahydrofuran or an alcohol e.g. methanol or ethanol, optionally in the presence of ammonia solution at a temperature from ambient to the reflux temperature, or by chemical reduction using for example a metal hydride e.g. lithium aluminium hydride, in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran, at a temperature from 0°C to the reflux temperature.

30

In another example, sulphur atoms in the compounds, for example when present in a group L¹ or L² may be oxidised to the corresponding sulfoxide or sulphone using an oxidising agent such as a peroxy acid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.

In a further example N-oxides of compounds of formula (1) may in general be prepared for example by oxidation of the corresponding nitrogen base as described above in relation to the preparation of intermediates of formula (5).

Salts of compounds of formula (1) may be prepared by reaction of compounds of formula (1) with an appropriate base in a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol using conventional procedures.

Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.

Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate

chiral intermediate in one of the processes described above. Alternatively, a particular enantiomer may be obtained by performing an enantiomer specific enzymatic biotransformation e.g. an ester hydrolysis using an esterase and then purifying only the enantiomerically pure hydrolysed acid from the
 5 unreacted ester antipode.

Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.

10

The following Examples illustrate the invention. All temperatures are in °C.

The following abbreviations are used:

- | | |
|--|------------------------|
| NMM - N-methylmorpholine; | EtOAc - ethyl acetate; |
| MeOH - methanol; | BOC - butoxycarbonyl; |
| 15 DCM - dichloromethane; | AcOH - acetic acid; |
| DIPEA - diisopropylethylamine; | EtOH - ethanol; |
| Pyr - pyridine; | Ar - aryl; |
| DMSO - dimethylsulphoxide; | iPr - isopropyl; |
| Et ₂ O - diethylether; | Me - methyl; |
| 20 THF - tetrahydrofuran; | h - hour; |
| MCPBA - 3-chloroperoxybenzoic acid; NBS - N-bromosuccinimide; | |
| Fmoc - 9-fluorenylmethoxycarbonyl; r.t. - room temperature; | |
| DBU - 1,8-Diazabicyclo[5,4-0]undec-7-ene; | |
| EDC - 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; | |
| 25 HOBT - 1-hydroxybenzotriazole hydrate; | |
| BINAP - 2,2'-bis(diphenylphosphino)-1-1'-binaphthyl; | |
| DMF - N,N-dimethylformamide; | |
| DME - Ethylene glycol dimethyl ether | |
| p.s.i. - pounds per square inch | |

30

All NMRs were obtained either at 300MHz or 400MHz.

Compounds were named with the aid of either Beilstein Autonom supplied by MDL Information Systems GmbH, Theodor-Heuss-Allee 108, D-60486

- 5 Frankfurt, Germany or ACD Labs Name (v.5.0 or v.6.0) supplied by Advanced Chemical Development, Toronto, Canada.

LCMS retention times (RT) quoted were generated on a Hewlett Packard 1100 LC/MS using the following following method: Phenomenex Luna 3 μ

- 10 C₁₈(2) 50x4.6mm column; mobile phase A = 0.1% formic acid in water; mobile phase B = 0.1% formic acid in MeCN; flow rate of 0.9mLmin⁻¹, column temperature 40°C.

Gradient:-	Time	%B
	Initial	5
15	2.00	95
	3.00	95
	5	end

Where stated alternative LCMS conditions (Conditions B) were used:

LCMS retention times (RT) quoted were generated on a Hewlett Packard

- 20 1100/ThermoFinnigan LCQ Duo LC/MS system using Electrospray ionisation and the following LC method: Phenomenex Luna C₁₈(2) 5 μ 100mm x 4.6mm column; mobile phase A = 0.08% formic acid in water; mobile phase B = 0.08% formic acid in MeCN; flow rate of 3.0 mLmin⁻¹, column temperature 35°C.

25

Gradient:-

Time (min)	%A	%B
0.00	95.0	5.0
4.40	5.0	95.0
5.30	5.0	95.0
5.32	95.0	5.0
6.50	95.0	5.0

5 Intermediate 1

Ethyl 3-aminothieno[2,3-b]pyridine-2-carboxylate

A mixture of 2-chloro-3-cyanopyridine (330g), ethyl 2-mercaptoacetate (361.2g), sodium carbonate (265g) and EtOH (1.2L) was heated to reflux for 4.5 hours. It was then cooled to ambient temperature, added to water (10L) and the addition was washed in with water (5L). The resulting slurry was stirred for 30 minutes and then it was filtered. The filter cake was washed with two portions of water (2 x 2.5L) and dried at the pump. The solids were then dried to constant weight under vacuum at 45°C to yield the title compound as a brown solid (493.1g, 93.2%). δ H (CDCl₃) 8.68 (1H, dd, *J* 4.7, 1.2Hz), 7.93 (1H, dd, *J* 8.5, 1.2Hz), 7.29 (1H, dd, *J* 8.5, 4.7Hz), 5.90 (2H, b), 4.38 (2H, q, *J* 7.0Hz), 1.40 (3H, t, *J* 7.0Hz). LCMS RT 2.9 minutes, 223 (M+H)⁺

Intermediate 2

20 Ethyl 3-bromothieno[2,3-b]pyridine-2-carboxylate

Intermediate 1 (363.6g) was added in portions over two hours to a mixture of copper(II) bromide (403.3g), t-butyl nitrite (220.6g) and acetonitrile (3.6L) stirred at a temperature of 20 to 25°C. The mixture was stirred at 20°C for 2 hours before it was slowly added to 2M HCl(aq) (4.2L). The reaction mixture slurry was filtered and the solids were washed with water (500mL). The

combined filtrate was extracted with ethyl acetate (8L), this ethyl acetate solution was washed with 2M HCl(aq) (2.2L). The solids were dissolved in ethyl acetate (6L), this solution was washed twice with 2M HCl(aq) (4.4L and 2.2L). The two ethyl acetate solutions were then combined and washed with
5 2M HCl(aq) (2.2L) and twice with water (2 x 2L). The ethyl acetate solution was then dried (MgSO₄), filtered and concentrated *in vacuo* at 40 mbar and 60°C to give a solid residue. This was broken up and dried to constant weight under vacuum at 45°C to yield the title compound as a brown solid (458.5g, 97.9%). δ H (DMSO-d₆) 8.89 (1H, d, *J* 4.7Hz), 8.47 (1H, d, *J* 8.6Hz),
10 7.71 (1H, dd, *J* 8.6, 4.7Hz), 4.46 (2H, q, *J* 7.2Hz), 1.40 (3H, t, *J* 7.2Hz). LCMS RT 3.8 minutes, 288 (M+H)⁺

Intermediate 3

Ethyl 3-Bromothieno[2,3-*b*]pyridine-2-carboxylate N-oxide

15 To a slurry of Intermediate 2 (214g, 0.747Mol) in DCM (2140mL) under nitrogen was added MCPBA (240g @ 70% = 168g, 0.97Mol) portion wise over 0.5h. The reaction was then stirred at room temperature for 18h. The reaction mixture was quenched with water (800mL) and pH adjusted to 8.5 with 10%w/v sodium carbonate solution (1250mL). The basic aqueous layer
20 was removed and the organic layer washed with water until pH 7. The organic layer was concentrated *in vacuo* and the crude title product was recovered as a tan solid. The crude product was purified by slurrying in tert-butylmethylether (600mL) for 1h at 0-5°C to give the title compound (174g, 77%). δ H (CDCl₃) 8.44 (1H, dd, *J* 6.2, 0.8Hz), 7.87 (1H, dd, *J* 8.3, 0.8Hz),
25 7.48 (1H, dd, *J* 8.3, 6.2Hz), 4.49 (2H, q, *J* 7.1Hz), 1.48 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 2.61 minutes, 302(M+H)⁺

Intermediate 4

Ethyl 3-bromo-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

30 A mixture of Intermediate 3 (500mg, 1.66mmol) and DMF (10mL) was set to stir at 0°C under nitrogen. To this reaction mixture was added trifluoroacetic

anhydride (3.49g, 2.36mL, 16.6mmol) in one portion via syringe. After stirring for 16 hours the volatiles were removed *in vacuo* and the residue co-evaporated with toluene (2x20mL). The crude material was then extracted with EtOAc (2x100mL). The EtOAc extracts were dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by a re-slurry in toluene (10mL) to give the title compound as a beige solid (260mg, 52%). δ H (DMSO-d₆) 12.20 (1H, brs), 7.75 (1H, d, *J* 9.0Hz), 6.50 (1H, d, *J* 9.0Hz), 4.15 (2H, q, *J* 7.1Hz), 1.12 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 2.86 minutes, 302 ((M+H)⁺, 100%). MP = 261.7-268.1°C.

10

Intermediate 5

Ethyl 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

To a 2 necked round bottomed flask was added in sequence Intermediate 4 (302mg, 1.00mmol), copper(II) acetate (278mg, 1.50mmol), phenylboronic acid (488mg, 4.00mmol), DCM (5mL) and pyridine (158mg, 2.00mmol). The reaction was stirred at room temperature for 18h with the exclusion of moisture. The reaction was then diluted with DCM (50mL), washed with 2M HCl(aq) (50mL), the aqueous was re-extracted with DCM (50mL). The combined organics were then washed with water (50mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by a slurry in methanol (12mL), to give the title compound as a beige solid (270mg, 72%). δ H (CDCl₃) 7.82 (1H, d, *J* 8.5Hz), 7.70-7.62 (3H, m), 7.54-7.42 (2H, m), 6.70 (1H, d, *J* 8.5Hz), 4.15 (2H, q, *J* 7.1Hz), 1.14 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.75 minutes, 378 (M+H)⁺. MP = 201.6-206.0°C.

25

Intermediate 6

3-Bromo-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid

Lithium hydroxide monohydrate (1.39g, 33.1mmol) was added to a suspension of Intermediate 4 (5.0g, 16.55mmol) in water (100mL) and the reaction stirred for 5 minutes. THF (10mL) was added and the reaction was

30

stirred at r.t. for 18h. 2M HCl(aq) (40mL) was added to pH 1-2 and the resultant precipitate was collected by filtration, washed sparingly with EtOH and dried *in vacuo* to give the title compound as an off-white solid (4.5g). δ H (DMSO-d₆) 7.90 (1H, d, *J* 9.2Hz), 6.67 (1H, d, *J* 9.2Hz), pyridone and
5 carboxylic acid protons not observed.

Intermediate 7

3-Bromo-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide

1,1'-Carbonyldiimidazole (3.18g, 19.6mmol) was added to a suspension of
10 Intermediate 6 (4.30g, 15.7mmol) in anhydrous DMF (50mL) and the reaction stirred at r.t. under nitrogen until solution was achieved (30minutes). Ammonium hydroxide (50mL of 28% NH₃ in water) was added and the reaction stirred for 15 minutes before removing solvents *in vacuo*. The residue was suspended in water (75mL) and treated with 2M HCl(aq) (20mL).
15 The resultant solid was collected by filtration, washed with water and dried in a vacuum oven to give the title compound as a pale brown solid (3.70g). δ H (DMSO-d₆) 7.69 (1H, d, *J* 9.1Hz), 6.49 (1H, d, *J* 9.1Hz), 7.30 (1H, bs). LCMS (ES⁺) 273 (M+H)⁺.

Intermediate 8

3-Bromo-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile

To a suspension of Intermediate 7 (3.70g, 13.55mmol) in DCM (200mL) was added pyridine (2.70mL, 34mmol) followed by trifluoroacetic anhydride (2.40mL, 17mmol). The reaction was stirred at r.t. for 8h before adding more
25 trifluoroacetic anhydride (1.20mL, 8.5mmol). The reaction was stirred for a further 8h and was then concentrated *in vacuo*. The residue was suspended in water, acidified to pH 2 with 2M HCl(aq) and the resultant solid collected by filtration, washed with water and dried *in vacuo* to give the title compound as a pale yellow solid (3.20g). δ H (DMSO-d₆) 7.92 (1H, d, *J* 8.8Hz), 6.73 (1H,
30 d, *J* 8.8Hz). LCMS (ES⁺) 255 (M+H)⁺.

Intermediate 9**3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- To an oven dried flask was added Intermediate 8 (2.0g, 7.84mmol), phenylboronic acid (1.19g, 15.7mmol), copper(II) acetate (1.42g, 7.84mmol),
- 5 anhydrous pyridine (1.3mL, 16mmol) and anhydrous DCM (50mL). The reaction mixture was stirred at r.t. with the exclusion of moisture for 48h. The reaction was diluted with DCM (50mL), washed with 2M HCl(aq) (100mL), saturated NaHCO₃(aq) (50mL), dried (Na₂SO₄) and concentrated *in vacuo*. The residue was purified by chromatography on silica (5-10% EtOAc in DCM)
- 10 to give the title compound as a white solid (1.24g). δ H (DMSO-d₆) 7.67 (1H, d, *J* 9.6Hz), 7.58-7.50 (3H, m), 7.32-7.29 (2H, m), 6.70 (1H, d, *J* 9.6Hz).

Intermediate 10**Sodium 3-cyano-6-oxo-1-phenyl-1,6-dihydro-pyridine-2-thiolate**

- 15 A solution of sodium methoxide in MeOH (30 wt%, 202.2g) was added to absolute EtOH (360mL) followed by 1,3-dimethyluracil (75g) and 2-cyano-*N*-phenyl-thioacetamide (Adhikari et al, Australian J. Chem., 1999, 52, 63-67) (90g). The resulting mixture was heated at reflux for 8h and then allowed to cool to ambient temperature overnight. The reaction mixture was then
- 20 cooled to +5° and maintained at this temperature for at least an hour when the product was recovered by filtration. The filter cake was washed with cold (+5°) absolute ethanol (450mL) and then dried to constant weight under vacuum at 45° to give the title compound as a pale pink solid (130.0g). The product thus obtained contains residual EtOH and MeOH, estimated at 12.2
- 25 wt% by ¹H nmr, corresponding to a corrected yield of 114.1g. δ H (DMSO-d₆) 7.32 (2H, m), 7.27-7.18 (1H, m), 7.16 (1H, d, *J* 9.1Hz), 6.92 (2H, m), 5.63 (1H, d, *J* 9.1Hz). LCMS(Conditions B) (ES⁺) RT 2.43 minutes, 229 (M+H)⁺.

Intermediate 11

- 30 **3-Amino-6-oxo-7-phenyl-6,7-dihydro-thieno[2,3-b]pyridine-2-carbonitrile**

A mixture of Intermediate 10 (100g at 100%) and chloroacetonitrile (30.4 mL) in acetonitrile (500 mL) was heated at reflux for 2h. The mixture was cooled, initially to 40° when water (300mL) was added, and then to +10°. The reaction was maintained at +10° for at least 1h when the product was recovered by filtration. The filter cake was washed with cold (+10°) water (500mL) followed by a cold (+10°) mixture of acetonitrile and water (1:1, 300mL). The product was dried under vacuum at 50° to constant weight to give the title compound as an off-white solid (100.9g). δ H (DMSO-d₆) 7.90 (1H, d, *J* 9.6Hz), 7.46-7.33 (3H, m), 7.25 (2H, m), 6.95 (2H, br s), 6.35 (1H, d, *J* 9.6Hz). LCMS (Conditions B) (ES⁺) RT 2.69 minutes, 268 (M+H)⁺.

Intermediate 12

3-Amino-6-oxo-7-phenyl-6,7-dihydro-thieno[2,3-b]pyridine-2-carboxylic acid ethyl ester

A mixture of Intermediate 10 (0.34g at 100%) and ethyl bromoacetate (0.197mL) in ethanol (6mL) were stirred at room temperature for 1h. Water (10mL) was then added. The solid was filtered and washed with more water (2mL). The product was dried under vacuum at 40° to constant weight to give the title compound as a pale pink solid (0.35g). δ H (DMSO-d₆) 8.2 (1H, d, *J* 9.6Hz), 7.6 (3H, m), 7.45 (2H, m), 7.15 (2H, br s), 6.55 (1H, d, *J* 9.6Hz), 4.15 (2H, q, *J* 7.1Hz), 1.2 (3H, t, *J* 7.1Hz). LCMS (Conditions B) (ES⁺) RT 3.29 minutes, 315 (M+H)⁺.

Intermediate 9 (alternative route)

3-Bromo-6-oxo-7-phenyl-6,7-dihydro-thienof[2,3-b]pyridine-2-carbonitrile

To a mixture of anhydrous copper (II) bromide (23.4g) and t-butylnitrite (14.8 mL) in acetonitrile (600 mL) at room temperature, was added Intermediate 12 (20g) portion wise, at such a rate to keep the internal temperature below 25°C. The addition took approximately 1 hour. Analysis by HPLC indicated almost complete conversion of starting material after a further 30 minutes of

stirring. The reaction mixture was then poured onto 500mL of 1M HCl (nb caution, brown fumes given off). This was then extracted with dichloromethane (2 x 400mL). The combined organic extracts were then washed with 1M HCl (3 x 300mL), dried over MgSO₄ and evaporated to dryness. The resulting crude product was then recrystallised from methyl isobutyl ketone (700mL). The product was dried under vacuum at 50° to constant weight to give the title compound as a light brown solid (15.14g). δ H (CDCl₃) 7.75 (1H, d, *J* 8.5Hz), 7.55-7.70 (3H, m), 7.35 (2H, m), 6.80 (1H, d, *J* 8.5Hz). LCMS (Conditions B) (ES⁺) RT 3.54 minutes, no parent ion observed.

Intermediate 13

3-Amino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile

Acetonitrile (10mL) was added to a solution of sodium bis(trimethylsilyl)amide (100mL, 1.0M in THF, 100mmol) in THF (50mL) at -78 °C to give a thick white precipitate. 2-Chlorophenyl isothiocyanate (7.72g, 45.45mmol) was added to give a brown solution. The mixture was allowed to warm to r.t. over 1h then diluted with EtOH (50mL). N,N-Dimethyluracil (6.4g, 45mmol) was added and the mixture heated at reflux for 24h. Volatiles were removed *in vacuo* and the residue dissolved in acetonitrile (100mL). Chloroacetonitrile (2.85mL, 45mmol) was added and the mixture heated at 50 °C for 1h, a second charge of chloroacetonitrile (2.85mL, 45mmol) was added and heating continued for 1.5h. Some of the acetonitrile (~50mL) was removed *in vacuo* and water was added to precipitate the product. The brown solid was filtered off, washed with water (50mL) and Et₂O (50mL) and dried to give the title compound as a brown solid (14.3g, quant.). δ H (DMSO-d₆) 8.10 (1H, d, *J* 9.7Hz), 7.75-7.73 (1H, m), 7.65-7.54 (3H, m), 7.14 (2H, br s, NH₂), 6.54 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 2.97 minutes, 302 (M+H)⁺.

Intermediate 14

3-Bromo-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- Intermediate 13 (1.17g, 3.88mmol) was suspended in acetonitrile (20mL). Copper (II) bromide (953mg, 4.27mmol) was added followed by t-butyl nitrite (0.64mL, 5.43mmol). The mixture was stirred at r.t. for 3h then partitioned between 2M HCl aq (100mL) and EtOAc (100mL). The organic layer was washed with 2M HCl aq (50mL), 2M NaOH aq (50mL) and water (25mL), dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 0 to 5% EtOAc in DCM) gave the title compound as a pale brown solid (980mg, 67%). δ H (CDCl₃) 7.70 (1H, d, *J* 9.7Hz), 7.61 (1H, dd, *J* 1.7, 7.7Hz), 7.52-7.44 (2H, m), 7.34 (1H, dd, *J* 1.7, 7.7Hz), 6.70 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.56 minutes, 365 (M+H)⁺.

Intermediate 15

- Sodium 3-cyano-1-(4-methylphenyl)-6-oxo-1,6-dihydropyridine-2-thiolate**

- Sodium bis(trimethylsilyl)amide (36.8mL, 1.0M in THF, 36.8mmol) was added slowly to a solution of 4-tolyl isothiocyanate (2.5g, 16.75mmol) in THF (30mL) and acetonitrile (5mL) at -78 °C. The mixture was warmed to r.t. over 1h. N,N-Dimethyluracil (2.35g, 16.75mmol) and EtOH (20mL) were added and the mixture heated at reflux for 4h. Volatiles were removed *in vacuo* and the residue was dissolved in EtOH (6mL). Et₂O (~60mL) was added slowly to produce a fine, off-white solid. The suspension was cooled to 0 °C and the solid filtered off, washed with Et₂O and dried to give the title compound as an off-white solid (1.7g, 39%). δ H (DMSO-d₆) 7.15-7.12 (3H, m), 6.80-6.77 (2H, m), 5.60 (1H, d, *J* 9.1Hz), 2.30 (3H, s).

Intermediate 16

- 3-Amino-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

Chloroacetonitrile (0.41mL, 6.4mmol) was added to a suspension of Intermediate 15 (1.7g, 6.44mmol) in acetonitrile (40mL). The mixture was heated at 45 °C for 2h. Solvent was removed *in vacuo* and the residual solid was suspended in water (30mL). The solid was filtered off, washed with
5 water (3 x 10mL) and ether (5mL) and dried to give the title compound as an off-white solid (1.22g, 67%). δ H (DMSO-d₆) 8.01 (1H, d, *J* 9.7Hz), 7.34-7.32 (2H, m), 7.27-7.25 (2H, m), 7.00 (2H, br s), 6.45 (1H, d, *J* 9.7Hz), 2.34 (3H, s). LCMS (ES⁺) RT 3.03 minutes, 282.0 (M+H)⁺

10 **Intermediate 17**

3-Bromo-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Intermediate 16 (562mg, 2.0mmol) was suspended in acetonitrile (15mL). Copper (II) bromide (419mg, 2.2mmol) was added followed by t-butyl nitrite
15 (0.33mL, 2.8mmol). The mixture was stirred at r.t. for 3h, then diluted with DCM (100mL), washed with 2M HCl aq (50mL) and 1M NaOH aq (50mL), dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 0% to 20% EtOAc in DCM) gave the title compound as a yellow solid (450mg, 65%). δ H (CDCl₃) 7.59 (1H, d, *J* 9.7Hz), 7.29-7.27
20 (2H, m), 7.13-7.10 (2H, m), 6.62 (1H, d, *J* 8.7Hz), 2.33 (3H, s). LCMS (ES⁺) RT 3.64 minutes, 345.0/347.0 (⁷⁹Br/⁸¹Br)(M+H)⁺

Intermediate 18

25 **3-[(4-Fluoro-3-methylphenyl)amino]-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

A mixture of Intermediate 17 (225mg, 0.65mmol), 4-fluoro-3-methyl aniline (98mg, 0.78mmol), caesium carbonate (297mg, 0.91mmol), BINAP (41mg, 0.065mmol, 10mol%) and tris(dibenzylideneacetone)dipalladium(0) (30mg, 0.0325mmol, 5mol%) in toluene (5mL) was heated at 100 °C under N₂ for
30 18h. The volatiles were removed *in vacuo* and the resulting solids suspended in water. The solid was filtered off, washed with water (2 x 15mL) and ether

(3 x 10mL) to give the title compound as a brown solid. This was used in the next step without further purification. LCMS (ES⁺) RT 3.66 minutes, 390.0 (M+H)⁺

5 Intermediate 19

Sodium 3-cyano-1-cyclopropyl-6-oxo-1,6-dihydropyridine-2-thiolate

- A solution of sodium bis(trimethylsilyl)amide (122mL of a 1.0M solution in THF, 122mmol) was added to a solution of cyclopropyl isothiocyanate (4.85g, 48.9mmol) and acetonitrile (25.5mL, 10eq) in THF (50mL) at -78 °C. The mixture was allowed to warm to r.t. over 2h. N,N-Dimethyluracil (5.9g, 49mmol) and EtOH (60mL) were added and the mixture heated at reflux for 3h then stirred at r.t. overnight. Volatiles were removed *in vacuo*. The residue was taken up in a mixture of EtOH and EtOAc then Et₂O was added. The sticky solid was filtered off and dried to give the title compound (11g, crude) which was used in the next step without further purification.

Intermediate 20

3-Amino-7-cyclopropyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- A mixture of crude Intermediate 19 (9g, assume 42mmol) and chloroacetonitrile (2.7mL, 42mmol) in acetonitrile (100mL) was heated at reflux for 3h. Volatiles were removed *in vacuo*. Water (100mL) was added to the residue and the solid obtained filtered off and dried. The crude material was partitioned between water and EtOAc and the aqueous phase extracted with EtOAc. The combined organic phases were concentrated *in vacuo*. The residue was dissolved in EtOH and the solution treated with Et₂O to give a solid which was filtered off and dried to give the title compound as a light brown solid (2.5g). δ H (CDCl₃) 7.42 (1H, d, J 9.6Hz), 6.52 (1H, d, J 9.6Hz), 4.6 (2H, br s), 3.08-3.00 (1H, m), 1.2-1.1 (2H, m), 1.08-1.0 (2H, m). LCMS (ES⁺) RT 2.532 minutes, 232 (M+H)⁺

Intermediate 21**3-Bromo-7-cyclopropyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

Copper (II) bromide (0.53g, 2.37mmol) and t-butyl nitrite (0.40mL, 3.02mmol) were added to a solution of Intermediate 20 (0.5g, 2.16mmol) in acetonitrile (15mL). The reaction mixture was stirred at r.t. for 4h. DCM (100mL) was added and the mixture washed with 2M HCl aq and 2M NaOH aq, dried (MgSO₄) and concentrated *in vacuo* to give the title compound (400mg, 63%). δ H (CDCl₃) 7.62 (1H, d, *J* 10.2Hz), 6.63 (1H, d, *J* 10.3Hz), 3.1-3.0 (1H, m), 1.3-1.2 (2H, m), 1.1-1.0 (2H, m). LCMS (ES⁺) RT 3.184 minutes, 296.8 (M+H)⁺

Intermediate 22**Sodium 3-cyano-1-(2-methylphenyl)-6-oxo-1,6-dihydropyridine-2-thiolate**

A solution of sodium bis(trimethylsilyl)amide (84mL of a 1.0M solution in THF, 84mmol) was added to a solution of o-tolyl isothiocyanate (5.0g, 33.5mmol) and acetonitrile (18mL, 0.345mol) in THF (100mL) at -78 °C. The mixture was allowed to warm to r.t. over 3h. N,N-Dimethyluracil (4.62g, 33mmol) and EtOH (75mL) were added and the mixture heated at reflux for 3h then stirred at r.t. overnight. Volatiles were removed *in vacuo*. The residue was used crude in the next step without further purification.

Intermediate 23**3-Amino-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

A mixture of crude Intermediate 22 (half of material obtained above) and chloroacetonitrile (1.94mL) in acetonitrile (25mL) was heated at reflux for 5h. Volatiles were removed *in vacuo*. The residue was treated with water to give a solid which was filtered off and dried to give the title compound (3.0g). δ H

(DMSO-d₆) 8.16 (1H, d, *J* 9.6Hz), 7.7-7.5 (4H, m), 7.19 (2H, s), 6.6 (1H, d, *J* 9.6Hz), 2.0 (3H, s). LCMS (ES⁺) RT 2.932 minutes, 281.9 (M+H)⁺

Intermediate 24

5 **3-Bromo-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

Prepared from Intermediate 23 by the method of Intermediate 14. δ H (CDCl₃) 7.8 (1H, d, *J* 9.6Hz), 7.55-7.4 (4H, m), 6.8 (1H, d, *J* 9.6Hz), 2.12 (3H, s). LCMS (ES⁺) RT 4.10 minutes, no mass ion observed.

10

Intermediate 25

7-(2-Methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Prepared from Intermediate 24 and m-toluidine by the method of example 1.

15 LCMS (ES⁺) RT 3.64 minutes, 372.0 (M+H)⁺

Intermediate 26

Ethyl 3-bromo-7-(1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

20 A mixture of 5-indolyl boronic acid (644mg, 4mmol), Intermediate 4 (604mg, 2mmol) and copper (I) acetate (363mg, 2mmol) in pyridine (2mL) was stirred at r.t. overnight. The mixture was partitioned between DCM and 2M HCl aq. The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the

25 **title compound** as a pale tan solid (650mg, 78%). δ H (DMSO-d₆) 11.61 (1H, br s), 8.01 (1H, d, *J* 9.3Hz), 7.80 (1H, d, *J* 2.0Hz), 7.74 (1H, d, *J* 8.6Hz), 7.65 (1H, m), 7.23 (1H, dd, *J* 8.6, 2.0Hz), 6.81 (1H, d, *J* 9.6Hz), 6.68 (1H, m), 4.33 (2H, q, *J* 7.1Hz), 1.32 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.53 minutes, 419/420 (⁷⁹Br/⁸¹Br) (M+H)⁺.

Intermediate 27**Ethyl 3-bromo-7-[1-(methanesulfonyl)-1H-indol-5-yl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 5 Sodium hydride (60% in mineral oil) (58mg, 1.44mmol) was added to a solution of Intermediate 26 (500mg, 1.2mmol) in THF (30mL) at 0°C. The mixture was stirred for 5min at 0°C and 15min at r.t. then methanesulfonyl chloride (0.124mL, 1.6 mmol) was added and stirring continued at r.t. overnight. Solvent was removed *in vacuo* and the residue dissolved in
- 10 EtOAc. The EtOAc solution was washed with brine (x2), dried (MgSO₄), and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound (240mg, 40%). δ H (CDCl₃) 8.20 (1H, d, *J* 8.8Hz), 7.82 (1H, d, *J* 9.7Hz), 7.70 (1H, d, *J* 2.0Hz), 7.55 (1H, d, *J* 3.7Hz), 7.37 (1H, dd, *J* 8.8, 2.0Hz), 6.80 (1H, d, *J* 3.7Hz), 6.75 (1H, d, *J*
- 15 9.7Hz), 4.30 (2H, q, *J* 7.1Hz), 3.21 (3H, s), 1.31 (3H, t, *J* 7.1Hz).

Intermediate 28**Ethyl 3-bromo-7-(1-methyl-1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 20 From Intermediate 26 and methyl iodide by the method of Intermediate 27. δ H (CDCl₃) 7.77 (1H, d, *J* 9.7Hz), 7.56 (1H, s), 7.45 (1H, d, *J* 8.6Hz), 7.11-7.07 (2H, m), 6.68 (1H, d, *J* 9.7Hz), 6.51 (1H, s), 4.21 (2H, q, *J* 7.1Hz), 3.80 (3H, s), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.84 minutes, 4.32 (M+H)⁺.

Intermediate 29**Ethyl 3-bromo-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- Sodium hydride (60% in mineral oil)(3.27g, 81.4mmol) was added in portions to a solution of Intermediate 4 (22.3g, 74mmol) in DMF (300mL) at 0°C. The
- 30 mixture was stirred at r.t. for 30min then cyclopropylmethyl bromide (10g, 74mmol) was added slowly and the mixture heated at 60 °C overnight. The

DMF was removed *in vacuo* and the residue partitioned between EtOAc and brine. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 0% to 10% EtOAc in DCM) gave the title compound as a yellow solid (12.5g, 47%). δ H (CDCl₃) 7.57 (1H, d, *J* 9.5Hz), 6.47 (1H, d, *J* 9.5Hz), 4.22 (2H, q, *J* 7.0Hz), 3.87 (2H, d, *J* 7.1Hz), 1.26-1.19 (4H, m), 0.43-0.37 (4H, m). LCMS (ES⁺) RT 3.80 minutes, 357 (M+H)⁺.

Intermediate 30

10 3-Bromo-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 8 by the method of Intermediate 29. Off-white solid. δ H (CDCl₃) 7.67 (1H, d, *J* 9.6Hz), 6.68 (1H, d, *J* 9.6Hz), 4.02 (2H, d, *J* 7.1Hz), 1.36-1.23 (1H, m), 0.75-0.51 (4H, m). LCMS (ES⁺) RT 3.45 minutes, 309.0 (M+H)⁺.

Intermediate 31

Ammonium 3-anilino-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

20 A solution of Example 44 (1.38g, 3.75mmol) and NaOH (160mg, 4.0mmol) in EtOH (50mL) and water (20mL) was heated at reflux for 2h. The bulk of the EtOH was removed *in vacuo* and water (30mL) added. The solution was treated with 10% NH₄Cl aq (100mL) and cooled. The precipitate was filtered off and dried to give the title compound as an off-white solid (1.15g, 90%). δ H (DMSO-d₆) 7.03-6.98 (2H, m), 6.91 (1H, d, *J* 9.5Hz), 6.72-6.68 (3H, m), 6.02 (1H, d, *J* 9.5Hz), 3.70 (2H, d, *J* 7.0Hz), 1.16-1.03 (1H, m), 0.32-0.24 (4H, m).

Intermediate 32

30 Ethyl 3-bromo-6-(cyclopropylmethoxy)thieno[2,3-b]pyridine-2-carboxylate

A mixture of intermediate 4 (5.0g, 16.5mmol), caesium carbonate (5.39g, 16.5mmol) and cyclopropylmethyl bromide (1.58mL, 16.5mmol) in DMF (150mL) was heated at 90 °C for 3 days. EtOAc was added and the solution washed with brine, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 20% EtOAc in hexane) gave the title compound (2.64g, 45%). δ H (CDCl₃) 7.95 (1H, d, *J* 8.85Hz), 6.81 (1H, d, *J* 8.88Hz), 4.34 (2H, q, *J* 7.2Hz), 4.18 (2H, d, *J* 8.8Hz), 1.35 (3H, t, *J* 7.1Hz), 1.26-1.22 (1H, m), 0.58 (2H, dd, *J* 4.8, 5.4Hz), 0.31-0.27 (2H, m). LCMS (ES⁺) RT 5.43 minutes, 357 (M+H)⁺

10

Intermediate 33

Ethyl 3-anilino-6-(cyclopropylmethoxy)thieno[2,3-b]pyridine-2-carboxylate

A mixture of Intermediate 32 (2.0g, 5.6mmol), aniline (0.61mL, 6.72mmol), caesium carbonate (2.55g, 7.8mmol), BINAP (690mg, 20mol%) and tris(dibenzylideneacetone)dipalladium(0) (510mg, 10mol%) in toluene (50mL) was heated at reflux for 3 days. Brine was added and the mixture extracted with EtOAc. The organic extract was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% EtOAc in hexane) gave the title compound (1.8g, 86%). δ H (CDCl₃) 8.72 (1H br s), 7.29-7.26 (2H, m), 7.18-7.13 (2H, m), 6.93-7.06 (3H, m), 6.39 (1H, d, *J* 9.01Hz), 4.22 (2H, q, *J* 7.1Hz), 4.05 (2H, d, *J* 7.2Hz), 1.26 (3H, t, *J* 7.1Hz), 0.48-0.46 (2H, m), 0.25-0.23 (2H, m).

25 Intermediate 34

Ethyl 3-anilino-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

Intermediate 33 (1.8g, 4.9mmol) was dissolved in MeOH (100mL), conc. HCl aq (10mL) was added and the mixture heated at reflux for 6h. The reaction mixture was extracted with CHCl₃ and the organic phase washed with brine, dried (MgSO₄) and concentrated *in vacuo* to give the title compound as a yellow solid (1.3g, 84%). δ H (CDCl₃) 8.75 (1H, br s), 7.34-7.20 (4H, m), 7.18-

30

7.02 (2H, m), 6.26 (1H, d, *J* 9.63Hz), 4.25 (2H, q, *J* 7.1Hz), 1.29 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.296 minutes, 314.9 (M+H)⁺

Intermediate 35

5 Ethyl 3-bromo-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

A mixture of intermediate 4 (2.36g, 7.5mmol), 2-thiophene boronic acid (2.0g, 15mmol) and copper (II) acetate (1.41g, 7.5mmol) in pyridine (3.7mL) was stirred at r.t. for 3 days. The mixture was diluted with DCM, washed with 2M HCl aq, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 50% EtOAc in hexane) gave the title compound (270mg). δ H (CDCl₃) 7.83 (1H, d, *J* 9.6Hz), 7.60-7.58 (2H, m), 7.18-7.16 (1H, m), 6.68 (1H, d, *J* 9.6Hz), 4.31 (2H, q, *J* 7.1Hz), 1.32 (3H, t, *J* 7.1Hz). LCMS (ES⁺) 386 (M+H)⁺

15

Intermediate 36

Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-(cyclopropylmethoxy)thieno[2,3-*b*]pyridine-2-carboxylate

From Intermediate 32 and 4-fluoro-3-methylaniline by the method of Intermediate 33. White solid. δ H (CDCl₃) 8.64 (1H, br s), 7.24-7.13 (1H, m), 6.82-6.75 (3H, m), 6.40 (1H, d, *J* 9.0Hz), 4.23 (2H, q, *J* 7.2Hz), 4.11 (2H, d, *J* 7.2Hz), 2.11 (3H, s), 1.27 (3H, t, *J* 7.2Hz), 1.20-1.11 (1H, m), 0.54-0.48 (2H, m), 0.26-0.20 (2H, m).

25 Intermediate 37

Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

From Intermediate 36 by the method of Intermediate 34. δ H (CDCl₃) 7.18-7.13 (3H, m), 6.95-6.84 (3H, m), 6.39 (1H, d, *J* 9.6Hz), 4.26 (2H, q, *J* 7.2Hz), 2.19 (3H, s), 1.30 (3H, t, *J* 7.2Hz). LCMS (ES⁺) RT 3.585 minutes, 346 (M+H)⁺

30

Intermediate 38**3-[(6-Methyl-1-oxidopyridin-2-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 5 Sodium hydride (330mg, 60% in mineral oil, 8.25mmol) was added to a suspension of Intermediate 11 (2g, 7.5mmol) in THF (150mL) and the mixture then heated to 70 °C for 5 min. 6-Chloropicoline N-oxide (1.13g, 8.25mmol) was added at r.t. and the mixture heated at 70 °C for 24h. The solvent was removed *in vacuo*. Purification of the residue by column
- 10 chromatography (silica, 50%THF in DCM to 40% MeOH in DCM) gave the title compound (1.54g, 55%). LCMS (ES⁺) RT 2.79 minutes, 375 (M+H)⁺.

Intermediate 39**Ethyl 3-bromo-7-[4-(methylthio)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 15 From Intermediate 4 and 4-thiomethylboronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.76 (1H, d, *J* 9.7Hz), 7.36 (2H, d, *J* 8.7Hz), 7.23 (2H, d, *J* 8.7Hz), 6.65 (1H, d, *J* 9.7Hz), 4.26 (2H, q, *J* 7.1Hz), 2.48 (3H, s), 1.27 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.91 minutes, 426 (M+H)⁺.

20

Intermediate 40**Ethyl 3-bromo-7-(4-formylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From Intermediate 4 and 4-formylphenylboronic acid by the method of Intermediate 5. δ H (CDCl₃) 10.03 (1H, s), 8.12-8.0 (2H, m), 7.85-7.78 (1H, m), 7.54 (2H, d, *J* 9.4Hz), 6.66 (1H, d, *J* 9.7Hz), 4.25 (2H, q, *J* 7.1Hz), 1.262 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.450 minutes, 408 (M+H)⁺.

25

Intermediate 41

- 30 **Ethyl 3-bromo-6-oxo-7-[4-(pyrrolidin-1-ylmethyl)phenyl]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

A mixture of Intermediate 40 (150mg, 0.36mmol), pyrrolidine (0.03mL, 0.36mmol) and sodium triacetoxyborohydride (117mg, 0.55mmol) in 1,2-dichloroethane (5mL) was heated at reflux overnight. The mixture was washed with sat NaHCO₃ aq. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% MeOH in DCM) gave the title compound (51mg, 31%). δ H (CDCl₃) 7.84 (2H, d, *J* 9.6Hz), 7.64 (2H, m), 7.30 (2H, m), 6.73 (2H, d, *J* 9.6Hz), 4.13 (2H, q, *J* 7.1Hz), 2.85 (1H, t, *J* 5.8Hz), 3.19 (5H, br s), 1.35 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 2.367 minutes, 463 (M+H)⁺.

10

Intermediate 42**Ethyl 3-bromo-7-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate**

From Intermediate 4 and (4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)boronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.75 (1H, d, *J* 9.6Hz), 7.17 (2H, d, *J* 8.8Hz), 6.96 (2H, d, *J* 8.8Hz), 6.64 (1H, d, *J* 9.6Hz), 4.26 (2H, q, *J* 7.1Hz), 1.27 (3H, t, *J* 7.1Hz), 0.94 (9H, s), 0.20 (6H, s). LCMS (ES⁺) RT 3.405 minutes, 508/510 (⁷⁹Br/⁸¹Br) (M+H)⁺.

20 **Intermediate 43****Ethyl 7-(4-[[*tert*-butyl(dimethyl)silyl]oxy]phenyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate**

From Intermediate 42 and 2,4-difluoroaniline by the method of Example 1. δ H (CDCl₃) 8.45 (1H, br s), 7.20-7.10 (3H, m), 7.00-6.77 (5H, m), 6.29 (1H, d, *J* 9.8Hz), 4.20 (2H, q, *J* 7.1Hz), 1.23 (3H, t, *J* 7.1Hz), 0.94 (9H, s), 0.20 (6H, s). LCMS (ES⁺) RT 3.890 minutes, 557 (M+H)⁺.

30 **Intermediate 44****Ethyl 3-[(2,4-difluorophenyl)amino]-7-(4-hydroxyphenyl)-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate**

Tetra butyl ammonium fluoride (483mg, 1.85mmol) was added to a solution of Intermediate 43 (1.0g, 1.80mmol) in THF (20mL). After 15min the reaction mixture was partitioned between EtOAc (50mL) and water (50mL). The organic phase was washed with brine, dried (MgSO₄) and concentrated *in vacuo* to give the title compound (745mg, 95%). δ H (DMSO-d₆) 8.65 (1H, br s), 7.50-7.27 (4H, m), 7.20-7.10 (2H, m), 6.99 (2H, d, *J* 8.8Hz), 6.40 (1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.1Hz), 1.21 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.590 minutes, 443 (M+H)⁺.

10 **Intermediate 45**

Ethyl 7-[4-(2-bromoethoxy)phenyl]-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

Di-isopropyl azodicarboxylate (0.334mL, 1.70mmol) was added to a solution of Intermediate 44 (500mg, 1.13mmol) and triphenylphosphine (445mg, 1.70mmol) in a mixture of DCM (10mL) and THF (5mL). 2-Bromoethanol (0.125mL, 1.70mmol) was added and the mixture stirred for 3 days. Water (30mL) was added and the organic phase dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% EtOAc in DCM) gave the title compound (375mg, 60%). δ H (CDCl₃) 8.40 (1H, br s), 7.18-7.11 (2H, m), 7.03-6.87 (4H, m), 6.81-6.68 (2H, m), 6.19 (1H, d, *J* 9.8Hz), 4.19 (2H, t, *J* 6.2Hz), 4.09 (2H, q, *J* 7.1Hz), 3.50 (2H, t, *J* 6.2Hz), 1.12 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.206 minutes, 549/551 (⁷⁹Br/⁸¹Br) (M+H)⁺.

Intermediate 46

25 **Ethyl 3-bromo-6-oxo-7-(4-vinylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 4 and (4-vinylphenyl)boronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.95 (1H, d, *J* 9.7Hz), 7.76-7.73 (2H, m), 7.47-7.44 (2H, m), 6.90 (1H, dd, *J* 17.6, 11.1Hz), 6.83 (1H, d, *J* 9.7Hz), 5.96 (1H, dd, *J* 17.6, 0.4Hz), 5.51 (1H, d, *J* 11.1Hz), 4.43 (2H, q, *J* 7.1Hz), 1.44 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.947 minutes, 404/406 (⁷⁹Br/⁸¹Br) (M+H)⁺.

Intermediate 47**3-Bromo-7-(4-([tert-butyl(dimethyl)silyl]oxy)phenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 5 From Intermediate 8 and (4-([tert-butyl(dimethyl)silyl]oxy)phenyl)boronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.52 (1H, d, *J* 9.6Hz), 7.05-6.99 (2H, m), 6.84-6.79 (2H, m), 6.54 (1H, d, *J* 9.6Hz), 0.80 (9H, s), 0.05 (6H, s). LCMS (ES⁺) RT 4.65 minutes, 461/463 (⁷⁹Br/⁸¹Br) (M+H)⁺.

10 **Intermediate 48**

7-(4-([tert-Butyl(dimethyl)silyl]oxy)phenyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- From Intermediate 47 and 2,4-difluoroaniline by the method of Example 1. δ H (CDCl₃) 7.14 (1H, d, *J* 9.7Hz), 7.04-7.00 (2H, m), 6.95-6.87 (1H, m), 6.80-6.63 (4H, m), 6.32 (1H, d, *J* 9.7Hz), 5.93 (1H, br s), 0.78 (9H, s), 0.04 (6H, s). LCMS (ES⁺) RT 4.81 minutes, 510 (M+H)⁺.

Intermediate 49

20 **3-[(2,4-Difluorophenyl)amino]-7-(4-hydroxyphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 48 by the method of Intermediate 44. δ H (d₃-MeOD) 8.14 (1H, d, *J* 9.6Hz), 7.54-7.32 (3H, m), 7.22-7.06 (4H, m), 6.74 (1H, d, *J* 9.6Hz). LCMS (ES⁺) RT 3.113 minutes, 396 (M+H)⁺.

25

Intermediate 50**3-[(2,4-Difluorophenyl)amino]-7-{4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl}-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 30 A mixture of Intermediate 49 (370mg, 0.94mmol), (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate (538mg, 1.88mmol) and

caesium carbonate (365mg, 1.1mmol) in DMF (2mL) was heated at 80 °C for 3 days. The mixture was partitioned between EtOAc and brine. The Organic phase was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 20% EtOAc in DCM) gave the title compound

- 5 (54mg). δ H (CDCl₃) 7.32-7.20 (3H, m), 7.12-7.02 (3H, m), 6.93-6.78 (2H, m), 6.49 (1H, d, *J* 9.7Hz), 6.12 (1H, s), 4.49-4.41 (1H, m), 4.15-3.84 (4H, m), 1.41 (3H, s), 1.35 (3H, s). LCMS (ES⁺) RT 3.516 minutes, 510 (M+H)⁺.

Intermediate 51

- 10 Ethyl 3-bromo-7-(2-nitrophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

Sodium hydride (440mg, 60% in mineral oil, 11mmol) was added portion-wise to a suspension of intermediate 4 (3.02g, 10mmol) in DMF (40mL) at r.t. After 15min, 2-fluoronitrobenzene (2.11mL, 20mmol) was added and the

- 15 mixture heated at 90 °C for 4 days. The DMF was removed *in vacuo* and the residue purified by column chromatography (silica, 0% to 3% THF in DCM). The title compound was obtained as a yellow solid (1.36g, 32%). δ H (DMSO-d₆) 8.37 (1H, dd, *J* 1.4, 8.1Hz), 8.10-8.06 (1H, m), 8.01-7.92 (3H, m), 6.71 (1H, d, *J* 9.7Hz), 4.27 (2H, q, *J* 7.1Hz), 1.24 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT
20 3.644 minutes, 424.9 (M+H)⁺.

Intermediate 52

Sodium 3-[(2,4-difluorophenyl)amino]-7-(2-nitrophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- 25 A mixture of Example 95 (405mg, 0.86mmol) and sodium hydroxide (38mg, 0.946mmol) in water (5mL) and EtOH (10mL) was heated at reflux for 90min. The solvent was removed *in vacuo* to give a brown solid, crude title compound. This was used in the next step without purification. LCMS (ES⁺) RT 3.262 minutes, 443.8 (M+H)⁺.

Intermediate 53**2-Amino-4-methyl-6-oxo-1-phenyl-1,6-dihydro-pyridine-3-carbonitrile**

The title compound was prepared according to Habashi et al, Liebigs Ann.

- 5 Chem. 1986, 1632-1638. δ H (DMSO- d_6) 7.63-7.45 (3H, m), 7.25 (2H, m), 6.70 (2H, br s), 5.68 (1H, s), 2.18 (3H, s). LCMS(Conditions B) (ES^+) RT 1.97 minutes, 226 (M+H) $^+$.

Intermediate 54

- 10 **2,5-Dibromo-4-methyl-6-oxo-1-phenyl-1,6-dihydro-pyridine-3-carbonitrile**

- To a stirred mixture of copper (II) bromide (10.35g) and *tert.* butyl nitrite (6.6mL) in acetonitrile (75mL), was added Intermediate 53 (7.45g) portionwise over 15 minutes. The resulting mixture was stirred at ambient
- 15 temperature for a further 2 hours when it was poured into 2M HCl(aq) (100mL). Ethyl acetate (150mL) was added and the mixture stirred for approximately one hour. After this time, the layers were separated and the aqueous phase was re-extracted with ethyl acetate (50mL). The combined organic extracts were washed with 2M HCl(aq) (100mL). Any insoluble
- 20 material was removed by filtration and the resulting filtrate was washed with brine and then concentrated *in vacuo*. The residue was purified by chromatography on silica eluting with DCM to give the title compound as a pale green solid (5.63g). δ H ($CDCl_3$) 7.55 (3H, m), 7.17 (2H, m), 2.65 (3H, s). LCMS (Conditions B) (ES^+) RT 3.59 minutes, 369 (M+H) $^+$.

25

Intermediate 55**Ethyl 3-amino-5-bromo-4-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- A mixture of Intermediate 54 (5.6g), ethyl 2-mercaptoacetate (2.1mL) and
- 30 sodium carbonate (1.70g) in absolute ethanol (56mL) was heated at reflux for 2.5 hours. After this time, the reaction was cooled to ambient temperature,

water (56mL) was added and the resulting mixture stirred for an additional hour. The product was collected by filtration, washed with water and dried *in vacuo* to give the title compound as an off-white solid (5.83g). δ H (CDCl₃) 7.55 (3H, m), 7.35 (2H, m), 6.15 (2H, br s), 4.25 (2H, q, *J* 7.0Hz), 2.86 (3H, s), 1.28 (3H, t, *J* 7.0Hz). LCMS (Conditions B) (ES⁺) RT 3.77 minutes, 407 (M+H)⁺.

Intermediate 56

Ethyl 3-amino-4-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

To a solution of Intermediate 55 (5.83g) in DCM (650mL) containing triethylamine (4mL), was added 5% palladium on carbon (Johnson Matthey type 38H paste; 0.58g) and the resulting mixture was stirred under a hydrogen atmosphere until hydrogen uptake ceased. The catalyst was removed by filtration and the organic phase washed with water (twice), and then evaporated *in vacuo* to leave the title compound as a white solid (4.73g). δ H (CDCl₃) 7.57 (3H, m), 7.35 (2H, m), 6.36 (1H, s), 6.09 (2H, br s), 4.25 (2H, q, *J* 7.0Hz), 2.63 (3H, s), 1.26 (3H, t, *J* 7.0Hz). LCMS (Conditions B) (ES⁺) RT 3.41 minutes, 329 (M+H)⁺.

Intermediate 57

Ethyl 3-bromo-4-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

To a stirred mixture of copper (II) bromide (2.9g) and *tert.* butyl nitrite (1.84mL) in acetonitrile (90mL), was added Intermediate 56 (3.05g) portionwise over 15 minutes. The resulting mixture was stirred at ambient temperature for a further 0.5h when 2M HCl(aq) (150mL) was added. The reaction mixture was extracted with ethyl acetate (twice) and the combined organic extracts were washed with water (75mL), brine (100mL) and then dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by chromatography on silica eluting with DCM to give the title compound as an

off-white solid (1.23g). δ H (CDCl₃) 7.63 (3H, m), 7.35 (2H, m), 6.53 (1H, s), 4.30 (2H, q, *J* 7.0Hz), 2.79 (3H, s), 1.32 (3H, t, *J* 7.0Hz). LCMS (Conditions B) (ES⁺) RT 3.98 minutes, 392 (M+H)⁺.

5 **Intermediate 58**

3-[(2,4-Difluorophenyl)amino]-7-phenylthieno[2,3-*b*]pyridin-6(7*H*)-one

From Intermediate 67 by the method of Example 15. δ H (CDCl₃) (DMSO-*d*6) 7.94 (1H, d, *J* 9.4Hz), 7.64-7.53 (3H, m), 7.46 (2H, m), 7.45 (1H, m), 7.20 (1H, m), 6.99 (1H, m), 6.48 1H, d, *J* 9.4Hz), 5.74 (1H, s). LCMS (ES⁺) RT 3.54 minutes, 354.9 (M+H)⁺.

Intermediate 59

tert-Butyl (2,4-difluorophenyl)(6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridin-3-yl)carbamate

15 Sodium bis(trimethylsilyl)amide (6.0mL, 1.0M in THF, 6mmol) was added to a solution of Intermediate 58 (2.0g, 5.65mmol) in THF (50mL) at 0 °C. After 30 min, di-*tert*-butyl dicarbonate (1.36g, 6.22mmol) was added and the mixture stirred at r.t. for 1h. The reaction mixture was partitioned between EtOAc and brine. The aqueous phase was extracted with EtOAc (x3), the combined
20 organic extracts washed with brine, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound (1.2g, 47%). δ H (CDCl₃) 7.45 (1H, d, *J* 9.5Hz), 7.43-7.30 (3H, m), 7.22-7.19 (2H, m), 7.08-7.03 (1H, m), 6.76-6.65 (2H, m), 6.49-6.45 (2H, m), 1.26 (9H, s). LCMS (ES⁺) RT 3.79 minutes, 455 (M+H)⁺.

25

Intermediate 60

tert-Butyl [2-(aminosulfonyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridin-3-yl](2,4-difluorophenyl)carbamate

n-Butyl lithium (0.18mL of a 2.5M solution in hexanes, 0.44mmol) was added
30 to a solution of Intermediate 59 (200mg, 0.44mmol) in THF (10mL) at -78 °C. After 3 min, sulfur dioxide gas was bubbled through the solution for 2 min.

- The reaction mixture was allowed to warm to r.t. and solvents were removed *in vacuo*. The residue was dissolved in DCM (15mL) and N-chlorosuccinimide (60mg, 0.44mmol) was added. After 20 min at r.t. aqueous ammonia (conc) (5mL) was added and the mixture stirred for a further 10min.
- 5 The mixture was diluted with DCM and washed with brine. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound (50mg, 21%). δ H (CDCl₃) 7.42-7.36 (3H, m), 7.23-7.16 (4H, m), 6.81-6.77 (1H, m), 6.75-6.63 (1H, m), 6.39 (1H, d, *J* 10.3Hz), 5.43 (2H, br s), 1.27 (9H, s). LCMS
- 10 (ES⁺) RT 3.58 minutes, 534 (M+H)⁺.

Intermediate 61

Ethyl 3-bromo-7-[2-(2-methoxyethoxy)ethyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- 15 Sodium hydride (60% in mineral oil, 240mg, 6mmol) was added to a suspension of Intermediate 4 (1.50g, 4.97mmol) in DMF (12mL). After 10min at r.t., bromomethoxyethoxyethane (1.0g, 5.5mmol), was added and the mixture heated at 60 °C for 4h. The mixture was partitioned between brine (200mL) and DCM (200mL). The organic phase was washed with brine (2 x
- 20 100mL), dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% to 15% THF in DCM) gave the title compound as a white solid (420mg, 21%). δ H (CDCl₃) 7.78 (1H, d, *J* 9.6Hz), 6.65 (1H, d, *J* 9.6Hz), 4.42 (2H, q, *J* 7.1Hz), 7.38-7.34 (2H, m), 3.96-3.07 (2H, m), 3.68-3.64 (2H, m), 3.48-3.45 (2H, m), 3.32 (3H, s), 1.41 (3H, t, *J* 7.1Hz).

25

Intermediate 62

Ethyl 3-bromo-6-oxo-7-(tetrahydro-2H-pyran-2-ylmethyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- Sodium hydride (60% in mineral oil, 320mg, 8mmol) was added to a
- 30 suspension of Intermediate 4 (2.0g, 6.67mmol) in DMF (15mL). After 10min at r.t., 2-(bromomethyl)-tetrahydro-2H-pyran (0.895mL, 7mmol), was added

and the mixture heated at 80 °C for 18h. The mixture was partitioned between brine (200mL) and EtOAc (120mL). The organic phase was washed with brine (3 x 75mL), dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 0% to 10% EtOAc in DCM) gave the title compound as a white solid (642mg, 24%). δ H (CDCl₃) 7.76 (1H, d, *J* 9.6Hz), 6.63 (1H, d, *J* 9.6Hz), 4.45-4.30 (3H, m), 3.93-3.78 (3H, m), 3.32-3.26 (1H, m), 1.90-1.86 (1H, m), 1.77-1.74 (1H, m), 1.66-1.38 (4H, m), 1.42 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.90 minutes, 440.0/402.0 (⁷⁹Br/⁸¹Br) (M+H)⁺.

10 **Intermediate 63**

Ethyl 3-bromo-7-benzyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 4 and benzyl bromide by the method of Intermediate 61.

δ H (CDCl₃) 7.80 (1H, d, *J* 9.6Hz), 7.41-7.32 (5H, m), 6.74 (1H, d, *J* 9.6Hz), 5.37 (2H, s), 4.38 (2H, q, *J* 7.1Hz), 1.40 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.89 minutes, 392.0/394.0 (⁷⁹Br/⁸¹Br) (M+H)⁺.

Intermediate 64

Ammonium 3-anilino-7-benzyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Example 102 by the method of Intermediate 31. δ H (DMSO-d₆) 7.47-7.25 (9H, m), 7.19-7.02 (3H, m), 6.43 (1H, d, *J* 9.6Hz), 5.35 (2H, s).

Intermediate 65

25 **Ethyl 3-bromo-7-[4-(dimethylamino)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 4 and 4-(dimethylamino)phenylboronic acid by the method of Intermediate 5. Light tan solid. δ H (CDCl₃) 7.68 (1H, d, *J* 9.7Hz), 7.08 (2H, d, *J* 9.0Hz), 6.71 (2H, d, *J* 9.0Hz), 6.59 (1H, d, *J* 9.7Hz), 4.20 (2H, q, *J*

30 7.1Hz), 2.93 (6H, s), 1.21 (3H, t, *J* 7.1Hz).

Intermediate 66**Ammonium 3-anilino-7-[4-(dimethylamino)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 5 From Example 105 by the method of Example 31. δ H (DMSO-d₆) 7.26-7.17 (6H, m), 6.93-6.89 (2H, m), 6.83 (2H, d, *J* 9.0Hz), 6.26 (1H, d, *J* 9.6Hz), 2.97 (6H, s). LCMS (ES⁺) RT 3.30 minutes, 406 (M+H)⁺.

Intermediate 67

- 10 **Ammonium 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Example 12 by the method of Intermediate 31. δ H (DMSO-d₆) 9.75 (1H, br s), 7.75-7.50 (3H, m), 7.49-7.37 (2H, m), 7.31-7.27 (2H, m), 7.00-6.80 (2H, br m), 6.35-6.31 (1H, br m). LCMS (ES⁺) RT 3.25 minutes, no (M+H)⁺ observed.

Intermediate 68**Ethyl 3-bromo-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 20 From Intermediate 4 and 4-fluorophenylboronic acid by the method of Intermediate 5. White solid. δ H (CDCl₃) 7.84 (1H, d, *J* 9.7Hz), 7.41-7.37 (2H, m), 7.32-7.25 (2H, m), 6.72 (1H, d, *J* 9.7Hz), 4.33 (2H, q, *J* 7.1Hz), 1.34 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.729 minutes, 397.8 (M+H)⁺.

- 25 **Intermediate 69**

Ethyl 3-bromo-7-(4-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 4 and 4-chlorophenylboronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.86 (1H, d, *J* 9.6Hz), 7.60 (2H, d, *J* 8.5Hz), 7.37

(2H, d, *J* 8.5Hz), 6.74 (1H, d, *J* 9.6Hz), 4.35 (2H, q, *J* 7.1Hz), 1.36 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.937 minutes, 413 (M+H)⁺.

Intermediate 70

5 **Ethyl 3-bromo-7-(3-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 4 and 3-methylphenylboronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.85 (1H, d, *J* 9.6Hz), 7.51-7.48 (1H, m), 7.38-7.27 (1H, m), 7.29 (2H, br m), 6.75 (1H, d, *J* 9.6Hz), 4.34 (2H, q, *J* 7.1Hz), 10 2.46 (3H, s), 1.35 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.865 minutes, 393 (M+H)⁺.

Intermediate 71

15 **3-[(3-(trifluoromethyl)phenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 3-(trifluoromethyl)aniline by the method of Example 1. LCMS (ES⁺) RT 3.63 minutes, 412 (M+H)⁺.

Intermediate 72

20 **3-Bromo-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 8 and 4-fluorophenylboronic acid by the method of Intermediate 5. δ H (DMSO-d₆) 8.1-8.0 (1H, m), 7.8-7.7 (2H, m), 7.65-7.6 (2H, m), 6.9-6.85 (1H, m). LCMS (ES⁺) RT 3.460 minutes, 350.8 (M+H)⁺.

25

Intermediate 73

3-Bromo-7-(4-methoxyphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 8 and 4-methoxyphenylboronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.53 (1H, d, *J* 9.7Hz), 7.10-7.05 (2H, m), 6.92-

30

6.87 (2H, m), 6.56 (1H, d, J 9.7Hz), 3.69 (3H, s). LCMS (ES⁺) RT 3.452 minutes, 361/363 (⁷⁹Br/⁸¹Br) (M+H)⁺.

Intermediate 74

5 **7-(4-Acetylphenyl)-3-bromo-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 8 and 4-acetylphenylboronic acid by the method of Intermediate 5. δ H (CDCl₃) 7.98 (2H, d, J 8.7Hz), 7.55 (1H, d, J 9.7Hz), 7.29 (2H, d, J 8.7Hz), 6.56 (1H, d, J 9.7Hz), 2.46 (3H, s). LCMS (ES⁺) 375 (M+Na)⁺.

Intermediate 75

Ammonium 3-[(3-chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

15 From Example 129 by the method of Intermediate 31. δ H (DMSO-d₆) 7.65-7.59 (3H, m), 7.52-7.50 (2H, m), 7.34-7.29 (2H, m), 7.10-7.21 (3H, br m), 6.99-6.95 (1H, m), 6.40 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 3.363 minutes.

Intermediate 76

20 **Ammonium 3-[(4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Example 127 by the method of Intermediate 31.

Intermediate 77

25 **Ammonium 3-[(3-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Example 3 by the method of Intermediate 31. δ H (DMSO-d₆) 7.65-7.57 (3H, m), 7.51-7.49 (2H, m), 7.34 (1H, d, J 9.6Hz), 7.28-7.22 (1H, m), 7.00-6.99 (1H, m), 6.96-6.89 (2H, m), 6.39 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 3.372 minutes, 396.8 (M+H)⁺.

Intermediate 78**tert-Butyl (imino{3-[(3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)methyl}carbamate**

- A solution of ethyl magnesium bromide (1M, 2.8mL, 2.8mmol) was added to
5 tert-butyl carbamate (328mg, 2.8mmol) in ether at r.t. After 10min, Example
139 (200mg, 0.56mmol) was added and the mixture heated at reflux for 1h.
THF (7mL) was added and the mixture heated at 60 °C for 18h. Water was
added and the mixture was extracted with DCM. The organic phase was
dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column
10 chromatography (silica, Et₂O) gave the title compound as a yellow solid
(46mg). δ H (CDCl₃) 9.53 (1H, s), 7.58-7.45 (3H, m), 7.34 (2H, d, *J* 7.7Hz),
7.19-7.12 (2H, m), 6.88-6.80 (3H, m), 6.29 (1H, d, *J* 9.7Hz), 2.27 (3H, s),
1.41 (9H, s). LCMS (ES⁺) RT 3.343 minutes, 475 (M+H)⁺.

Intermediate 79**Pentafluorophenyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- CDI (1.42g, 7.42mmol) was added to a solution of Intermediate 67 (2.5g,
6.18mmol) in DMF (100mL). After 20min, pentafluorophenol (1.71g,
9.27mmol) was added and the mixture stirred at r.t. overnight. Solvent was
20 removed *in vacuo*, the residue partitioned between DCM and water and the
aqueous phase was extracted with DCM. The combined organics were dried
(MgSO₄) and concentrated *in vacuo*. Purification by column chromatography
(silica, 20% to 100% EtOAc in hexane) gave the title compound as a white
25 solid (666mg, 19%). δ H (CDCl₃) 8.66 (1H, br s), 7.76 (3H, m), 7.58 (2H, m),
7.47 (1H, m), 7.14 (3H, m), 6.54 (1H, d, *J* 9.9Hz). LCMS (ES⁺) RT 4.57
minutes, 564.9 (M+H)⁺.

Intermediate 80

- 30 **2-[4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]propan-2-ol**

A mixture of 2-(4-bromophenyl)propan-2-ol (3.50g, 16.3mmol), bis(neopentylglycolato)diboron (4.05g, 17.93mmol), KOAc (2.40g, 24.45mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (665mg, 0.815mmol) in DMF (25mL) was heated at 60 °C for 18h. The DMF was removed *in vacuo* and the residue azeotroped with toluene (x 3). The residue was dissolved in Et₂O, filtered, and the filtrate concentrated *in vacuo* to give the title compound as a brown solid (3.08g). δ H (CDCl₃) 7.70 (2H, d, *J* 9.8Hz), 7.41 (2H, d, *J* 9.8Hz), 3.69 (4H, s), 1.51 (6H, s), 0.95 (6H, s).

10

Intermediate 81**Ethyl 3-bromo-7-[4-(1-hydroxy-1-methylethyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 4 and Intermediate 80 by the method of Intermediate 5.

15 White solid. δ H (CDCl₃) 7.77 (1H, d, *J* 9.7Hz), 7.66 (2H, d, *J* 8.5Hz), 7.28 (2H, d, *J* 8.5Hz), 6.66 (1H, d, *J* 9.6Hz), 4.26 (2H, q, *J* 7.1Hz), 1.75 (1H, br s), 1.58 (6H, s), 1.27 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.41 minutes, 438 (M+H)⁺.

20 **Intermediate 82****Ethyl 3-bromo-7-[4-[(*tert*-butoxycarbonyl)amino]phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 4 and {4-[(*tert*-butoxycarbonyl)amino]phenyl}boronic acid

by the method of Intermediate 5. δ H (CDCl₃) 8.85 (1H, d, *J* 8.8Hz), 7.61 (2H, d, *J* 8.8Hz), 7.32 (2H, d, *J* 8.8Hz), 6.75 (1H, s), 6.73 (1H, d, *J* 9.6Hz), 4.34 (2H, q, *J* 7.1Hz), 1.56 (9H, s), 1.36 (3H, t, *J* 7.1Hz).

Intermediate 83**Ethyl 7-[4-[(*tert*-butoxycarbonyl)amino]phenyl]-3-[(2,4-**

30 **difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From Intermediate 82 and 2,4-difluoroaniline by the method of Example 1. δ H (CDCl₃) 8.56 (1H, s), 7.78 (2H, d, *J* 9.8Hz), 7.45 (2H, d, *J* 8.6Hz), 7.35-7.28 (1H, m), 7.20 (1H, d, *J* 9.8Hz), 7.14-6.99 (2H, m), 6.84 (1H, s), 6.51 (1H, d, *J* 9.8Hz), 4.41 (2H, q, *J* 7.1Hz), 1.69 (9H, s), 1.45 (3H, t, *J* 7.1Hz). LCMS (ES⁺)
- 5 RT 4.288 minutes, 542 (M+H)⁺.

Intermediate 84

Ethyl 7-(4-aminophenyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- 10 Trifluoroacetic acid (0.5mL) was added to a solution of Intermediate 83 in DCM (2mL). After 1h at r.t., the solvent was removed *in vacuo* and the residue azeotroped with heptane. The residue was dissolved in DCM and the solution washed with aq NaHCO₃. The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica,
- 15 EtOAc) gave the title compound (72mg, 82%). δ H (CDCl₃) 8.30 (1H, s), 7.05-6.97 (3H, m), 6.89 (1H, d, *J* 9.7Hz), 6.83-6.68 (3H, m), 6.66 (1H, d, *J* 8.6Hz), 6.20 (1H, d, *J* 9.8Hz), 4.11 (2H, q, *J* 7.1Hz), 3.80 (2H, br s), 1.14 (3H, t, *J* 7.1Hz).

Intermediate 85

Ethyl 7-(4-[bis(methylsulfonyl)amino]phenyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- A mixture of Intermediate 84 (70mg, 0.16mmol), methanesulfonylchloride (18mg, 0.16mmol) and triethylamine (0.023mL, 0.16mmol) in DCM (2mL)
- 25 was stirred overnight at r.t. The volatiles were removed *in vacuo* and the residue dissolved in DCM. The solution was washed with aq NaHCO₃, dried (Na₂SO₄), and concentrated *in vacuo*. Purification by column chromatography (silica, EtOAc) gave the title compound (50mg, 53%). δ H
- 30 (CDCl₃) 8.50 (1H, s), 7.51 (2H, d, *J* 6.5Hz), 7.45 (2H, d, *J* 6.5Hz), 7.11 (1H, m), 7.01 (1H, d, *J* 9.8Hz), 6.93-6.72 (2H, m), 6.30 (1H, d, *J* 9.8Hz), 4.22 (2H,

q, J 7.1 Hz), 3.39 (6H, s), 1.25 (3H, t, J 7.1 Hz). LCMS (ES⁺) RT 3.704 minutes, 598 (M+H)⁺.

Intermediate 86

5 Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

From Intermediate 5 and 4-fluoro-3-methylaniline by the method of Example

1. White solid. δ H (DMSO-*d*₆) 8.72 (1H, s), 7.67-7.60 (3H, m), 7.51-7.49 (2H, m), 7.18-7.10 (3H, m), 7.09-6.99 (1H, m), 6.39 (1H, d, J 9.7 Hz), 4.15 (2H, q, J 7.07 Hz), 2.22 (3H, s), 1.72 (3H, t, J 7.08 Hz). LCMS (ES⁺) 423 (M+H)⁺.

Intermediate 87

Ammonium 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

- 15 From Intermediate 86 by the method of Intermediate 31 Beige solid. δ H (DMSO-*d*₆) 7.81-7.75 (3H, m), 7.64-7.62 (2H, m), 7.41-7.38 (1H, d, J 9.55 Hz), 7.20-7.15 (1H, t, J 9.01 Hz), 7.04-7.03 (1H, br m), 6.93-6.90 (1H, br m), 6.48-6.46 (1H, d, J 9.54 Hz), 2.35 (3H, s). LCMS (ES⁺) 395 (M+H)⁺.

20 Intermediate 88

Pentafluorophenyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

EDC (0.163g, 0.852mmol) was added to a solution of Intermediate 87 (0.284g, 0.710mmol) in DMF (10mL) and the mixture stirred at r.t. for 30 min.

- 25 Pentafluorophenol (0.196g, 1.065mmol) was added and the mixture stirred at r.t. for 24hr. The solvent was removed *in vacuo* and the residue was dissolved in DCM which was then washed with water, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 50 % Hexane/ EtOAc) to produce the title compound as a white solid (0.226g). δ H (DMSO-*d*₆) 8.96 (1H, s), 7.07-6.95 (5H, br m), 7.55-7.39 (4H, br m), 6.29 (1H, d, J 9.86 Hz), 2.08 (3H, s). LCMS (ES⁺) 561 (M+H)⁺.

Intermediate 89**2-Acetyl-3-amino-7-phenylthieno[2,3-b]pyridin-6(7H)-one**

A mixture of Intermediate 10 (2.5g, 10mmol) and chloroacetone (0.88mL, 11mmol) in acetonitrile (45mL) was heated at 50 °C for 2h. The solvent was removed *in vacuo* and purification by column chromatography (silica, 2.5% to 3% MeOH in DCM) gave the title compound as a yellow solid (2.32g, 82%).
δH (DMSO-d₆) 8.27 (1H, d, *J* 9.6Hz), 7.92 (2H, br s), 7.72-7.63 (3H, m), 7.59-7.50 (2H, m), 6.61 (1H, d, *J* 9.6Hz), 2.18 (3H, s). LCMS (ES⁺) RT 2.883 minutes, 284.9 (M+H)⁺.

Intermediate 90**2-Acetyl-3-bromo-7-phenylthieno[2,3-b]pyridin-6(7H)-one**

From Intermediate 89 by the method of Intermediate 14. Light brown solid.
δH (DMSO-d₆) 7.98 (1H, d, *J* 9.7Hz), 7.74-7.65 (3H, m), 7.59-7.56 (2H, m), 6.77 (1H, d, *J* 9.7Hz), 2.68 (3H, s). LCMS (ES⁺) RT 3.388 minutes, 349.8 (M+H)⁺.

Intermediate 91**3-Amino-6-oxo-7-pyridin-3-yl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

Acetonitrile (5mL) was added to a solution of sodium bis(trimethylsilyl)amide (16.1mL of 1M solution in THF, 16.1mmol) in THF (50mL) at -78 °C. Pyridylisothiocyanate (0.820mL, 7.34mmol) was added and the mixture allowed to warm to r.t. over 2h. EtOH (30mL) and N,N-dimethyluracil (1.03g, 7.34mmol) were added and the mixture heated at reflux for 18h. Volatiles were removed *in vacuo*. The residue was dissolved in acetonitrile (20mL), chloroacetonitrile (0.470mL, 7.34mmol) was added and the mixture heated at 50 °C for 3h. The bulk of the solvent was removed *in vacuo*, water (50mL) was added and the mixture cooled to 0 °C. The precipitate was filtered off, washed with water and ether and dried to give the title compound as a brown

solid (1.47g, 75%). δ H (DMSO- d_6) 8.80-8.64 (2H, m), 8.13-7.95 (2H, m), 7.60-7.56 (1H, m), 7.09 (2H, s), 6.48 (1H, d, J 9.5Hz). LCMS (ES⁺) RT 2.493 minutes, 268.9 (M+H)⁺.

5 **Intermediate 92**

3-Bromo-6-oxo-7-pyridin-3-yl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 91 by the method of Intermediate 14. LCMS (ES⁺) RT 2.954 minutes, 331.8 (M+H)⁺.

10

Intermediate 93

Benzyl 3-[(3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl)amino]pyrrolidine-1-carboxylate

- 15 To a solution of Intermediate 79 (250mg, 0.44mmol) in DCM (5mL) was added benzyl 3-amino-pyrrolidine-1-carboxylate (350mg, 1.6mmol) and the reaction stirred at room temperature for 18h. An additional equivalent of the aminopyrrolidine (96mg, 0.44mmol) was added and the reaction stirred for a further 18h. Solvent was then removed *in vacuo* and the crude residue
- 20 subject to column chromatography (silica, 60% EtOAc in isohexane) to give the title compound as a yellow oil (141mg, 53%). LCMS (ES⁺) RT 3.63 minutes, 601 (M+H)⁺.

Example 1

25 **Ethyl 3-(phenylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- Tris(dibenzylideneacetone)dipalladium(0) (12mg, 0.0133mmol, 5mol%) was added to a mixture of Intermediate 5 (100mg, 0.265mmol), caesium carbonate (120mg, 0.37mmol), aniline (0.030mL, 0.32mmol) and BINAP
- 30 (17mg, 0.027mmol, 10mol%) in anhydrous toluene (2mL) and the reaction heated to reflux under nitrogen for 18h. Solvent was removed *in vacuo* and

the crude residue purified by chromatography on silica (0-20% EtOAc in DCM) to give the title compound as a white solid (80mg). δ H (CDCl₃) 8.70 (1H, bs), 7.57-7.47 (3H, m), 7.33-7.25 (4H, m), 7.20-7.10 (4H, m), 6.27 (1H, d, *J* 9.7Hz), 4.19 (2H, q, *J* 7.1Hz), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.10 minutes, 391 (M+H)⁺.

General procedure for the preparation of Ethyl 3-anilino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylates

The compounds of Examples 2-13 were prepared by parallel synthesis using a Radleys Carousel reaction station (Radleys Ltd., Saffron Walden, U.K.) following a procedure similar to that described for Example 1. Therefore to each oven dried reaction tube in the Carousel was added a magnetic stirrer, the appropriate substituted aniline (0.64mmol), anhydrous toluene (3mL), Intermediate 5 (200mg, 0.53mmol), caesium carbonate (240mg, 0.74mmol) and tris(dibenzylideneacetone)dipalladium(0) (48mg, 0.053mmol, 10mol%) and BINAP (66mg, 0.106mmol, 20mol%). The reactions were heated to reflux under nitrogen and with magnetic stirring for 48h. Each reaction was then diluted with DCM (10mL), washed with water (10mL), dried (MgSO₄) and concentrated *in vacuo*. The crude products were purified on silica eluting with 0-20% EtOAc in DCM to give the title compounds as solids.

Example 2

Ethyl 3-[(2-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

From 2-chloroaniline to give the title compound (92mg). δ H (CDCl₃) 8.60 (1H, bs), 7.56-7.48 (3H, m), 7.40-7.38 (1H, m), 7.36-7.32 (2H, m), 7.20-7.15 (2H, m), 7.14-7.05 (1H, m), 7.05-6.98 (1H, m), 6.35 (1H, d, *J* 9.8Hz), 4.21 (2H q, *J* 7.1Hz), 1.23 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.38 minutes, 425 (M+H)⁺.

Example 3**Ethyl 3-[(3-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 5 From 3-chloroaniline to give the title compound (65mg). δ H (CDCl₃) 8.60 (1H, bs), 7.57-7.50 (3H, m), 7.36-7.30 (2H, m), 7.20-7.18 (1H, m), 7.18 (1H, d, *J* 9.7Hz), 7.05 (1H, d, *J* 1.5Hz), 7.05-7.04 (1H, m), 6.96-6.92 (1H, m), 6.35 (1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.1Hz), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.30 minutes, 425 (M+H)⁺.

10

Example 4**Ethyl 3-[(4-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From 4-chloroaniline to give the title compound (115mg). δ H (CDCl₃) 8.63
15 (1H, bs), 7.56-7.50 (3H, m), 7.34-7.31 (2H, m), 7.28-7.24 (2H, m), 7.12 (1H, d, *J* 9.8Hz), 7.02-6.99 (2H, m), 6.32 (1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.2Hz), 1.22 (3H, t, *J* 7.2Hz). LCMS (ES⁺) RT 4.32 minutes, 425 (M+H)⁺.

Example 5

- 20 **Ethyl 3-[methyl(phenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From N-methylaniline to give the title compound (53mg). δ H (CDCl₃) 7.61-7.43 (3H, m), 7.40-7.32 (2H, m), 7.26 (1H, d, *J* 9.6Hz), 7.22-7.10 (2H, m), 6.77 (1H, t, *J* 7.3Hz), 6.67 (2H, dd, *J* 8.7, 1.0Hz), 6.43 (1H, d, *J* 9.6Hz), 4.10
25 (2H, q, *J* 7.1Hz), 3.33 (3H, s), 1.11 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.01 minutes, 405 (M+H)⁺.

Example 6**Ethyl 3-[(2-methoxyphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 5 From 2-methoxyaniline to give the title compound (133mg). δ H (CDCl₃) 8.53 (1H, bs), 7.58-7.41 (3H, m), 7.36-7.29 (2H, m), 7.26 (1H, d, *J* 9.7Hz), 7.07-6.96 (2H, m), 6.89-6.75 (2H, m), 6.30 (1H, d, *J* 9.7Hz), 4.18 (2H, q, *J* 7.2Hz), 3.84 (3H, s), 1.22 (3H, t, *J* 7.2Hz). LCMS (ES⁺) RT 4.06 minutes, 421 (M+H)⁺.

10

Example 7**Ethyl 6-oxo-7-phenyl-3-[(3-trifluoromethoxyphenyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From 3-trifluoromethoxyaniline to give the title compound (60mg). δ H (CDCl₃)
15 8.66 (1H, bs), 7.58-7.41 (3H, m), 7.34 (2H, d, *J* 8.0Hz), 7.28 (1H, t, *J* 8.3Hz), 7.20 (1H, d, *J* 9.8Hz), 6.98-6.93 (1H, m), 6.92-6.83 (2H, m), 6.35 (1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.1Hz), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.39 minutes, 475 (M+H)⁺.

20 **Example 8****Ethyl 3-[(4-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From 4-cyanoaniline to give the title compound (110mg). δ H (CDCl₃) 8.59 (1H, bs), 7.61-7.45 (5H, m), 7.36-7.31 (2H, m), 7.28 (1H, d, *J* 9.7Hz), 7.02
25 (2H, d, *J* 8.6Hz), 6.43 (1H, d, *J* 9.7Hz), 4.20 (2H, q, *J* 7.1Hz), 1.23 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.71 minutes, 416 (M+H)⁺.

Example 9**Ethyl 3-[(3-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 5 From 3-cyanoaniline to give the title compound (100mg). δ H (CDCl₃) 8.58 (1H, bs), 7.61-7.43 (3H, m), 7.40-7.20 (6H, m), 7.14 (1H, d, *J* 9.8Hz), 6.38 (1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.1Hz), 1.23 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.78 minutes, 416 (M+H)⁺.

10 **Example 10**

Ethyl 3-[(2-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- From 2-cyanoaniline to give the title compound (133mg). δ H (CDCl₃) 8.72 (1H, bs), 7.61-7.47 (4H, m), 7.43-7.40 (1H, m), 7.36-7.31 (2H, m), 7.22-7.15 (1H, m), 7.11-7.00 (2H, m), 6.40 (1H, d, *J* 9.8Hz), 4.22 (2H, q, *J* 7.1Hz), 1.24 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.80 minutes, 416 (M+H)⁺.
- 15

Example 11**Ethyl 3-[(3-fluoro-4-methoxyphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 20 From 3-fluoro-4-methoxyaniline to give the title compound (122mg). δ H (CDCl₃) 8.63 (1H, bs), 7.58-7.40 (3H, m), 7.32-7.25 (2H, m), 6.99 (1H, d, *J* 9.8Hz), 6.93-6.78 (3H, m), 6.28 (1H, d, *J* 9.8Hz), 4.18 (2H, q, *J* 7.1Hz), 3.85 (3H, s), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.99 minutes, 439 (M+H)⁺.

25

Example 12**Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From 2,4-difluoroaniline to give the title compound (99mg). δ H (CDCl₃) 8.49 (1H, bs), 7.58-7.40 (3H, m), 7.32-7.25 (2H, m), 7.13-7.04 (1H, m), 7.01 (1H, d,
- 30

J 9.8Hz), 6.93-6.86 (1H, m), 6.82-6.75 (1H, m), 6.31 (1H, d, *J*, 9.8Hz), 4.20 (2H, q, *J* 7.1Hz), 1.23 (3H, *J* 7.1Hz). LCMS (ES⁺) RT 4.06 minutes, 427 (M+H)⁺.

5 **Example 13**

Ethyl 6-oxo-7-phenyl-3-[(3-tolyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From 3-toluidine to give the title compound (95mg). δ H (CDCl₃) 8.66 (1H, bs), 7.59-7.41 (3H, m), 7.36-7.27 (2H, m), 7.22-7.13 (1H, m), 7.11 (1H, d, *J* 9.8Hz), 6.95-6.84 (3H, m), 6.27 (1H, d, *J* 9.8Hz), 4.18 (2H, q, *J* 7.1Hz), 2.28 (3H, s), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.36 minutes, 405 (M+H)⁺.

Example 14

Ammonium 6-oxo-3-(phenylamino)-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

Lithium hydroxide monohydrate (302mg, 7.2mmol) was added to a suspension of the compound of Example 1 (1.49g, 3.6mmol) in THF (20mL) and water (20mL) and the mixture heated at 60°C for 18h. The reaction was cooled to r.t. and bulk of THF removed *in vacuo*. The remaining concentrate was diluted with saturated ammonium chloride(aq) (50mL) and the solid precipitate filtered and washed with water (2x20mL), Et₂O (2x20mL) and dried *in vacuo* to give the title compound as a white solid in quantitative yield. LCMS (ES⁺) RT 3.24 minutes, 363 (M+H)⁺.

25 **Example 15**

3-(Phenylamino)-7-phenylthieno[2,3-b]pyridin-6(7H)-one

To a solution of the compound of Example 14 (200mg) in 1,4-dioxan (10mL) was added 2M HCl(aq) (0.5mL) and the reaction mixture heated at 70°C for 1h. The reaction was diluted with water (30mL), extracted with EtOAc (3x20mL) and the EtOAc extracts dried (MgSO₄) and concentrated *in vacuo*. The crude residue was purified by chromatography on silica (0-5% EtOAc in

DCM) to give the title compound as a white solid (90mg). δ H (DMSO- d_6) 8.21 (1H, bs), 7.96 (1H, d, J 9.6Hz), 7.63-7.47 (3H, m), 7.43-7.36 (2H, m), 7.25-7.11 (2H, m), 7.10-7.03 (2H, m), 6.82-6.71 (1H, m), 6.46 (1H, d, J 9.6Hz), 6.44 (1H, s). LCMS (ES⁺) RT 3.54 minutes, 319 (M+H)⁺.

5

Example 16

6-Oxo-3-(phenylamino)-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

To a suspension of the compound of Example 14 (370mg, 1.02mmol) in anhydrous DMF (5mL) was added 1,1'-carbonyldiimidazole (182mg, 1.12mmol) and the reaction stirred at r.t. under nitrogen for 20mins. Ammonium hydroxide (2mL of 28% NH₃ in water) was added and the reaction stirred for 72h. Solvents were removed *in vacuo* and the crude residue purified by chromatography on silica (0-15% THF in DCM) to give the title compound as a white solid (123mg). δ H (DMSO- d_6) 8.74 (1H, s), 7.67-7.34 (3H, m), 7.33-7.27 (2H, m), 7.22-7.00 (5H, m), 6.82-6.71 (3H, m), 6.21 (1H, d, J 9.7Hz). LCMS (ES⁺) RT 3.04 minutes, 362 (M+H)⁺.

15

Example 16 (alternative route)

6-Oxo-7-phenyl-3-phenylamino-6,7-dihydro-thieno[2,3-b]pyridine-2-carboxamide

To a 100mL round bottomed flask, fitted with nitrogen inlet/outlet was added Example 18 (1.45g) and 13.3mL of a solution of 0.382g of sodium hydroxide in water (20mL), plus 30mL of absolute ethanol. The reaction was then set to reflux. After approximately 1 hour at reflux the reaction had gone to completion. The reaction mixture was cooled to ambient, and poured onto 100mL of 1M HCl. This mixture was then extracted with 2 x 75mL of dichloromethane. The combined organics were washed with 1M HCl (2 x 50mL), dried (MgSO₄) and evaporated to dryness. The resulting crude product was then passed down a silica column eluting with 4:1 DCM:EtOAc. The product was then dried under vacuum at 50°C, to give the title

25

30

compound as a light yellow solid (1.47g). δ H (DMSO- d_6) 8.85 (1H, s), 7.60-7.40 (5H, m), 7.30-7.10 (5H, m), 6.80 (3H, m), 6.30 (1H, d, J 8.5Hz). LCMS (Conditions B) (ES⁺) RT 2.92 minutes, 362 (M+H)⁺.

5 **Example 17**

6-Oxo-N-(2-piperidinoethyl)-3-(phenylamino)-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

To a suspension of the compound of Example 14 (90mg, 0.23mmol) in DCM (2mL) was added EDC (60mg, 0.30mmol) and HOBT (41mg, 0.30mmol) and
10 the mixture stirred at r.t. for 15 minutes. A solution 1-(2-aminoethyl)piperidine (45mg, 0.35mmol) in DCM (0.5mL) was added and the reaction stirred at r.t. for 18h. The reaction mixture was diluted with DCM (10mL), washed with water (2x5mL), dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by chromatography on silica (0-20% THF in DCM) to give the title
15 compound as an off-white solid (23mg). δ H (CDCl₃) 8.61 (1H, s), 7.61-7.43 (3H, m), 7.40-7.27 (2H, m), 7.25-7.13 (3H, m), 7.00-6.89 (3H, m), 6.50 (1H, bs), 6.33 (1H, d, J 9.7Hz), 3.43-3.25 (2H, m), 2.47-2.32 (2H, m), 2.31-2.11 (4H, m), 1.50-1.40 (4H, m), 1.39-1.25 (2H, m). LCMS (ES⁺) RT 2.40 minutes, 473 (M+H)⁺.

20

Example 18

6-Oxo-3-(phenylamino)-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Tris(dibenzylideneacetone)dipalladium(0) (34mg, 0.0375mmol, 5mol%) was
25 added to a mixture of Intermediate 9 (250mg, 0.75mmol), caesium carbonate (342mg, 1.05mmol), aniline (0.082mL, 0.9mmol) and BINAP (47mg, 0.075mmol, 10mol%) in anhydrous toluene (7mL) and the reaction heated to reflux under nitrogen for 24h. The reaction mixture was partitioned between DCM (60mL) and water (25mL) and the DCM extracts dried (Na₂SO₄) and
30 concentrated *in vacuo*. The crude residue was purified by chromatography on silica (10-15% EtOAc in DCM) to give the title compound as an off-white solid

(185mg). δ H (CDCl₃) 7.79-7.71 (3H, m), 7.56-7.41 (5H, m), 7.33-7.29 (1H, m), 7.24(2H, dd, *J* 7.5, 1.0Hz), 6.65 (1H, d, *J* 9.8Hz), 6.59 (1H, bs). LCMS (ES⁺) 344 (M+H)⁺.

5 **Example 18 (alternative route)**

6-Oxo-7-phenyl-3-phenylamino-6,7-dihydro-thieno[2,3-*b*]pyridine-2-carbonitrile

To a dry 50ml 2 necked round bottomed flask, fitted with nitrogen inlet/outlet was added Cs₂CO₃ (1.38g), (+/-)-BINAP (188mg), intermediate 9 (1.00g) and
10 tris(dibenzylideneacetone)dipalladium(0) (138.4mg). To this mixture was added 20ml of anhydrous toluene, which had been thoroughly degassed. The reaction mixture was then put through a vacuum and nitrogen cycle. To the reaction mixture was added aniline (0.338g) via syringe. The reaction was then set to reflux. After 16 hours at reflux the reaction had gone to
15 completion. The reaction mixture was cooled to ambient, held at this temperature for 1 hour. The solid was then collected by filtration. This crude solid was then slurried in 10mL of 1.0M HCl for 1 hour. The beige coloured solid was collected by filtration, washing with 10mL of water. The product was then dried under vacuum at 50°C, to give the title compound as a light
20 brown solid (0.68g). δ H (DMSO-*d*₆) 9.60 (1H, s), 8.25 (1H, d, *J* 8.5Hz), 7.75-7.90 (5H, m), 7.50 (2H, m), 7.40 (2H, m), 7.30 (1H, t, *J* 7.5Hz), 6.85 (1H, d, *J* 8.5Hz). LCMS (Conditions B) (ES⁺) RT 3.58 minutes, 344 (M+H)⁺

Example 19

25 **3-(3-Bromophenylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile**

The title compound was prepared from 3-bromoaniline (155mg, 0.9mmol) following the method described for the compound of Example 18 to give the product as a pale yellow solid (183mg). δ H (CDCl₃) 7.91-7.83 (3H, m), 7.83-
30 7.66 (2H, m), 7.62 (1H, d, *J* 9.7Hz), 7.52-7.44 (3H, m), 7.23 (1H, dt, *J* 7.1,

1.7Hz), 6.81 (1H, d, *J* 9.7Hz), 6.74 (1H, bs). LCMS (ES⁺) 422 (M+H)⁺ ⁷⁹Br, 424 (M+H)⁺ ⁸¹Br.

Example 20

5 **3-(3-chlorophenylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

The title compound was prepared from 3-chloroaniline (115mg, 0.9mmol) following the method described for the compound of Example 18 to give the product as a pale yellow solid (125mg). δ H (CDCl₃) 7.67-7.58 (3H, m), 7.44-
10 7.41 (2H, m), 7.39 (1H, d, *J* 9.7Hz), 7.31-7.26 (1H, m), 7.12-7.09 (1H, m), 7.04 (1H, t, *J* 2.0Hz), 6.95-6.92 (1H, m), 6.57 (1H, d, *J* 9.7Hz), 6.54 (1H, bs). LCMS (ES⁺) 378 (M+H)⁺ ³⁵Cl, 380 (M+H)⁺ ³⁷Cl.

Example 21

15 **7-(2-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

A mixture of Intermediate 14 (500mg, 1.37mmol), 4-fluoro-3-methyl aniline (206mg, 1.64mmol), caesium carbonate (625mg, 1.92mmol), BINAP (85mg, 0.37mmol, 10mol%) and tris(dibenzylideneacetone)dipalladium(0) (63mg, 0.0685mmol, 5mol%) in toluene was heated at reflux for 18h. A second
20 charge of BINAP (42mg, 5mol%) and tris(dibenzylideneacetone)-dipalladium(0) (31.5mg, 2.5mol%) was added and the mixture heated at reflux for a further 4 days. The mixture was partitioned between DCM (100mL) and water (50mL). The organic layer was dried (Na₂SO₄) and
25 concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound as an off-white solid (160mg, 28%). δ H (DMSO-d₆) 9.39 (1H, s), 8.17 (1H, d, *J* 9.7Hz), 7.87 (1H, dd, *J* 1.7, 7.9Hz), 7.79 (1H, dd, *J* 2.1, 7.9Hz), 7.75-7.66 (2H, m), 7.24-7.12 (3H, m), 6.71 (1H, d, *J* 9.7Hz), 2.29 (3H, d, *J* 1.7Hz). LCMS (ES⁺) RT 3.63 minutes, 410
30 (M+H)⁺

Example 22**7-(2-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- Sodium hydroxide (0.68mL of a 0.25M aq. solution, 0.17mmol) was added to
- 5 Example 21 (136mg, 0.33mmol) in ethanol (6mL) and the mixture heated at reflux for 1h. The mixture was concentrated *in vacuo*, the residue suspended in water and the solid filtered off and dried. Purification by column chromatography (silica, 20% EtOAc in DCM) gave the title compound as a pale yellow solid (65mg, 46%). δ H (CDCl₃) 9.08 (1H, br s), 7.60-7.57 (1H, m),
- 10 7.48-7.41 (2H, m), 7.38-7.35 (1H, m), 7.06 (1H, d, *J* 9.8Hz), 6.93-6.85 (3H, m), 6.29 (1H, d, *J* 9.8Hz), 5.18 (2H, br s), 2.20 (3H, d, *J* 1.4Hz). LCMS (ES⁺) RT 3.28 minutes, 428 (M+H)⁺

Example 23

- 15 **3-Anilino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- Prepared from Intermediate 14 and aniline by the method of Example 21.
- Pale yellow solid (100mg, 32%). δ H (DMSO-d₆) 9.45 (1H, br s), 8.12 (1H, d, *J* 9.7Hz), 7.90-7.87 (1H, m), 7.80-7.78 (1H, m), 7.74-7.69 (2H, m), 7.44-7.39
- 20 (2H, m), 7.27-7.24 (2H, m), 7.17-7.13 (1H, m), 6.71 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.95 minutes, 378.0 (M+H)⁺.

Example 24

- 25 **3-Anilino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- Sodium hydroxide (1.44mL of a 0.25M aq. solution, 0.24mmol) was added to Example 23 (90mg, 0.24mmol) in ethanol (10mL) and the mixture heated at reflux for 1h. The mixture was concentrated *in vacuo*, the residue suspended in water and the solid filtered off and dried to give the title compound as an
- 30 off-white solid (66mg, 70%). δ H (DMSO-d₆) 9.04 (1H, br s), 7.89-7.86 (1H, m), 7.81-7.79 (1H, m), 7.74-7.67 (2H, m), 7.43 (2H, br s), 7.42-7.40 (1H, m),

7.36-7.32 (2H, m), 7.04-6.99 (3H, m), 6.50 (1H, d, J 9.7Hz). LCMS (ES⁺) RT 3.07 minutes, 396.0 (M+H)⁺

Example 25

5 **3-[4-Fluoro-3-methylphenyl]amino]-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide**

Sodium hydroxide (2.0mL of a 0.25M aq. solution, 0.5mmol) was added to Intermediate 18 (350mg, 0.65mmol) in ethanol (20mL) and the mixture heated at reflux for 1h. The mixture was concentrated *in vacuo*, the residue
10 suspended in water (2 x 15mL) and the solid filtered off and dried. Purification by column chromatography (silica, 20% EtOAc in DCM) gave a pale brown solid which was triturated with Et₂O/hexane (1:2, 20mL). The solid was filtered off to give the title compound as a pale brown solid (80mg, 30%). δ H(DMSO-*d*₆) 9.00 (1H, br s), 7.43-7.36 (4H, m), 7.29 (2H, br s), 7.24
15 (1H, d, J 9.7Hz), 7.06-7.01 (1H, m), 6.92-6.89 (1H, m), 6.79-6.77 (1H, m), 6.37 (1H, d, J 9.7Hz), 2.41 (3H, s), 2.18 (3H, d, J_{HF} 1.2Hz). LCMS (ES⁺) RT 3.33 minutes, 408.0 (M+H)⁺

Example 26

20 **7-(4-Methylphenyl)-3-[3-methylphenyl]amino]-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile**

A mixture of Intermediate 17 (225mg, 0.65mmol), 3-methylaniline (0.165mL, 0.78mmol), caesium carbonate (297mg, 0.91mmol), BINAP (41mg, 0.065mmol) and tris(dibenzylideneacetone)dipalladium(0) (30mg, 0.0325mmol) in toluene (5mL) was heated at 100 °C under N₂ for 18h. The
25 mixture was partitioned between DCM (100mL) and water (50mL). The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5 to 10% EtOAc in DCM) gave the title compound as a pale brown solid (63mg, 26%). δ H (DMSO-*d*₆) 9.04 (1H, br
30 s), 7.77 (1H, d, J 9.7Hz), 7.23-7.16 (4H, m), 7.02-6.98 (1H, m), 6.77-6.74

(2H, m), 6.68-6.66 (1H, m), 6.37 (1H, d, *J* 9.7Hz), 2.21 (3H, s), 2.08 (3H, s).
LCMS (ES⁺) RT 3.72 minutes, 372.0 (M+H)⁺

Example 27

5 7-(4-Methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-

dihydrothieno[2,3-*b*]pyridine-2-carboxamide

Sodium hydroxide (0.30mL of a 0.25M aq. solution, 0.075mmol) was added to Example 26 (56mg, 0.15mmol) in ethanol (4mL) and the mixture heated at reflux for 1h. The mixture was concentrated *in vacuo*, the residue suspended

- 10 in water, acidified with 1M HCl aq, and the solid filtered off and dried to give the title compound (40mg, 68%). δ H(DMSO-*d*₆) 8.93 (1H, br s), 7.44-7.37 (4H, m), 7.30 (2H, br s), 7.29 (1H, d, *J* 9.6Hz), 7.14 (1H, t, *J* 7.6Hz), 6.78-6.71 (3H, m), 6.39 (1H, d, *J* 9.6Hz), 2.42 (3H, s), 2.25 (3H, s). LCMS (ES⁺) RT 3.29 minutes, 390.0 (M+H)⁺

15

Example 28

7-Cyclopropyl-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-

dihydrothieno[2,3-*b*]pyridine-2-carbonitrile

Prepared from Intermediate 21 and 4-fluoro-3-methylaniline by the method of

- 20 Example 21. Light yellow solid. δ H (CDCl₃) 7.19 (1H, d, *J* 9.7Hz), 6.97-6.84 (3H, m), 6.51 (1H, br s), 6.35 (1H, d, *J* 9.7Hz), 3.08-3.02 (1H, m), 2.25 (3H, s), 1.32-1.23 (2H, m), 1.14-1.07 (2H, m). LCMS (ES⁺) RT 3.385 minutes, 339.9 (M+H)⁺

25 Example 29

7-Cyclopropyl-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-

dihydrothieno[2,3-*b*]pyridine-2-carboxamide

Prepared from Example 28 by the method of Example 22. Light yellow solid.

- δ H (CDCl₃) 9.0-8.8 (1H, br s), 7.01 (1H, d, *J* 9.7Hz), 6.98-6.84 (3H, m), 6.23 (1H, d, *J* 9.7Hz), 5.51 (2H, br s), 3.07-3.03 (1H, m), 2.22 (3H, s), 1.30-1.23 (2H, m), 1.15-1.12 (2H, m). LCMS (ES⁺) RT 3.009 minutes, 358.0 (M+H)⁺

Example 30**7-Cyclopropyl-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 5 Prepared from Intermediate 21 and m-toluidine by the method of Example 21. Light yellow solid. δ H (CDCl₃) 7.25 (1H, d, *J* 9.6Hz), 7.20-7.16 (1H, m), 6.04 (1H, d, *J* 7.6Hz), 7.82-7.80 (2H, m), 6.67 (1H, s), 6.33 (1H, d, *J* 9.6Hz), 3.07-3.02 (1H, m), 2.31 (3H, s), 1.32-1.17 (2H, m), 1.14-1.07 (2H, m). LCMS (ES⁺) RT 3.336 minutes, 321.9 (M+H)⁺

10

Example 31**7-Cyclopropyl-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- Prepared from Intermediate 30 by the method of Example 22. Light yellow
15 solid. δ H (CDCl₃) 8.65 (1H, br s), 7.25-7.11 (2H, m), 6.88 (1H, d, *J* 7.5Hz), 6.83-6.80 (2H, m), 6.24 (1H, d, *J* 9.7Hz), 5.68 (2H, br s), 3.08-3.05 (1H, m), 2.3 (3H, s), 1.34-1.23 (2H, m), 1.15-1.13 (2H, m). LCMS (ES⁺) RT 2.888 minutes, 340.0 (M+H)⁺

20 **Example 32**

3-[(4-fluoro-3-methylphenyl)amino]-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- Prepared from Intermediate 24 and 4-fluoro-3-methyl aniline by the method
of Example 21. δ H (CDCl₃) 7.52-7.38 (4H, m), 7.28-7.26 (1H, m), 7.03-6.90
25 (3H, m), 6.50 (1H, d, *J* 9.7Hz), 6.27 (1H, s), 2.29 (3H, s), 2.14 (3H, s). LCMS (ES⁺) RT 3.641 minutes, 389.9 (M+H)⁺

Example 33

- 3-[(2,4-Difluorophenyl)amino]-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**
- 30

Prepared from Intermediate 24 and 2,4-difluoroaniline by the method of Example 21. δ H (CDCl₃) 7.5-7.34 (4H, m), 7.26-7.24 (1H, m), 7.2-7.14 (1H, m), 7.0-6.88 (2H, m), 6.57 (1H, d, *J* 9.7Hz), 6.36 (1H, br s), 2.14 (3H, s). LCMS (ES⁺) RT 3.464 minutes, 394.0 (M+H)⁺

5

Example 34**7-(2-Methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide**

Prepared from Intermediate 25 by the method of Example 22. δ H (CDCl₃) 7.48-7.36 (3H, m), 7.28-7.18 (3H, m), 6.95-6.89 (3H, m), 6.36 (1H, d, *J* 9.8Hz), 5.48 (2H, br s), 2.34 (3H, s), 2.13 (3H, s). LCMS (ES⁺) RT 3.24 minutes, 390.0 (M+H)⁺

Example 35**3-[(4-Fluoro-3-methylphenyl)amino]-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide**

Prepared from Example 32 by the method of Example 22. δ H (CDCl₃) 7.48-7.37 (3H, m), 7.27-7.26 (1H, m), 7.13 (1H, d, *J* 9.8Hz), 7.0-6.91 (3H, m), 6.36 (1H, d, *J* 9.8Hz), 5.39 (2H, br s), 2.27 (3H, s), 2.13 (3H, s). LCMS (ES⁺) RT 3.29 minutes, 408.0 (M+H)⁺

Example 36**3-[(2,4-Difluorophenyl)amino]-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide**

Prepared from Example 33 by the method of Example 22. δ H (DMSO-*d*₆) 9.27 (1H, s), 7.59-7.40 (7H, m), 7.35-7.31 (1H, m), 7.19-7.06 (2H, m), 6.48 (1H, d, *J* 9.7Hz), 2.55 (3H, s). LCMS (ES⁺) RT 3.18 minutes, 412.0 (M+H)⁺

Example 37

Ethyl 3-anilino-7-(1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 26 and aniline by the method of Example 1. Pale yellow solid. δ H (CDCl₃) 8.70 (1H, br s), 8.56 (1H, br s), 7.56 (1H, br s), 7.41-7.26

- 5 (3H, m), 7.21-7.09 (5H, m), 7.01 (1H, dd, *J* 8.5, 2.0Hz), 6.53 (1H, br s), 6.32 (1H, d, *J* 9.7Hz), 4.15 (2H, q, *J* 7.1Hz), 1.18 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.77 minutes, 430 (M+H)⁺.

Example 38

- 10 **3-Anilino-7-(1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

A mixture of Example 37 (200mg) and liquid ammonia (5mL) in ethoxyethanol (10mL) was heated in a sealed vessel at 80 °C at 400 p.s.i. for 48h. The solvent was removed *in vacuo* and purification by column

- 15 chromatography (silica, 10% to 40% EtOAc in DCM) gave the title compound (42mg). δ H (CDCl₃) 9.00 (1H, br s), 8.65 (1H, br s), 7.57 (1H, s), 7.37 (1H, d, *J* 8.5Hz), 7.30-7.24 (2H, m), 7.20-7.18 (2H, m), 7.16 (1H, d, *J* 9.7Hz), 7.18-6.98 (3H, m), 6.52 (1H, br s), 6.33 (1H, d, *J* 9.7Hz), 5.20 (2H, br s). LCMS (ES⁺) RT 3.77 minutes, 430 (M+H)⁺. LCMS (ES⁺) RT 2.93 minutes, 401
- 20 (M+H)⁺.

Example 39

Ethyl 3-[(2-cyanophenyl)amino]-7-(1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

- 25 From Intermediate 26 and 2-cyanoaniline by the method of Example 1. δ H (CDCl₃) 8.96 (1H, br s), 8.67 (1H, br s), 7.89-7.74 (2H, m), 7.72-7.56 (2H, m), 7.48-7.44 (2H, m), 7.31-7.27 (3H, m), 6.79 (1H, br s), 6.66 (1H, d, *J* 9.7Hz), 4.41 (2H, q, *J* 7.1Hz), 1.42 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.53 minutes, 455 (M+H)⁺.

30

Example 40

3-[(2-Cyanophenyl)amino]-7-(1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 39 by the method of Example 38. δ H (DMSO- d_6) 11.21 (1H, br s), 9.33 (1H, m), 7.51-7.49 (1H, m), 7.44 (1H, d, J 1.8Hz), 7.38 (1H, d, J 8.5Hz), 7.28-7.19 (4H, m), 7.10 (1H, d, J 9.6Hz), 6.87 (1H, dd, J 8.6, 2.0Hz), 6.85-6.73 (1H, m), 6.72-6.63 (1H, m), 6.33 (1H, m), 6.20 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 2.89 minutes, 426 (M+H)⁺.

Example 41

10 **Ethyl 3-[(2-cyanophenyl)amino]-7-[1-(methylsulfonyl)-1H-indol-5-yl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 27 and 2-cyanoaniline by the method of Example 1. δ H (CDCl₃) 8.73 (1H, br s), 8.08 (1H, d, J 8.7Hz), 7.64 (1H, s), 7.60 (1H, d, J 7.7Hz), 7.53 (1H, d, J 3.8Hz), 7.44 (1H, t, J 7.9Hz), 7.32 (1H, dd, J 8.7, 1.8Hz), 7.19 (1H, d, J 2.4Hz), 7.09-7.04 (1H, d, J 9.7Hz), 6.74 (1H, d, J 3.6Hz), 6.42 (1H, d, J 9.7Hz), 4.21 (2H, q, J 7.2Hz), 3.15 (3H, s), 1.22 (3H, t, J 7.2Hz). LCMS (ES⁺) RT 3.68 minutes, 533 (M+H)⁺.

Example 42

20 **Ethyl 3-[(2-cyanophenyl)amino]-7-(1-methyl-1H-indol-5-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 28 and 2-cyanoaniline by the method of Example 1. δ H (CDCl₃) 8.73 (1H, br s), 7.58-7.55 (2H, m), 7.47-7.41 (2H, m), 7.18 (1H, d, J 1.7Hz), 7.13-7.11 (2H, m), 7.07-7.04 (2H, m), 6.52 (1H, d, J 2.4Hz), 6.42 (1H, d, J 9.7Hz), 4.19 (2H, q, J 7.1Hz), 3.80 (3H, s), 1.19 (3H, t, J 7.1Hz). LCMS (ES⁺) RT 3.83 minutes, 469 (M+H)⁺.

Example 43

30 **3-Anilino-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

A mixture of Intermediate 30 (225mg, 0.73mmol), aniline (0.082mL, 0.9mmol), caesium carbonate (342mg, 1.08mmol), BINAP (47mg, 10mol%) and tris(dibenzylideneacetone)dipalladium(0) (34mg, 5mol%) in toluene (7mL) was heated at 105 °C for 24h. The mixture was partitioned between
5 EtOAc (75mL) and water (75mL). The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% THF in DCM) gave the title compound as a pale yellow solid (110mg, 47%). δ H (CDCl₃) 7.29-7.25 (2H, m), 7.19 (1H, d, *J* 9.7Hz), 7.15-7.04 (1H, m), 7.00-6.97 (2H, m), 6.40 (1H, br s), 6.34 (1H, d, *J* 9.7Hz), 3.91 (2H, d, *J*
10 7.1Hz), 1.33-1.19 (1H, m), 0.80-0.45 (4H, m). LCMS (ES⁺) 322.0 (M+H)⁺.

Example 44

Ethyl 3-anilino-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

15 From Intermediate 29 and aniline by the method of Example 1. Pale yellow solid. δ H (CDCl₃) 8.71 (1H, br s), 7.29-7.22 (2H, m), 7.10-6.97 (4H, m), 6.18 (1H, d, *J* 9.7Hz), 4.27 (2H, q, *J* 7.1Hz), 3.94 (2H, d, *J* 7.2Hz), 1.40-1.33 (1H, m), 1.32 (3H, t, *J* 7.1Hz), 0.53-0.48 (4H, m). LCMS (ES⁺) RT 3.79 minutes, 369.0 (M+H)⁺

20

Example 45

3-Anilino-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

A mixture of 1,1'-carbonyldiimidazole (433mg, 2.7mmol), and Intermediate 31
25 (650mg, 1.91mmol) in DMF (10mL) was stirred at r.t. for 30min. conc. NH₃ aq (15mL) was added and the mixture stirred for 2h then diluted with water (100mL) and extracted with EtOAc (100mL). The organic extract was washed with brine (3 x 50mL), dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 15% to 25% EtOAc in DCM) gave the title
30 compound as a white solid (210mg, 32%). δ H (CDCl₃) 8.62 (1H, br s), 7.09-7.03 (2H, m), 6.90 (1H, d, *J* 9.7Hz), 6.88-6.82 (3H, m), 6.07 (1H, d, *J* 9.7Hz),

5.28 (2H, br s), 3.78 (2H, d, J 7.1Hz), 1.20-1.14 (1H, m), 0.40-0.33 (4H, m).
LCMS (ES⁺) 340.0 (M+H)⁺.

Example 46

5 **3-Anilino-7-(cyclopropylmethyl)-N-methoxy-N-methyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

Prepared from Intermediate 31 and N,O-dimethylhydroxylamine hydrochloride by the method of Example 17. Pale yellow solid δ H (CDCl₃) 9.98 (1H, brs), 7.24-7.19 (2H, m), 7.07 (1H, d, J 9.7Hz), 7.04-7.00 (3H, m),
10 6.18 (1H, d, J 9.7Hz), 3.96 (2H, d, J 7.1Hz), 3.76 (3H, s), 3.26 (3H, s), 1.41-1.31 (1H, m), 0.54-0.50 (4H, m). LCMS (ES⁺) 384.0 (M+H)⁺.

Example 47

15 **7-(cyclopropylmethyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 29 and 2,4-difluoroaniline by the method of Example 1. Pale yellow solid. δ H (CDCl₃) 8.68 (1H, br s), 7.25-7.19 (1H, m), 7.09 (1H, d, J 9.7Hz), 7.06-6.91 (2H, m), 6.39 (1H, d, J 9.7Hz), 4.45 (2H, q, J 7.1Hz), 4.11 (2H, d, J 7.2Hz), 1.57-1.50 (1H, m), 1.49 (3H, t, J 7.1Hz), 0.70-0.65 (4H, m).
20 LCMS (ES⁺) 384.0 (M+H)⁺.

Example 48

25 **7-(Cyclopropylmethyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

7-(Cyclopropylmethyl)-3-[(2,4-difluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid was prepared from Example 47 by the method of Intermediate 31. The title compound was prepared from this acid by the method of Example 46. δ H (CDCl₃) 8.72 (1H, br s), 7.02-6.94 (2H, m), 6.89-6.82 (1H, m), 6.78-6.73 (1H, m), 6.26 (1H, d, J 9.7Hz), 5.46
30 (2H, br s), 3.94 (2H, d, J 7.2Hz), 1.37-1.29 (1H, m), 0.50-0.48 (4H, m). LCMS (ES⁺) 376.0 (M+H)⁺.

Example 49**7-(Cyclopropylmethyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 5 From Intermediate 30 and m-toluidine by the method of Example 1. Orange solid. δ H (CDCl₃) 7.26-7.18 (3H, m), 6.94 (1H, d, *J* 7.6Hz), 7.84 (1H, d, *J* 8.7Hz), 6.39 (1H, d, *J* 9.7Hz), 6.38 (1H, s), 3.97 (2H, d, *J* 7.2Hz), 2.32 (3H, s), 1.41-1.31 (1H, m), 0.62-0.53 (4H, m). LCMS (ES⁺) RT 3.593 minutes, 335.9 (M+H)⁺.
- 10

Example 50**7-(Cyclopropylmethyl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 30 and 4-fluoro-3-methylaniline by the method of Example

- 15 1. Yellow solid. δ H (CDCl₃) 7.19 (1H, d, *J* 9.6Hz), 7.0-6.87 (3H, m), 6.42 (1H, d, *J* 9.6Hz), 6.36 (1H, s), 3.98 (2H, d, *J* 7.2Hz), 2.27 (3H, s), 1.42-1.32 (1H, m), 0.67-0.52 (4H, m). LCMS (ES⁺) RT 3.577 minutes, 354 (M+H)⁺.

Example 51

- 20 **3-[(3-Chloro-4-fluorophenyl)amino]-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 30 and 3-chloro-4-fluoroaniline by the method of Example

1. Yellow solid. δ H (CDCl₃) 7.27-7.25 (1H, d, *J* 9.6Hz), 7.16-7.11 (2H, m), 6.97-6.93 (1H, m), 6.48 (1H, d, *J* 9.6Hz), 6.41 (1H, s), 4.0 (2H, d, *J* 7.2Hz),
25 1.40-1.26 (1H, m), 0.65-0.54 (4H, m). LCMS (ES⁺) RT 3.608 minutes, 374 (M+H)⁺.

Example 52**7-(Cyclopropylmethyl)-3-[(2,4-dimethylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 30

From Intermediate 30 and 2,4-dimethylaniline by the method of Example 1.
Orange-yellow solid. δ H (CDCl₃) 7.08-6.95 (4H, m), 6.34 (1H, d, *J* 9.6Hz),
6.08 (1H, s), 3.97 (2H, d, *J* 7.2Hz), 2.31 (3H, s), 2.28 (3H, s), 1.41-1.27 (1H,
m), 0.62-0.51 (4H, m). LCMS (ES⁺) RT 3.626 minutes, 350.0 (M+H)⁺.

5

Example 53**7-(Cyclopropylmethyl)-3-[(3,4-dimethylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 30 and 3,4-dimethylaniline by the method of Example 1.

- 10 Yellow solid. δ H (CDCl₃) 7.19 (1H, d, *J* 9.6Hz), 7.09 (1H, d, *J* 7.9Hz), 6.88-6.81 (2H, m), 6.38 (1H, d, *J* 9.6Hz), 6.31 (1H, s), 3.98 (2H, d, *J* 7.2Hz), 2.22 (3H, s), 2.21 (3H, s), 1.41-1.34 (1H, m), 0.63-0.53 (4H, m). LCMS (ES⁺) RT 3.693 minutes, 350.0 (M+H)⁺.

15 **Example 54**

7-(Cyclopropylmethyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 49 by the method of Example 22. δ H (CDCl₃) 8.76 (1H, br s),
7.20-7.14 (2H, m), 6.93-6.85 (3H, m), 6.31 (1H, d, *J* 9.7Hz), 5.46 (2H, br s),

- 20 4.02 (2H, d, *J* 7.1Hz), 2.37 (3H, s), 1.48-1.38 (1H, m), 0.63-0.54 (4H, m).
LCMS (ES⁺) RT 3.153 minutes, 353.9 (M+H)⁺.

Example 55**7-(Cyclopropylmethyl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- 25 From Example 50 by the method of Example 22. Yellow solid. δ H (CDCl₃)
9.06 (1H, br s), 7.04 (1H, d, *J* 9.7Hz), 7.0-6.80 (3H, m), 6.29 (1H, d, *J* 9.7Hz),
5.34 (2H, br s), 4.0 (2H, d, *J* 7.1Hz), 2.25 (3H, s), 1.46-1.37 (1H, m), 0.63-0.54 (4H, m). LCMS (ES⁺) RT 3.207 minutes, 370.4 (M+H)⁺.

30

Example 56**7-(Cyclopropylmethyl)-3-[(3-chloro-4-fluorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 51 by the method of Example 22. Yellow solid. δ H (CDCl₃)

- 5 9.06 (1H, br s), 7.14-7.06 (3H, m), 6.96-6.92 (1H, m), 6.36 (1H, d, *J* 9.7Hz), 5.4 (2H, br s), 4.02 (2H, d, *J* 7.1Hz), 1.45-1.37 (1H, m), 0.64-0.55 (4H, m). LCMS (ES⁺) RT 3.202 minutes, 391.9 (M+H)⁺.

Example 57

- 10 **7-(Cyclopropylmethyl)-3-[(2,4-dimethylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 52 by the method of Example 22. δ H (CDCl₃) 9.2 (1H, br s),

- 7.01 (1H, s), 6.98 (2H, s), 6.89 (1H, d, *J* 9.8Hz), 6.25 (1H, d, *J* 9.7Hz), 5.33 (2H, br s), 4.03 (2H, d, *J* 7.1Hz), 2.37 (3H, s), 2.33 (3H, s), 1.48-1.40 (1H, m), 15 0.65-0.56 (4H, m). LCMS (ES⁺) RT 3.389 minutes, 368.0 (M+H)⁺.

Example 58**7-(Cyclopropylmethyl)-3-[(3,4-dimethylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- 20 From Example 53 by the method of Example 22. δ H (CDCl₃) 8.9 (1H, br s), 7.10 (1H, d, *J* 9.7Hz), 7.05 (1H, d, *J* 8Hz), 6.87 (1H, s), 6.81 (1H, d, *J* 7.2Hz), 6.27 (1H, d, *J* 9.7Hz), 5.39 (2H, br s), 4.0 (2H, d, *J* 7.2Hz), 2.24 (3H, s), 2.22 (3H, s), 1.45-1.37 (1H, m), 0.62-0.53 (4H, m). LCMS (ES⁺) RT 3.321 minutes, 368.0 (M+H)⁺.

25

Example 59**Ethyl 3-[(2-cyano-3-methylphenyl)amino]-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 29 and 2-cyano-3-methylaniline by the method of

- 30 Example 1. δ H (CDCl₃) 8.75 (1H, br s), 7.33-7.29 (1H, m), 7.17 (1H, d, *J*

9.6Hz), 6.97 (1H, d, *J* 7.5Hz), 6.85 (1H, d, *J* 8.2Hz), 6.36 (1H, d, *J* 9.6Hz), 4.37 (2H, q, *J* 7.1Hz), 4.03 (2H, d, *J* 7.1Hz), 2.57 (3H, s), 1.48-1.38 (4H, m), 0.63-0.55 (4H, m). LCMS (ES⁺) RT 4.044 minutes, 408.0 (M+H)⁺.

5 **Example 60**

3-[(2-Cyano-3-methylphenyl)amino]-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 59 by the method of Example 38. Yellow solid. δ H (CDCl₃) 8.4 (1H, br s), 7.30-7.22 (1H, m), 7.19 (1H, d, *J* 9.6Hz), 6.94 (1H, d, *J* 7.6Hz), 10 6.72 (1H, d, *J* 8.2Hz), 6.42 (1H, d, *J* 9.6Hz), 5.78 (2H, br s), 4.02 (2H, d, *J* 7.2Hz), 2.56 (3H, s), 1.44-1.35 (1H, m), 0.64-0.55 (4H, m). LCMS (ES⁺) RT 3.05 minutes, 378.9 (M+H)⁺.

Example 61

15 **3-Anilino-7-(cyclopropylmethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 31 and 1-(2-aminoethyl)piperidine by the method of Example 17. δ H (CDCl₃) 7.22-7.17 (2H, m), 7.13 (1H, d, *J* 9.7Hz), 6.98-6.92 (3H, m), 6.79 (1H, br s), 6.26 (1H, d, *J* 9.7Hz), 3.97 (2H, d, *J* 7.1Hz), 3.44- 20 3.40 (2H, m), 2.50-2.48 (2H, m), 2.47-2.39 (4H, m), 1.54-1.51 (4H, m), 1.41-1.32 (3H, m), 0.54-0.50 (4H, m). LCMS (ES⁺) RT 2.42 minutes, 451 (M+H)⁺.

Example 62

25 **Ethyl 3-[(3-bromophenyl)amino]-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 29 and 3-bromoaniline by the method of Example 1. δ H (CDCl₃) 8.50 (1H, br s), 7.25-6.99 (4H, m), 6.86-6.82 (1H, m), 6.15 (1H, d, *J* 9.7Hz), 4.16 (2H, q, *J* 7.4Hz), 3.84 (2H, d, *J* 7.2Hz), 1.86 (3H, t, *J* 7.4Hz), 1.05-0.95 (1H, m), 0.43-0.38 (4H, m). LCMS (ES⁺) RT 4.54 minutes, 448/449 30 (⁷⁹Br/⁸⁰Br) (M+H)⁺.

Example 63

3-[(3-bromophenyl)amino]-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 62 by the method of Example 38. δ H (CDCl₃) 8.72 (1H, br s), 7.14-7.05 (4H, m), 6.89-6.86 (1H, m), 6.30 (1H, d, *J* 9.6Hz), 5.57 (2H, s),
5 3.95 (2H, d, *J* 7.1Hz), 0.54-0.48 (5H, m). LCMS (ES⁺) RT 3.202 minutes, 419 (M+H)⁺.

Example 64

Ethyl 3-anilino-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

10 A mixture of Intermediate 34 (20mg, 0.63mmol), 3-thiophene boronic acid (161mg, 1.26mmol) and copper (II) acetate (115mg, 0.63mmol) in pyridine (0.29mL) was stirred at r.t. for 24h. More copper (II) acetate (115mg, 0.63mmol) was added and reaction continued for a further 24h. The mixture
15 was diluted with DCM, washed with 2M HCl aq, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 20% EtOAc in hexane) gave the title compound (30mg, 12%). δ H (CDCl₃) 8.67 (1H, br s), 7.48-7.45 (2H, m), 7.29-7.25 (2H, m), 7.10-7.05 (5H, m), 6.23 (1H, d, *J* 9.8Hz), 4.20 (2H, q, *J* 7.1Hz), 1.24 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT
20 3.898 minutes, 397 (M+H)⁺

Example 65

3-Anilino-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

25 A mixture of Example 64 (129mg), 2-ethoxyethanol and liquid ammonia was placed in a sealed pressure vessel and heated at 80 °C and 400 p.s.i. for 24h. The volatiles were removed *in vacuo* and the residue purified by column chromatography (silica, 50% to 100% EtOAc in hexane) to give the title compound (20mg). δ H (CDCl₃) 8.75 (1H, br s), 7.36-7.34 (2H, m), 7.16-7.11
30 (2H, m), 7.03 (1H, d, *J* 9.7Hz), 6.99-6.88 (4H, m), 6.17 (1H, d, *J* 9.7Hz), 5.47 (2H, br s). LCMS (ES⁺) RT 2.927 minutes, 368 (M+H)⁺

Example 66**Ethyl 3-[(2-cyanophenyl)amino]-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 5 A mixture of Intermediate 35 (270mg, 0.7mmol), 2-cyano aniline (122mg, 0.84mmol), caesium carbonate (319mg, 0.98mmol), BINAP (87mg, 20mol%) and tris(dibenzylideneacetone)dipalladium(0) (64mg, 10mol%) in toluene (1mL) was heated at reflux for 3 days. Brine was added and the mixture extracted with EtOAc. The organic extract was dried (MgSO₄) and
- 10 concentrated *in vacuo*. Purification by column chromatography (silica, 20% to 40% EtOAc in hexane) gave the title compound (120mg, 41%). δ H (CDCl₃) 8.7 (1H, br s), 7.67 (1H, d, *J* 7.8Hz), 7.58 (2H, m), 7.50 (1H, t, *J* 7.9Hz), 7.26-7.09 (4H, m), 6.46 (1H, d, *J* 9.8Hz), 4.33 (2H, q, *J* 7.1Hz), 1.35 (3H, t, *J* 7.2Hz). LCMS (ES⁺) RT 3.624 minutes, 421.9 (M+H)⁺

15

Example 67**3-[(2-Cyanophenyl)amino]-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- A mixture of Example 66 (100mg), 2-ethoxyethanol and liquid ammonia was
- 20 placed in a sealed pressure vessel and heated at 80 °C and 400 psi for 48h. The volatiles were removed *in vacuo* and the residue purified by column chromatography (silica, EtOAc) to give the title compound (30mg). δ H (CDCl₃) 7.59-7.46 (4H, m), 7.28-7.21 (3H, m), 7.20 (1H, t, *J* 2.0Hz), 7.01 (1H, d, *J* 8.3Hz), 6.49 (1H, d, *J* 9.7Hz), 5.55 (2H, br s). LCMS (ES⁺) RT 2.845
- 25 minutes, 392.9 (M+H)⁺

Example 68**Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 30 From Intermediate 37 by the method of Example 64. δ H (CDCl₃) 8.7 (1H, br s), 7.55 (1H, br s), 7.28 (1H, br s), 7.17 (1H, m), 7.07-6.99 (4H, m), 6.33 (1H,

d, *J* 9.8Hz), 4.30 (2H, q, *J* 7.2Hz), 2.29 (3H, s), 1.28 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.276 minutes, 429 (M+H)⁺

Example 69

5 **3-[(4-Fluoro-3-methylphenyl)amino]-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 68 by the method of Example 65. White solid. δ H (CDCl₃) 9.03 (1H, br s), 7.48-7.45 (2H, m), 7.09-7.08 (1H, m), 7.03-7.00 (1H, d, *J* 9.8Hz), 6.92-6.82 (3H, m), 6.27 (1H, d, *J* 9.8Hz), 5.12 (2H, br s), 2.19 (3H, s).

10 LCMS (ES⁺) RT 3.144 minutes, 401 (M+H)⁺

Example 70

Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-(3-thienyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

15 From Intermediate 35 and 2,4-difluoroaniline by the method of Example 1. δ H (CDCl₃) 8.64 (1H, br s), 7.65-7.62 (2H, m), 7.30-7.22 (2H, m), 7.15 (1H, d, *J* 9.8Hz), 7.09-6.94 (2H, m), 6.45 (1H, d, *J* 9.8Hz), 4.39 (2H, q, *J* 7.1Hz), 1.41 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.962 minutes, 434 (M+H)⁺

20 **Example 71**

Ethyl 6-oxo-7-phenyl-3-(pyridin-3-ylamino)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 5 and 3-aminopyridine by method of Example 1. Pale yellow solid. δ H (CDCl₃) 8.56 (1H, br s), 8.35-8.32 (1H, m), 8.22-8.20 (1H, m), 7.45-7.37 (3H, m), 7.25-7.16 (3H, m), 7.11-7.06 (1H, m), 6.98 (1H, d, *J* 9.8Hz), 6.21 (1H, d, *J* 9.8Hz), 4.07 (2H, q, *J* 7.1Hz), 1.10 (3H, t, *J* 7.1Hz). LCMS (ES⁺) 392.1 (M+H)⁺.

Example 72

30 **Ethyl 3-[(2-chloropyridin-3-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 5 and 3-amino-2-chloropyridine by method of Example 1.

Off-white solid. δ H (CDCl₃) 8.52 (1H, br s), 8.02 (1H, d, *J* 4.5Hz), 7.57-7.48 (3H, m), 7.34 (2H, m), 7.25-7.08 (3H, m), 6.42 (1H, d, *J* 9.6Hz), 4.21 (2H, q, *J* 7.0Hz), 1.23 (3H, t, *J* 7.0Hz). LCMS (ES⁺) 426.0 (³⁵Cl)(M+H)⁺.

5

Example 74

3-[(6-Methylpyridin-2-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Phosphorous trichloride (0.175mL, 2.01mmol) was added to a solution of
10 Intermediate 38 (500mg, 1.34mmol) in chloroform (15mL) and the mixture heated at 90 °C for 4h. The mixture was cooled, diluted with DCM, washed with water, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10%EtOAc in DCM) gave the title compound (75mg). δ H (CDCl₃) 7.65-7.40 (6H, m), 7.38-7.25 (2H, m), 6.75 (1H, d, *J* 7.4Hz), 6.60-
15 6.40 (2H, m), 2.38 (3H, s). LCMS (ES⁺) RT 3.15 minutes, 359 (M+H)⁺.

Example 75

3-[(6-Methylpyridin-2-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

20 From Example 74 by the method of Example 22. δ H (CDCl₃) 9.00 (1H, br s), 7.65-7.45 (4H, m), 7.42-7.25 (3H, m), 6.70 (1H, d, *J* 7.4Hz), 6.54 (1H, d, *J* 8.1Hz), 6.46 (1H, d, *J* 9.7Hz), 5.44 (2H, br s), 2.36 (3H, s). LCMS (ES⁺) RT 2.18 minutes, 377 (M+H)⁺.

25 **Example 76**

3-[(6-Chloropyridin-2-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

Sodium hydride (90mg, 60% in mineral oil, 2.25mmol) was added to a solution of Intermediate 11 (500mg, 1.87mmol) in DMSO. After 10min, 2,6-dichloropyridine (277mg, 1.87mmol) was added and the mixture heated at 70
30 °C overnight. The mixture was poured in to brine and this was then extracted

with EtOAc (x3). The organics were dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound as a pale yellow solid (440mg, 62%). δ H (CDCl₃) 7.58-7.41 (5H, m), 7.28-7.24 (2H, m), 7.16 (1H, br s), 6.81 (1H, d, *J* 7.6Hz),
5 6.57 (1H, d, *J* 8.1Hz), 6.50 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.34 minutes, 379 (M+H)⁺.

Example 77

10 3-[(6-Chloropyridin-2-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 76 by the method of Example 22. δ H (CDCl₃) 9.55 (1H, br s), 7.79-7.66 (4H, m), 7.61-7.58 (3H, m), 7.48 (2H, br s), 6.95 (1H, d, *J* 7.5Hz), 6.84 (1H, d, *J* 8.1Hz), 6.54 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 2.91

15 Example 78

Ethyl 3-[(2-cyanophenyl)amino]-7-[4-(methylthio)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 39 and 2-cyanoaniline by the method of Example 1. δ H (CDCl₃) 8.81 (1H, br s), 7.68 (1H, br d, *J* 7.8Hz), 7.53-7.45 (3H, m), 7.36-7.32
20 (2H, m), 7.28-7.24 (1H, m), 7.18-7.11 (2H, m), 6.48 (1H, d, *J* 9.7Hz), 4.32 (2H, m), 2.58 (3H, s), 1.34 (3H, m). LCMS (ES⁺) RT 3.96 minutes, 462 (M+H)⁺.

Example 79

25 Ethyl 3-[(2-cyanophenyl)amino]-7-[4-(methylsulfinyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

A mixture of Example 78 (1.0g, 2.17mmol) and *m*-chloroperbenzoic acid (534mg, 1eq) in DCM (50mL) was stirred at r.t. for 2h. The mixture was diluted with DCM, washed with NaHCO₃ aq, dried (MgSO₄) and concentrated
30 *in vacuo*. Purification by column chromatography (silica, 50% EtOAc in DCM) gave the title compound (850mg, 82%). δ H (CDCl₃) 8.80 (1H, s), 8.12-7.70

(2H, m), 7.65-7.53 (3H, m), 7.50 (1H, t, *J* 7.4Hz), 7.27 (1H, d, *J* 9.8Hz), 7.17-7.09 (2H, m), 6.45 (1H, d, *J* 9.8Hz), 4.28 (2H, q, *J* 7.1Hz), 2.83 (3H, s), 1.30 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.16 minutes, 478 (M+H)⁺.

5 **Example 80**

3-[(2-Cyanophenyl)amino]-7-[4-(methylsulfinyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 79 by the method of Example 38. δ H (DMSO-d₆) 9.32 (1H, br s), 7.85-7.75 (2H, m), 7.62-7.57 (3H, m), 7.38-7.33 (3H, m), 7.19 (1H, d, *J* 9.7Hz), 6.91 (1H, t, *J* 7.5Hz), 6.76 (1H, d, *J* 8.3Hz), 6.30 (1H, d, *J* 9.7Hz), 2.70 (3H, s). LCMS (ES⁺) RT 2.57 minutes, 449 (M+H)⁺.

Example 81

15 **Ethyl 3-anilino-7-[4-(methylthio)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 39 and aniline by the method of Example 1. δ H (CDCl₃) 8.79 (1H, br s), 7.47-7.19 (10H, m), 6.36 (1H, d, *J* 9.6Hz), 4.28 (2H, q, *J* 7.1Hz), 2.57 (3H, s), 1.32 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.268 minutes, 437 (M+H)⁺.

20

Example 82

Ethyl 3-anilino-7-[4-(methylsulfinyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Example 81 by the method of Example 79. δ H (CDCl₃) 8.70 (1H, s), 7.85 (1H, br s), 7.75 (1H, br s), 7.53 (2H, m), 7.31-7.27 (2H, m), 7.10-7.08 (4H, m), 6.27 (1H, d, *J* 9.8Hz), 4.20 (2H, q, *J* 7.1Hz), 2.76 (3H, s), 1.24 (3H, t, *J* 6.7Hz). LCMS (ES⁺) RT 3.325 minutes, 452.8 (M+H)⁺.

Example 83

30 **Ethyl 3-[(3-methylphenyl)amino]-7-[4-(methylthio)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 39 and m-toluidine by the method of Example 1. δ H (CDCl₃) 8.65 (1H, br s), 7.36-7.25 (2H, m), 7.23-7.11 (4H, m), 6.92-6.87 (3H, m), 6.27 (1H, d, *J* 9.7Hz), 4.18 (2H, q, *J* 7.12Hz), 2.48 (3H, s), 2.27 (3H, s), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.613 minutes, 451 (M+H)⁺.

5

Example 84**Ethyl 3-[(3-methylphenyl)amino]-7-[4-(methylsulfonyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

A mixture of Example 83 (100mg, 0.22mmol) and m-chloroperbenzoic acid (54mg, 2 eq) in DCM (5mL) was stirred at r.t. overnight. The mixture was diluted with DCM, washed with NaHCO₃ aq, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 50% EtOAc in hexane) gave the title compound (10mg). δ H (CDCl₃) 8.66 (1H, br s), 8.11 (2H, d, *J* 8.5Hz), 7.59 (2H, d, *J* 8.5Hz), 7.19-7.13 (2H, m), 6.94-6.89 (3H, m), 6.26 (1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.1Hz), 3.08 (3H, s), 2.28 (3H, s), 1.18 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.713 minutes, 483 (M+H)⁺.

15

Example 85**3-[(3-Methylphenyl)amino]-7-[4-(methylsulfonyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

20

From Example 84 by the method of Example 38. δ H (CDCl₃) 8.21 (2H, d, *J* 8.6Hz), 7.70 (2H, d, *J* 8.6Hz), 7.26-7.21 (3H, m), 6.97-6.92 (3H, m), 6.40 (1H, d, *J* 9.8Hz), 3.17 (3H, s), 2.36 (3H, s). LCMS (ES⁺) RT 2.954 minutes, 454 (M+H)⁺.

25

Example 86**Ethyl 3-anilino-6-oxo-7-[4-(pyrrolidin-1-ylmethyl)phenyl]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 41 and aniline by the method of Example 1. δ H (CDCl₃) 8.62 (1H, br s), 7.60-7.53 (4H, m), 7.37-7.25 (4H, m), 7.18-7.07 (4H, m), 6.26

30

(1H, d, *J* 9.8Hz), 4.19 (2H, q, *J* 7.1Hz), 2.63 (4H, m), 1.82 (4H, m), 1.22 (3H, t, *J* 7.09Hz). LCMS (ES⁺) RT 2.479 minutes, 474 (M+H)⁺.

Example 87

5 **Ethyl 3-[(2,4-difluorophenyl)amino]-7-[4-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

A mixture of Intermediate 45 (375mg, 0.68mmol), 2-methylimidazole (84mg, 1.02mmol) and caesium carbonate (332mg, 1.02mmol) in DMF (5mL) was heated at 80 °C for 18h. The mixture was partitioned between DCM and
10 water and the aqueous phase was extracted with DCM (2 x 20mL). The combined organics were washed with water (2 x 20mL) and brine, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 5% MeOH in DCM) gave the title compound (165mg). δ H (DMSO-d₆) 8.65 (1H, s), 7.43-7.30 (4H, m), 7.20-7.10 (4H, m), 6.77 (1H, d, *J* 1.2Hz),
15 6.40 (1H, d, *J* 9.8Hz), 4.40-4.34 (4H, br m), 4.17 (2H, q, *J* 7.1Hz), 2.47 (3H, s), 1.19 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 1.929 minutes, 551 (M+H)⁺.

Example 88

20 **3-[(2,4-Difluorophenyl)amino]-7-[4-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 87 by the method of Example 38. δ H (d₃-MeOD) 7.32-7.25 (3H, m), 7.07-6.91 (5H, m), 6.86-6.74 (2H, m), 6.34 (1H, d, *J* 9.6Hz), 4.31-4.25 (4H, br m), 2.36 (3H, s). LCMS (ES⁺) RT 2.356 minutes, 522 (M+H)⁺.

25

Example 89

Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-(4-vinylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 46 and 2,4-difluoroaniline by the method of Example 1. δ H (CDCl₃) 8.5 (1H, br s), 7.6 (2H, d, *J* 2.3Hz), 7.28 (2H, d, *J* 2.4Hz), 7.23-6.68 (5H, m), 6.309 (1H, d, *J* 9.8Hz), 5.78 (1H, d, *J* 17Hz), 5.32 (1H, d, *J* 11.8Hz),
30

4.2 (2H, q, *J* 7.1Hz), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.225 minutes, 453 (M+H)⁺.

Example 90

5 **Ethyl 3-anilino-6-oxo-7-(4-vinylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 46 and aniline by the method of Example 1. δ H (CDCl₃) 8.72 (1H, br s), 7.53-7.50 (2H, m), 7.32-7.26 (4H, m), 7.13-7.05 (4H, m), 6.72 (1H, dd, *J* 17.5, 11.0Hz), 6.27 (1H, d, *J* 9.8Hz), 5.78 (1H, d, *J* 17.5Hz), 5.32 (1H, d, *J* 11.0Hz), 4.18 (2H, q, *J* 7.1Hz), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.324 minutes, 417 (M+H)⁺.

10

Example 91

3-Anilino-6-oxo-7-(4-vinylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

15 From Example 90 by the method of Example 38. δ H (CDCl₃) 8.96 (1H, br s), 7.54 (2H, d, *J* 10.5Hz), 7.29-7.03 (8H, m), 6.72 (1H, dd, *J* 17.6, 11.0Hz), 6.31 (1H, d, *J* 9.8Hz), 5.78 (1H, dd, *J* 17.6, 0.4Hz), 5.32 (1H, d, *J* 11.0Hz), 5.23 (2H, s). LCMS (ES⁺) RT 3.214 minutes, 388 (M+H)⁺.

20

Example 92

Ethyl 3-anilino-7-[4-(1,2-dihydroxyethyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

A mixture of Example 91 (134mg, 0.32mmol), 4-methylmorpholine N-oxide (113mg, 0.97mmol) and osmium tetroxide (98mg of a 2.5 wt.% solution in 2-methyl-2-propanol, 0.1mmol) in acetone/water (8:1)(10mL) and EtOAc (10mL) was stirred at r.t. overnight. Sodium sulfite solution (sat. 10mL) was added and the mixture stirred for 15min. The mixture was extracted with EtOAc (2 x 20mL) and the combined organics washed with brine, dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, EtOAc) gave the title compound (104mg, 72%). δ H (DMSO-d₆) 8.70

25

30

(1H, s), 7.54-7.49 (2H, m), 7.37-7.35 (2H, m), 7.28-7.23 (2H, m), 7.15 (1H, d, *J* 9.7Hz), 7.07-7.00 (3H, m), 6.31 (1H, d, *J* 9.7Hz), 5.35 (1H, d, *J* 4.3 Hz), 4.75 (1H, t, *J* 5.7Hz), 4.59-4.58 (1H, m), 4.08 (2H, q, *J* 7.1Hz), 4.03-4.00 (1H, m), 3.48-3.45 (1H, br m), 1.09 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.3 minutes, 451 (M+H)⁺.

Example 93

3-Anilino-7-[4-(1,2-dihydroxyethyl)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

10 From Example 91 by the method of Example 92. δ H (CDCl₃) 8.93 (1H, s), 7.56 (10H, m), 6.31 (1H, d, *J* 9.7Hz), 5.23 (2H, s), 4.85-4.82 (1H, m), 3.79-3.75 (1H, m), 3.66-3.59 (2H, m), 2.22 (1H, br s). LCMS (ES⁺) RT 2.62 minutes, 422 (M+H)⁺.

Example 94

3-[(2,4-Difluorophenyl)amino]-7-(4-[(2R)-2,3-dihydroxypropyl]oxy)phenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

A mixture of Intermediate 50 (49mg, 0.1mmol) and Dowex (50X4 200) (cat. amount) in EtOH (2mL) and water (0.5mL) was heated at 50 °C overnight. The mixture was diluted with EtOH (3mL) and filtered hot. The filtrate was concentrated *in vacuo* to give the title compound (33mg). δ H (CDCl₃) 7.30 (1H, d, *J* 9.7Hz), 7.25-7.23 (2H, m), 7.11-7.03 (3H, m), 6.92-6.82 (2H, m), 6.49 (1H, d, *J* 9.7Hz), 6.10 (1H, s), 4.12-4.05 (3H, m), 3.81 (1H, dd, *J* 11.3, 3.7Hz), 3.71 (1H, dd, *J* 11.3, 5.0Hz). LCMS (ES⁺) RT 2.864 minutes, 470 (M+H)⁺.

Example 95

Ethyl 3-[(2,4-difluorophenyl)amino]-7-(2-nitrophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

30

A mixture of Intermediate 51 (423mg, 1.0mmol), 2,4-difluoroaniline (0.122mL, 1.2mmol), caesium carbonate (456mg, 1.4mmol), BINAP (62mg, 10mol%) and tris(dibenzylideneacetone)dipalladium(0) (46mg, 5mol%) in toluene (10mL) was heated at reflux for 24h. The mixture was diluted with DCM, washed with 1M HCl aq and 10% NaOH aq, dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 0 to 2% THF in DCM) gave the title compound as a yellow gum (411mg, 87%). δ H (DMSO-d₆) 8.78 (1H, s), 8.42 (1H, dd, *J* 1.3, 8.1Hz), 8.14-8.10 (1H, m), 8.03-7.97 (2H, m), 7.50-7.38 (2H, m), 7.31 (1H, d, *J* 9.8Hz), 7.21-7.16 (1H, m), 6.47 (1H, d, *J* 9.8Hz), 4.22 (2H, q, *J* 7.1Hz), 1.22 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.916 minutes, 471.9 (M+H)⁺.

Example 96

3-[(2,4-Difluorophenyl)amino]-7-(2-nitrophenyl)-6-oxo-6,7-

15 dihydrothieno[2,3-*b*]pyridine-2-carboxamide

CDI (211mg, 1.29mmol) was added to crude Intermediate 52 (0.86mmol) in DMF (10mL). After 90min, conc. ammonia (5mL) was added and the mixture stirred for 4h. Volatiles were removed *in vacuo* and the residue partitioned between DCM and water. The DCM layer was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 20% EtOAc in DCM) gave the title compound as a yellow solid (218mg, 57%). δ H (DMSO-d₆) 9.21 (1H, s), 8.43-8.41 (1H, m), 8.15-8.11 (1H, m), 8.05-8.03 (1H, m), 8.00-7.96 (1H, m), 7.49-7.39 (3H, m), 7.36 (1H, d, *J* 9.7Hz), 7.14-7.08 (2H, m), 6.47 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.125 minutes, 442.8 (M+H)⁺.

Example 97

Ethyl 3-anilino-4-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate

A mixture of Intermediate 57 (1.20g, 3.06mmol), aniline (0.334mL, 3.67mmol), caesium carbonate (1.40g, 4.28mmol), BINAP (190mg,

0.306mmol) and tris(dibenzylideneacetone)dipalladium(0) (140mg, 0.153mmol) in toluene (30mL) was heated at reflux for 3 days. The solvent was removed *in vacuo* and the residue partitioned between DCM and water. The organic phase was washed with 1M HCl aq, dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatograph (silica, 2% THF in DCM) gave the title compound as a yellow powder (1.15g, 77%). ¹H (CDCl₃) 8.01 (1H, s), 7.47-7.55 (3H, m), 7.33-7.37 (2H, m), 7.17-7.22 (2H, m), 6.93 (1H, t, *J* 7.4Hz), 6.80 (2H, d, *J* 7.9Hz), 6.25 (1H, s), 4.16 (2H, q, *J* 7.1Hz), 2.03 (3H, s), 1.19 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.04 minutes, 405 (M+H)⁺

Example 98

3-Anilino-4-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide

A mixture of Example 97 (150mg, 0.37mmol), ethoxyethanol and liquid ammonia was heated in a sealed vessel at 80°C at 400 psi for 16h. The mixture was concentrated *in vacuo* and the solid recrystallised from MeOH to give the title compound as a yellow solid (92mg, 66%). ¹H (DMSO-*d*₆) 8.05 (1H, s), 7.68-7.59 (3H, m), 7.53-7.51 (2H, m), 7.5 (1H, br), 7.24-7.20 (2H, m), 6.80 (1H, t, *J* 7.3Hz), 6.64 (2H, d, *J* 7.7Hz), 6.29 (1H, s), 2.22 (3H, s). LCMS (ES⁺) RT 3.074 minutes, 375.9 (M+H)⁺

Example 99

3-[(2,4-Difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-sulfonamide

A mixture of Intermediate 60 (50mg), trifluoroacetic acid (2mL) and DCM (10mL) was stirred at r.t. overnight. Solvents were removed *in vacuo* and the residue azeotroped with toluene (x3). The residue was dissolved in DCM, treated with triethylamine (3mL) and the mixture concentrated *in vacuo*. Purification by column chromatography (silica, 5% EtOAc in DCM) gave the title compound (25mg, 63%). ¹H (CDCl₃) 7.51-7.47 (3H, m), 7.33-7.29 (2H,

m), 7.07-6.98 (3H, m), 6.93-6.78 (2H, m), 6.38 (1H, d, *J* 9.2Hz), 4.87 (2H, br s). LCMS (ES⁺) RT 3.17 minutes, 434 (M+H)⁺.

Example 100

5 **Ethyl 3-anilino-7-[2-(2-methoxyethoxy)ethyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 61 and aniline by the method of Example 1. δ H (CDCl₃) 8.85 (1H, br s), 7.42-7.30 (2H, m), 7.24-7.19 (4H, m), 6.34 (1H, d, *J* 9.7Hz), 4.45 (2H, q, *J* 7.1Hz), 4.41-3.98 (2H, m), 3.79-3.75 (2H, m), 3.65-3.62 (2H, m), 3.60-3.55 (2H, m), 3.47 (3H, s), 1.49 (3H, t, *J* 7.1Hz). LCMS (ES⁺) 417.1 (M+H)⁺.

Example 101

15 **Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-(tetrahydro-2H-pyran-2-ylmethyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 62 and 2,4-difluoroaniline by the method of Example 1. δ H (CDCl₃) 8.45 (1H, br s), 7.05-6.99 (1H, m), 6.95 (1H, d, *J* 9.7Hz), 6.89-6.72 (2H, m), 6.21 (1H, d, *J* 9.7Hz), 4.33-4.23 (2H, m), 4.21-4.13 (1H, m), 3.89-3.74 (3H, m), 3.31-3.22 (1H, m), 1.97-1.78 (2H, m), 1.68-1.39 (4H, m), 1.32 (3H, t, *J* 7.1Hz). LCMS (ES⁺) 449.0 (M+H)⁺.

Example 102

25 **Ethyl 3-anilino-7-benzyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 63 and aniline by the method of Example 1. Pale yellow solid. δ H (CDCl₃) 8.52 (1H, br s), 7.20-7.05 (7H, m), 6.98-6.88 (4H, m), 6.11 (1H, d, *J* 9.7Hz), 5.11 (2H, s), 4.10 (2H, q, *J* 7.1Hz), 1.15 (3H, t, *J* 7.1Hz). LCMS (ES⁺) 405 (M+H)⁺.

30 **Example 103**

3-Anilino-7-benzyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

- From Intermediate 64 by the method of Example 45. δ H (DMSO-d₆) 8.69 (1H, br s), 7.43 (2H, br s), 7.40-7.30 (6H, m), 7.25-7.20 (2H, m), 6.91-6.84 (3H, m), 6.45 (1H, d, *J* 9.6Hz), 5.32 (2H, s). LCMS (ES⁺) 376 (M+H)⁺.

Example 104

3-Anilino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbohydrazide

- 10 To a stirred solution of Example 1 (200mg, 0.5mmol) in ethoxyethanol (5mL) was added hydrazine hydrate (1.5mmol). The reaction mixture was heated to 120 °C for 6 h. Upon cooling the reaction mixture was poured into sat NaHCO₃ aq and extracted with DCM (x 2). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. Purification by flash column
- 15 chromatography (silica, 5% EtOH in DCM) gave the title compound (86mg, 46%). δ H (CDCl₃) 8.76 (1H, br s), 8.60 (1H, br s), 7.55-7.7 (3H, m), 7.4-7.5 (2H, m), 7.25-7.35 (3H, m), 6.9-7.0 (2H, m), 6.35 (1H, d, *J* 10Hz), 4.3 (2H, br s). LCMS (ES⁺) RT 2.84 minutes, 377 (M+H)⁺.

Example 105

- 20 **Ethyl 3-anilino-7-[4-(dimethylamino)phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From Intermediate 65 and aniline by the method of Example 1. δ H (CDCl₃) 8.69 (1H, br s), 7.26 (2H, t, *J* 8.0Hz), 7.14 (2H, d, *J* 9.0Hz), 7.10-7.05 (4H, m), 6.75 (2H, d, *J* 9.0Hz), 6.26 (1H, d, *J* 9.7Hz), 4.17 (2H, q, *J* 7.1Hz), 2.96 (6H, s), 1.21 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.31 minutes, 434 (M+H)⁺.

Example 106

3-Anilino-7-[4-(dimethylamino)phenyl]-N-methoxy-N-methyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

- 30 From Intermediate 66 and N,O-dimethylhydroxylamine hydrochloride by the method of Example 17. δ H (CDCl₃) 9.92 (1H, br s), 7.26-7.13 (6H, m), 7.05-

7.01 (2H, m), 6.75 (2H, d, *J* 8.8Hz), 6.26 (1H, d, *J* 9.7Hz), 3.57 (3H, s), 3.19 (3H, s), 2.97 (6H, s). LCMS (ES⁺) RT 3.77 minutes, 449 (M+H)⁺.

Example 107

5 **3-Anilino-7-[4-(dimethylamino)phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 66 and 1-(3-aminopropyl)imidazole by the method of Example 17. δ H (CDCl₃) 8.52 (1H, br s), 7.35 (1H, s), 7.24 (1H, m), 7.21-7.12 (3H, m), 7.02-6.95 (4H, m), 6.81 (1H, s), 6.74 (2H, d, *J* 9.0Hz), 6.31 (1H, d, *J* 9.6Hz), 5.89 (1H, br t, *J* 6.0Hz), 3.86 (2H, t, *J* 6.4Hz), 3.23 (2H, q, *J* 6.3Hz), 2.96 (6H, s), 1.93-1.89 (2H, m). LCMS (ES⁺) RT 2.39 minutes, 513 (M+H)⁺.

Example 108

15 **3-Anilino-7-[4-(dimethylamino)phenyl]-6-oxo-N-(2-piperidin-1-ylethyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 66 and 1-(2-aminoethyl)piperidine by the method of Example 17. δ H (CDCl₃) 8.63 (1H, br s), 7.23-7.14 (5H, m), 6.97-6.94 (3H, m), 6.76-6.73 (2H, m), 6.43 (1H, br s), 6.31 (1H, d, *J* 9.7Hz), 3.33 (2H, q, *J* 5.7Hz), 2.96 (6H, s), 2.39 (2H, t, *J* 4.9Hz), 2.35-2.22 (4H, m), 1.53-1.43 (4H, m), 1.29-1.28 (2H, m). LCMS (ES⁺) RT 2.44 minutes, 516 (M+H)⁺.

Example 109

25 **3-Anilino-N,N-dimethyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 14 and dimethylamine hydrochloride by the method of Example 17. δ H (CDCl₃) 8.45 (1H, br), 7.55-7.46 (3H, m), 7.36-7.30 (3H, m), 7.23-7.18 (2H, m), 6.95-6.92 (3H, m), 6.36 (1H, d, *J* 9.7Hz), 2.98 (6H, s). LCMS (ES⁺) RT 3.18 minutes, 390 (M+H)⁺.

30 **Example 110**

3-Anilino-N,N-diethyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and diethylamine by the method of Example 17. δ H (CDCl₃) 7.55-7.45 (3H, m), 7.37-7.30 (3H, m), 7.23-7.18 (2H, m), 6.94-6.91 (3H, m), 6.37 (1H, d, *J* 9.7Hz), 3.38 (4H, q, *J* 7.1Hz), 1.05 (6H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.49 minutes, 418 (M+H)⁺.

Example 111

3-Anilino-N-methoxy-N-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and N,O-dimethylhydroxylamine hydrochloride by the method of Example 17. δ H (CDCl₃) 9.93 (1H, br s), 7.54-7.44 (3H, m), 7.35-7.32 (2H, m), 7.27-7.23 (2H, m), 7.16 (1H, d, *J* 9.7Hz), 7.07-7.02 (3H, m), 6.27 (1H, d, *J* 9.7Hz), 3.54 (3H, s), 3.19 (3H, s). LCMS (ES⁺) RT 3.64 minutes, 376 (M+H)⁺.

Example 112

3-Anilino-N-[3-(4-methylpiperazin-1-yl)propyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and 1-(3-aminopropyl)-4-methylpiperazine by the method of Example 17. δ H (CDCl₃) 9.21 (1H, br s), 7.55-7.45 (3H, m), 7.38-7.30 (2H, m), 7.27-7.17 (3H, m), 7.01-6.98 (3H, m), 6.33 (1H, d, *J* 9.7Hz), 3.39-3.35 (2H, m), 2.50-2.05 (10H, m), 2.07 (3H, s), 1.64-1.60 (2H, m). LCMS (ES⁺) RT 2.26 minutes, 502 (M+H)⁺.

Example 113

3-Anilino-N-[3-(1H-imidazol-1-yl)propyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and 1-(3-aminopropyl)imidazole by the method of Example 17. δ H (CDCl₃) 8.51 (1H, br s), 7.56-7.39 (3H, m), 7.34-7.30 (3H, m), 7.26-

7.18 (3H, m), 7.02-6.96 (3H, m), 6.92 (1H, s), 6.80 (1H, s), 6.31 (1H, d, *J* 9.7Hz), 6.14 (1H, m), 3.85 (2H, t, *J* 6.8Hz), 3.22 (2H, q, *J* 6.3Hz), 1.90 (2H, m). LCMS (ES⁺) RT 2.36 minutes, 470 (M+H)⁺.

5 **Example 114**

3-Anilino-N-[2-(diethylamino)ethyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and N,N-diethylethylenediamine by the method of Example 17. δ H (CDCl₃) 8.72 (1H, br s), 7.56-7.47 (3H, m), 7.36-7.33 (2H, m), 7.25-
10 7.19 (3H, m), 7.01-6.94 (3H, m), 6.33 (1H, d, *J* 9.7Hz), 6.42-6.28 (1H, br s), 3.31-3.27 (2H, m), 2.50-2.40 (6H, m), 0.88 (6H, t, *J* 7.1Hz). LCMS (ES⁺) RT 2.40 minutes, 461 (M+H)⁺.

Example 115

15 **3-Anilino-N-[2-(diethylamino)ethyl]-N-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 14 and N,N-diethyl-N'-methylethylenediamine by the method of Example 17. δ H (CDCl₃) 8.35 (1H, br s), 7.47-7.38 (3H, m), 7.29-7.25 (2H, m), 7.20 (1H, d, *J* 9.7Hz), 7.15-7.12 (2H, m), 6.88-6.85 (3H, m), 6.28 (1H, d, *J* 9.7Hz), 3.38 (2H, t, *J* 7.0Hz), 2.92 (3H, s), 2.44 (2H, t, *J* 7.0Hz), 2.39-2.33
20 (4H, m), 0.81 (6H, m). LCMS (ES⁺) RT 2.35 minutes, 475 (M+H)⁺.

Example 116

25 **3-Anilino-N-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 14 and methylamine by the method of Example 17. δ H (CDCl₃) 8.73 (1H, br s), 7.54-7.45 (3H, m), 7.35-7.31 (2H, m), 7.26-7.18 (3H, m), 7.03-6.97 (3H, m), 6.31 (1H, d, *J* 9.7Hz), 5.57-5.54 (1H, br m), 2.78 (3H, d, *J* 4.8Hz). LCMS (ES⁺) RT 3.22 minutes, 376 (M+H)⁺.

30

Example 117

3-Anilino-N-ethyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and ethylamine by the method of Example 17. δ H (CDCl₃) 8.84 (1H, br s), 7.56-7.47 (3H, m), 7.36-7.33 (2H, m), 7.26-7.19 (3H, m),
5 7.02-6.99 (3H, m), 6.33 (1H, d, *J* 9.7Hz), 5.40 (1H, m), 3.28 (2H, m), 1.07 (3H, t, *J* 7.3Hz). LCMS (ES⁺) RT 3.39 minutes, 390 (M+H)⁺.

Example 118

3-Anilino-N-(2-morpholin-4-ylethyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

10 From Example 14 and 4-(2-aminoethyl)morpholine by the method of Example 17. δ H (CDCl₃) 8.47 (1H, br s), 7.58-7.49 (3H, m), 7.37-7.35 (2H, m), 7.25-7.17 (3H, m), 7.01-6.91 (3H, m), 6.35 (1H, d, *J* 9.7Hz), 6.37-6.33 (1H, br m), 3.55-3.53 (4H, m), 3.37-3.34 (2H, m), 2.43-2.41 (2H, m), 2.35-2.33 (4H, m).
15 LCMS (ES⁺) RT 2.34 minutes, 475 (M+H)⁺.

Example 119

3-Anilino-N-[2-(dimethylamino)ethyl]-N-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

20 From Example 14 and N,N-dimethyl-N'-methylethylenediamine by the method of Example 17. δ H (CDCl₃) 8.32 (1H, br s), 7.55-7.48 (3H, m), 7.37-7.34 (2H, m), 7.26 (1H, d, *J* 9.7Hz), 7.25-7.18 (2H, m), 6.96-6.92 (3H, m), 6.36 (1H, d, *J* 9.7Hz), 3.52 (2H, t, *J* 6.7Hz), 2.97 (3H, s), 2.41 (2H, t, *J* 6.7Hz), 2.19 (6H, s). LCMS (ES⁺) RT 2.27 minutes, 447 (M+H)⁺.
25

Example 120

3-Anilino-N-(3-morpholin-4-ylpropyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 14 and 4-(3-aminopropyl)morpholine by the method of
30 Example 17. δ H (CDCl₃) 9.30 (1H, br s), 7.72 (1H, br s), 7.65-7.56 (3H, m),

7.46-7.43 (2H, m), 7.35-7.28 (3H, m), 7.11-7.08 (3H, m), 6.42 (1H, d, *J* 9.7Hz), 3.51-3.44 (6H, m), 2.52-2.44 (6H, m), 1.74-1.68 (2H, m). LCMS (ES⁺) RT 2.33 minutes, 489 (M+H)⁺.

5 **Example 121**

3-[(2,4-Difluorophenyl)amino]-N-methoxy-N-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Intermediate 67 and N,O-dimethylhydroxylamine hydrochloride by the method of Example 17. δ H (CDCl₃) 9.90 (1H, br s), 7.73-7.63 (3H, m), 7.51-7.47 (2H, m), 7.25-7.19 (2H, m), 7.06-6.90 (2H, m), 6.46 (1H, d, *J* 9.7Hz), 3.70 (3H, s), 3.36 (3H, s). LCMS (ES⁺) RT 3.67 minutes, 442 (M+H)⁺.

Example 122

15 **3-[(2,4-Difluorophenyl)amino]-6-oxo-7-phenyl-N-(2-piperidin-1-ylethyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 67 and 1-(2-aminoethyl)piperidine by the method of Example 17. δ H (CDCl₃) 8.40 (1H, s), 7.43-7.58 (3H, m), 7.32-7.37 (2H, m), 7.13 (1H, d, *J* 9.7Hz), 6.82-6.98 (2H, m), 6.74 (1H, tq, *J* 1.5, 7.9Hz), 6.55 (1H, s), 6.37 (1H, d, *J* 9.7Hz), 3.34 (2H, q, *J* 5.8Hz), 2.22-2.44 (6H, m), 1.32-20 1.48 (6H, m). LCMS (ES⁺) RT 2.42 minutes, 509 (M+H)⁺.

Example 123

3-Anilino-N-(2-hydroxy-1,1-dimethylethyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

25 A mixture of Example 1 and 2-amino-2-methyl-1-propanol (1.22mL, 13mmol) was heated at 150 °C for 16h. The mixture was partitioned between DCM (60mL) and 10% citric acid (75mL). The aqueous phase was extracted with DCM (20mL). The combined organics were dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 40% EtOAc in DCM)
30 gave the title compound as a pale brown solid (45mg, 16%). δ H (CDCl₃) 8.44 (1H, br s), 7.56-7.46 (3H, m), 7.34-7.31 (2H, m), 7.26-7.20 (3H, m), 7.03-6.96

(3H, m), 6.33 (1H, d, *J* 9.7Hz), 5.65 (1H, br s), 4.21-4.18 (1H, br m), 3.49 (2H, d, *J* 5.5Hz), 1.18 (6H, s). LCMS (ES⁺) 434 (M+H)⁺.

Example 124

5 **Ethyl 3-[(3-chloro-2-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 5 and 2-amino-6-chlorobenzonitrile by the method of Example 1. δ H (DMSO-d₆) 8.96 (1H, br s), 7.63-7.53 (4H, m), 7.45-7.29 (3H, m), 7.15 (1H, d, *J* 9.6Hz), 6.90 (1H, d, *J* 8.3Hz), 6.44 (1H, d, *J* 9.6Hz), 4.01 (2H, q, *J* 7.1Hz), 1.0 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.916 minutes, 450.0 (M+H)⁺.

Example 125

15 **Ethyl 3-[(2-cyano-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 5 and 2-amino-6-methylbenzonitrile by the method of Example 1. δ H (DMSO-d₆) 8.91 (1H, s), 7.74-7.48 (7H, m), 7.16 (1H, d, *J* 7.6Hz), 7.03 (1H, d, *J* 8.2Hz), 6.53 (1H, d, *J* 9.7Hz), 4.20 (2H, q, *J* 7.1Hz), 2.57 (3H, s), 1.20 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.888 minutes, 430.0 (M+H)⁺.

Example 126

25 **Ethyl 3-[(2-cyano-5-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 5 and 2-amino-4-methylbenzonitrile by the method of Example 1. δ H (DMSO-d₆) 9.06 (1H, s), 7.86-7.78 (4H, m), 7.72-7.69 (2H, m), 7.63 (1H, d, *J* 9.7Hz), 7.20-7.17 (2H, m), 6.66 (1H, d, *J* 9.7Hz), 4.32 (2H, q, *J* 7.1Hz), 2.47 (3H, s), 1.31 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.914 minutes, 430.0 (M+H)⁺.

30

Example 127

Ethyl 3-[(4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 5 and 4-fluoroaniline by the method of Example 1. Off-white solid. δ H (DMSO- d_6) 8.68 (1H, s), 7.46-7.58 (3H, m), 7.37-7.43 (2H, m), 7.05-7.12 (5H, m), 6.30 (1H, d, J 9.7Hz), 4.05 (2H, q, J 7.1Hz), 1.06 (3H, t, J 7.1Hz). LCMS (ES⁺) RT 3.98 minutes, 409 (M+H)⁺.

Example 128

10 **Ethyl 3-[(4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 5 and 4-amino-2-chlorobenzonitrile by the method of Example 1. Pale orange solid. δ H (CDCl₃) 8.53 (1H, br s), 7.58-7.49 (4H, m), 7.37-7.34 (2H, m), 7.30 (1H, d, J 9.7Hz), 7.04 (1H, d, J 2.3Hz), 6.89 (1H, dd, J 8.6, 2.3Hz), 6.48 (1H, d, J 9.7Hz), 4.20 (2H, q, J 7.1Hz), 1.22 (3H, t, J 7.1Hz). LCMS (ES⁺) RT 3.77 minutes, 450 (M+H)⁺.

Example 129

Ethyl 3-[(3-chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

20 From Intermediate 5 and 3-chloro-4-fluoroaniline by the method of Example 1. δ H (CDCl₃) 8.70 (1H, s), 7.67-7.59 (3H, m), 7.44-7.41 (2H, m), 7.24-7.02 (4H, m), 6.43 (1H, d, J 9.8Hz), 4.28 (2H, q, J 7.1Hz), 1.31 (3H, t, J 7.1Hz). LCMS (ES⁺) RT 4.245 minutes, 443 (M+H)⁺.

25 **Example 130**

Ethyl 3-[(2-cyanophenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate

From Intermediate 68 and anthranilonitrile by the method of Example 1. δ H (CDCl₃) 8.77 (1H, br s), 7.62 (1H, d, J 7.6Hz), 7.47 (1H, t, J 6.6Hz), 7.40-7.37 (2H, m), 7.28-7.21 (3H, m), 7.13-7.07 (2H, m), 6.42 (1H, d, J 9.7Hz), 4.29

(2H, q, *J* 7.0Hz), 1.28 (3H, t, *J* 7.0Hz). LCMS (ES⁺) RT 3.770 minutes, 433.9 (M+H)⁺.

Example 131

5 **Ethyl 3-[(2-cyano-3-methylphenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 68 and 2-amino-6-methylbenzonitrile by the method of Example 1. Light yellow solid. δ H (CDCl₃) 8.76 (1H, br s), 7.40-7.19 (6H, m), 6.97 (1H, d, *J* 7.6Hz), 6.89 (1H, d, *J* 8.2Hz), 6.4 (1H, d, *J* 9.7Hz), 4.26 (2H, q, *J* 7.0Hz), 2.54 (3H, s), 1.28 (3H, t, *J* 7.0Hz). LCMS (ES⁺) RT 3.937 minutes, 448.0 (M+H)⁺.

10

Example 132

15 **Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 68 and 4-fluoro-3-methylaniline by the method of Example 1. Light yellow solid. δ H (CDCl₃) 8.78 (1H, br s), 7.38-7.35 (2H, m), 7.28-7.24 (2H, m), 7.04-6.96 (4H, m), 6.3 (1H, d, *J* 9.8Hz), 4.24 (2H, q, *J* 7.1Hz), 2.25 (3H, s), 1.28 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.298 minutes, 441.0 (M+H)⁺.

20

Example 133

25 **Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 69 and 4-fluoro-3-methylaniline by the method of Example 1. δ H (CDCl₃) 8.72 (1H, br s), 7.58-7.38 (2H, m), 7.35-7.28 (2H, m), 6.99-6.98 (4H, m), 6.34 (1H, d, *J* 9.8Hz), 4.28 (2H, q, *J* 7.1Hz), 2.29 (3H, s), 1.32 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.57 minutes, 457 (M+H)⁺.

Example 134

30 **Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-7-(3-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- From Intermediate 70 and 4-fluoro-3-methylaniline by the method of Example 1. δ H (CDCl₃) 8.63 (1H, br s), 7.4-7.15 (1H, m), 7.30-7.27 (1H, m), 7.18-7.10 (2H, m), 7.04-6.90 (4H, m), 6.27 (1H, d, *J* 9.7Hz), 4.18 (2H, q, *J* 7.1Hz), 2.21 (3H, s), 2.20 (3H, s), 1.21 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.469 minutes, 437 (M+H)⁺.

Example 135**Ethyl 3-[(3-methylphenyl)amino]-7-(3-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate**

- 10 From Intermediate 70 and 3-methylaniline by the method of Example 1. δ H (CDCl₃) 8.55 (1H, br s), 7.32-7.28 (1H, m), 7.27-7.17 (1H, m), 7.08-7.00 (4H, m), 7.88-7.75 (3H, m), 6.15 (1H, d, *J* 9.8Hz), 4.08 (2H, q, *J* 7.1Hz), 2.27 (3H, s), 2.17 (3H, s), 1.12 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 4.543 minutes, 419 (M+H)⁺.
- 15

Example 136**3-[(2,4-Difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- From Intermediate 9 and 2,4-difluoroaniline by the method of Example 1. Off-white solid. δ H (DMSO-d₆) 9.34 (1H, s), 8.20 (1H, d, *J* 9.6Hz), 7.42-7.72 (7H, m), 7.19 (1H, dq, *J* 1.1, 9.6Hz), 6.70 (1H, d, *J* 9.6Hz). LCMS (ES⁺) RT 3.43 minutes, 380 (M+H)⁺.
- 20

Example 137

- 25 **3-[(3-Chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- From Intermediate 9 and 3-chloro-4-fluoroaniline by the method of Example 1. δ H (DMSO-d₆) 9.30 (1H, br s), 7.87 (1H, d, *J* 9.7Hz), 7.55-7.48 (3H, m), 7.42-7.38 (2H, m), 7.31-7.23 (2H, m), 7.09-7.00 (1H, m), 6.51 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.578 minutes, 396 (M+H)⁺.
- 30

Example 138**3-[(2-Methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 5 From Intermediate 9 and 2-methylaniline by the method of Example 1.
Orange solid. δ H (DMSO- d_6) 8.9 (1H, s), 8.08 (1H, d, J 9.6Hz), 7.6-7.4 (5H, m), 7.26 (1H, s), 7.25-7.15 (3H, m), 6.6 (1H, d, J 9.6Hz), 2.2 (3H, s). LCMS (ES⁺) RT 3.46 minutes, 358 (M+H)⁺.

10 **Example 139**

3-[(3-Methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- From Intermediate 9 and 3-methylaniline by the method of Example 1.
Orange solid. δ H (DMSO- d_6) 9.2 (1H, s), 8.0 (1H, d, J 9.6Hz), 7.6-7.5 (5H, m), 7.2 (3H, m), 6.9 (1H, m), 6.6 (1H, d, J 9.6Hz), 2.2 (3H, s). LCMS (ES⁺) RT 3.54 minutes, 358 (M+H)⁺.
- 15

Example 140**3-[(3,5-Dichlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-****b]pyridine-2-carbonitrile**

- From Intermediate 9 and 3,5-dichloroaniline by the method of Example 1.
Off-white solid. δ H (DMSO- d_6) 9.3 (1H, s), 7.65 (1H, d, J 9.6Hz), 7.4-7.3 (5H, m), 6.9 (1H, s), 6.8 (2H, s), 6.4 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 3.63 minutes, 412 (M+H)⁺.
- 20

25

Example 141**3-[(3-Nitrophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 3-nitroaniline by the method of Example 1. Yellow solid. δ H (DMSO- d_6) 9.8 (1H, s), 8.0 (1H, d, J 9.6Hz), 7.9-7.5 (9H, m), 6.6 (1H, d, J 9.6Hz). LCMS (ES^+) RT 3.42 minutes, 389 ($M+H$) $^+$.

5 **Example 142**

6-Oxo-7-phenyl-3-([2-(trifluoromethoxy)phenyl]amino)-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 9 and 2-(trifluoromethoxy)aniline by the method of Example 1. δ H (DMSO- d_6) 9.31 (1H, s), 8.10 (1H, d, J 9.7Hz), 7.7-7.3 (9H, m), 6.69 (1H, d, J 9.7Hz). LCMS (ES^+) RT 3.676 minutes, 427.8 ($M+H$) $^+$.

Example 143

3-([2,6-Dichlorophenyl]amino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

15 From Intermediate 9 and 2,6-dichloroaniline by the method of Example 1. δ H (DMSO- d_6) 9.60 (1H, s), 8.32 (1H, d, J 9.7Hz), 7.71-7.46 (8H, m), 6.73 (1H, d, J 9.7Hz). LCMS (ES^+) RT 3.454 minutes, 411.8 ($M+H$) $^+$.

Example 144

20 **3-([2-(Difluoromethoxy)phenyl]amino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 2-(difluoromethoxy)aniline by the method of Example 1. δ H (DMSO- d_6) 9.15 (1H, s), 8.13 (1H, d, J 9.7Hz), 7.70-7.04 (10H, m), 6.66 (1H, d, J 9.7Hz). LCMS (ES^+) RT 3.425 minutes, 409.8 (M+H) $^+$.

Example 145

3-([2,6-Difluorophenyl]amino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 9 and 2,6-difluoroaniline by the method of Example 1. δ H (DMSO- d_6) 8.43 (1H, s), 8.10 (1H, d, J 9.7Hz), 7.54-7.42 (5H, m), 7.31 (1H, m), 7.12 (2H, t, J 8.0Hz), 6.55 (1H, d, J 9.7Hz). LCMS (ES⁺) RT 3.300 minutes, 380.0 (M+H)⁺.

5

Example 146**3-[(4-Fluoro-2-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 2-methyl-4-fluoroaniline by the method of Example

- 10 1. δ H (DMSO- d_6) 8.99 (1H, s), 8.08 (1H, d, J 9.7Hz), 7.58-7.43 (5H, m), 7.23 (1H, dd, J 5.5, 8.7Hz), 7.11 (1H, dd, J 2.9, 9.7Hz), 7.00 (1H, dt, J 2.9, 8.6Hz), 6.56 (1H, d, J 9.7Hz), 2.18 (3H, s). LCMS (ES⁺) RT 3.422 minutes, 376.0 (M+H)⁺.

15 **Example 147****6-Oxo-7-phenyl-3-[(3-[(trifluoromethyl)thio]phenyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 3-trifluoromethylthioaniline by the method of

- 20 Example 1. δ H (DMSO- d_6) 9.62 (1H, s), 8.00 (1H, d, J 9.7Hz), 7.74-7.65 (3H, m), 7.60 (2H, dt, J 1.7, 6.5Hz), 7.55 (1H, t, J 7.9Hz), 7.48 (1H, t, J 1.7Hz), 7.40 (2H, dt, J 2.4, 7.9Hz), 6.68 (1H, d, J 9.7Hz). LCMS (ES⁺) RT 3.786 minutes, 444.0 (M+H)⁺.

Example 14825 **3-[(3-Bromo-4-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 3-bromo-4-methylaniline by the method of Example

1. δ H (DMSO- d_6) 9.31 (1H, s), 7.91 (1H, dd, J 2.1, 9.7Hz), 7.61-7.52 (3H, m), 7.46 (2H, m), 7.29 (1H, d, J 2.1Hz), 7.24 (1H, d, J 8.3Hz), 7.03 (1H, dd, J 2.1,

8.2Hz), 6.56 (1H, d, *J* 9.7Hz), 2.25 (3H, s). LCMS (ES⁺) RT 3.722 minutes, 438.0 (M+H)⁺.

Example 149

5 **3-[(3-Bromo-2-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 9 and 3-bromo-2-methylaniline by the method of Example 1. ¹H (DMSO-d₆) 9.15 (1H, s), 8.04 (1H, d, *J* 9.7Hz), 7.68-7.50 (3H, m), 7.47-7.44 (3H, m), 7.20 (1H, dd, *J* 0.9, 7.9Hz), 7.11 (1H, t, *J* 7.9Hz), 6.56 (1H, d, *J* 9.7Hz), 2.26 (3H, s). LCMS (ES⁺) RT 3.63 minutes, 437.9 (M+H)⁺.

Example 150

6-oxo-7-phenyl-3-[(3-(trifluoromethoxy)phenyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

15 From Intermediate 9 and 3-trifluoromethoxyaniline by the method of Example 1. ¹H (DMSO-d₆) 9.60 (1H, s), 8.00 (1H, d, *J* 9.7Hz), 7.81-8.65 (3H, m), 7.61-7.59 (2H, m), 7.50 (1H, t, *J* 8.2Hz), 7.20 (1H, dd, *J* 1.5, 8.2Hz), 7.12 (1H, s), 7.04 (1H, d, *J* 8.2Hz), 6.68 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.654 minutes, 428.0 (M+H)⁺.

20

Example 151

3-[(3-(Methylthio)phenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 9 and 3-(methylthio)aniline by the method of Example 1. ¹H (DMSO-d₆) 9.24 (1H, s), 7.87 (1H, d, *J* 9.7Hz), 7.62-7.46 (3H, m), 7.42-7.39 (2H, m), 7.14 (1H, t, *J* 7.9Hz), 6.90 (1H, t, *J* 1.9Hz), 6.82-6.79 (2H, m), 6.49 (1H, d, *J* 9.7Hz), 2.37 (3H, s). LCMS (ES⁺) RT 3.504 minutes, 389.9 (M+H)⁺.

30 **Example 152**

3-[(4-Fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 9 and 4-fluoro-3-methylaniline by the method of Example

1. δ H (DMSO- d_6) 9.33 (1H, s), 8.10 (1H, d, J 9.7Hz), 7.77-7.64 (3H, m), 7.59-
5 7.56 (2H, m), 7.20-7.09 (3H, m), 6.68 (1H, d, J 9.7Hz), 2.28 (3H, s). LCMS
(ES^+) RT 3.509 minutes, 376.0 (M+H) $^+$.

Example 153

3-[(3-Ethylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- 10 From Intermediate 9 and 3-ethylaniline by the method of Example 1. δ H
($CDCl_3$) 7.48-7.57 (3H, m), 7.30-7.37 (2H, m), 7.25 (1H, d, J 9.7Hz), 7.18
(1H, t, J 6.6Hz), 6.93 (1H, d, J 7.7Hz), 6.80-6.88 (2H, m), 6.42 (1H, d, J
9.7Hz), 6.38 (1H, s), 2.56 (2H, q, J 7.6Hz), 1.16 (3H, t, J 7.6Hz). LCMS (ES^+)
15 RT 3.69 minutes, 372 (M+H) $^+$.

Example 154

7-(4-Fluorophenyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

- 20 From Intermediate 72 and m-toluidine by the method of Example 1. δ H
($CDCl_3$) 7.42-7.18 (6H, m), 6.94 (1H, d, J 7.53Hz), 6.86-6.83 (2H, m), 6.76
(1H, s), 6.46 (1H, d, J 9.2Hz), 2.32 (3H, s). LCMS (ES^+) RT 3.547 minutes,
375.9 (M+H) $^+$.

25 **Example 155**

3-[(2,4-difluorophenyl)amino]-7-(4-methoxyphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 73 and 2,4-difluoroaniline by the method of Example 1. δ H
(DMSO- d_6) 9.46 (1H, br s), 8.28 (1H, d, J 7.7Hz), 7.60-7.51 (4H, m), 7.33-

7.25 (3H, m), 6.77 (1H, d, J 9.7Hz), 4.00 (3H, s). LCMS (ES⁺) RT 3.430 minutes, 410 (M+H)⁺.

Example 156

5 **3-[(2,4-Difluorophenyl)amino]-7-(4-[(2S)-2,3-dihydroxypropyl]oxy)phenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

Prepared by the same route as Example 94 with (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate instead of the (R) enantiomer

10 . δ H (CDCl₃) 7.30 (1H, d, J 9.7Hz), 7.25-7.23 (2H, m), 7.11-7.03 (3H, m), 6.92-6.82 (2H, m), 6.49 (1H, d, J 9.7Hz), 6.10 (1H, s), 4.12-4.05 (3H, m), 3.81 (1H, dd, J 11.3, 3.7Hz), 3.71 (1H, dd, J 11.3, 5.0Hz). LCMS (ES⁺) RT 2.864 minutes, 470 (M+H)⁺.

15 **Example 157**

7-(4-Acetylphenyl)-3-[(3-chlorophenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile

From Intermediate 74 and 3-chloroaniline by the method of Example 1. δ H (CDCl₃) 8.22 (2H, d, J 8.7Hz), 7.57 (2H, d, J 8.7Hz), 7.39 (1H, d, J 9.7Hz),

20 7.31 (1H, t, J 8.0Hz), 7.13 (1H, ddd, J 8.0, 1.9, 0.8Hz), 7.05 (1H, t, J 2.1Hz), 6.95 (1H, dd, J 7.9, 1.8Hz), 6.57 (1H, d, J 9.8Hz), 6.49 (1H, s), 2.71 (3H, s). LCMS (ES⁺) RT 3.51 minutes, 442 (M+Na)⁺.

Example 158

25 **7-(2-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 14 and 4-fluoro-3-methylaniline by the method of Example

1. Light yellow solid. δ H (CDCl₃) 7.73-7.64 (1H, m), 7.60-7.38 (3H, m), 7.32-7.26 (1H, m), 7.07-6.88 (3H, m), 6.5 (1H, d, J 9.8Hz), 6.30 (1H, s), 2.29 (3H, s). LCMS (ES⁺) RT 3.619 minutes, 409.9 (M+H)⁺.

30

Example 159**7-(2-Chlorophenyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- From Intermediate 14 and 3-methylaniline by the method of Example 1. Off-white solid. δ H (CDCl₃) 7.73-7.64 (1H, m), 7.60-7.40 (3H, m), 7.32 (1H, d, *J* 9.8Hz), 7.29-7.20 (1H, m), 7.05-6.85 (3H, m), 6.49 (1H, d, *J* 9.8Hz), 6.40 (1H, s), 2.36 (3H, s). LCMS (ES⁺) RT 3.565 minutes, 391.9 (M+H)⁺.

Example 160

- 10 **3-[(2-hydroxyphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- From Intermediate 5 and 2-aminophenol by the method of Example 1. δ H (DMSO-d₆) 10.02 (1H, s), 8.65 (1H, s), 7.80-7.69 (3H, m), 7.15 (1H, dd, *J* 8.1, 2.0Hz), 7.29-7.07 (4H, m), 6.93 (1H, t, *J* 7.3Hz), 6.47 (1H, dd, *J* 9.8, 1.5Hz), 4.30 (2H, q, *J* 7.1Hz), 1.32 (3H, t, *J* 7.1Hz).

Example 161**3-[(3-hydroxyphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

- 20 From Intermediate 5 and 3-aminophenol by the method of Example 1. δ H (DMSO-d₆) 9.62 (1H, s), 8.81 (1H, s), 7.82-7.69 (3H, m), 7.68-7.63 (2H, m), 7.45 (1H, dd, *J* 2.2, 9.8Hz), 7.27 (1H, t, *J* 8.0Hz), 6.73-6.65 (3H, m), 6.59 (1H, dd, *J* 1.0, 9.7Hz), 4.32 (2H, q, *J* 7.1Hz), 1.33 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.69 minutes, 377 (M+H)⁺.

25

Example 162**7-(4-Fluorophenyl)-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- From Example 154 by the method of Example 22. Yellow solid. δ H (CDCl₃) 8.7 (1H, br s), 7.32-7.29 (2H, m), 7.19-7.08 (4H, m), 6.84 (1H, d, *J* 7.5Hz),

30

6.8-6.76 (2H, m), 6.26 (1H, d, *J* 9.7Hz), 5.64 (2H, br s), 2.24 (3H, s). LCMS (ES⁺) RT 3.163 minutes, 394 (M+H)⁺.

Example 163

5 **3-[(2,4-Difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 136 by the method of Example 22. White solid. δ H (DMSO-d₆) 9.1 (1H, s), 7.6-7.26 (8H, m), 7.24 (1H, d, *J* 9.7Hz), 7.18-7.0 (2H, m), 6.4 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.091 minutes, 397 (M+H)⁺.

10

Example 164

6-Oxo-7-phenyl-3-[(3-(trifluoromethyl)phenyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Intermediate 71 by the method of Example 22. δ H (DMSO-d₆) 9.05 (1H, s), 7.59-7.75 (5H, m), 7.40-7.53 (4H, m), 7.23-7.31 (2H, m), 7.13 (1H, dd, *J* 1.8, 8.0Hz), 6.54 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.30 minutes, 430 (M+H)⁺.

15

Example 165

20 **3-[(3,5-Dichlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 140 by the method of Example 22. δ H (DMSO-d₆) 7.73-7.40 (8H, m), 7.05 (1H, t, *J* 1.8Hz), 6.87 (2H, d, *J* 1.8Hz), 6.57 (1H, d, *J* 9.6Hz). LCMS (ES⁺) RT 3.35 minutes, 430 (M+H)⁺.

25

Example 166

3-[(3-Bromophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 19 by the method of Example 22. δ H (DMSO-d₆) 8.88 (1H, s), 7.72-7.35 (8H, m), 7.21 (1H, d, *J* 8.0Hz), 7.12-7.05 (2H, m), 6.87 (1H, dd, *J*

30

1.5, 7.9Hz), 6.51 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.20 minutes, 440 (M+H)⁺.

Example 167

5 **6-Oxo-7-phenyl-3-[[2-(trifluoromethoxy)phenyl]amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 142 by the method of Example 22. δ H (DMSO-d₆) 8.99 (1H, s), 7.5-6.7 (12H, m), 6.26 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 3.370 minutes, 445.8 (M+H)⁺.

10

Example 168

3-[[2-(Difluoromethoxy)phenyl]amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 144 by the method of Example 22. δ H (DMSO-d₆) 9.10 (1H, s), 8.06-7.31 (10H, m), 7.20 (1H, d, *J* 1.3, 7.7Hz), 7.08 (1H, dt, *J* 1.5, 7.7Hz), 6.96 (1H, dd, *J* 1.3, 8.0Hz), 6.50 (1H, d, *J* 9.6Hz). LCMS (ES⁺) RT 3.151 minutes, 427.9 (M+H)⁺.

15

Example 169

20 **3-[[2,6-Dichlorophenyl]amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 143 by the method of Example 22. δ H (DMSO-d₆) 10.02 (1H, s), 7.71-7.43 (8H, m), 7.30 (2H, br s), 6.67 (1H, d, *J* 9.8Hz), 6.36 (1H, d, *J* 9.8Hz). LCMS (ES⁺) RT 3.23 minutes, 428.8 (M+H)⁺.

25

Example 170

3-[[3-Methylphenyl]amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 139 by the method of Example 22. δ H (DMSO-d₆) 8.92 (1H, s), 7.67-7.60 (3H, m), 7.55-7.50 (2H, m), 7.35-7.32 (3H, m), 7.15 (1H, t, *J*

30

7.7Hz), 6.79-6.77 (2H, m), 6.73-6.71 (1H, m), 6.42 (1H, d, *J* 9.7Hz), 2.26 (3H, s). LCMS (ES⁺) RT 3.191 minutes, 375.9 (M+H)⁺.

Example 171

5 **3-[(3-Bromo-4-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 148 by the method of Example 22. δ H (DMSO-d₆) 8.93 (1H, s), 7.72-7.54 (6H, m), 7.47-7.42 (2H, m), 7.35-7.08 (1H, m), 7.26-7.21 (1H, m), 6.89-6.86 (1H, m), 6.51 (1H, d, *J* 9.6Hz), 2.55 (3H, s). LCMS (ES⁺) RT 3.314 minutes, 456 (M+H)⁺.

Example 172

3-[(3-(Methylthio)phenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

15 From Example 151 by the method of Example 22. δ H (DMSO-d₆) 8.95 (1H, s), 7.76-7.59 (5H, m), 7.47-7.36 (3H, m), 7.24 (1H, t, *J* 7.9Hz), 6.86 (2H, m), 6.70 (1H, dd, *J* 1.6, 7.8Hz), 6.51 (1H, d, *J* 9.6Hz), 2.55 (3H, s). LCMS (ES⁺) RT 3.140 minutes, 408.0 (M+H)⁺.

20 **Example 173**

6-Oxo-7-phenyl-3-[(3-(trifluoromethoxy)phenyl)amino]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 150 by the method of Example 22. δ H (DMSO-d₆) 8.88 (1H, s), 7.61-7.47 (5H, m), 7.38-7.25 (4H, m), 6.80-6.76 (3H, m), 6.40 (1H, d, *J* 9.6Hz). LCMS (ES⁺) RT 3.251 minutes, 445.9 (M+H)⁺.

Example 174

3-[(4-Fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 152 by the method of Example 22. δ H (DMSO- d_6) 9.05 (1H, s), 7.72-7.57 (5H, m), 7.38-7.31 (3H, m), 7.13-7.08 (1H, m), 6.99-6.96 (1H, m), 6.86-6.82 (1H, m), 6.46 (1H, d, J 9.6Hz), 2.92 (3H, s). LCMS (ES^+) RT 3.317 minutes, 394.0 (M+H) $^+$.

5

Example 175**6-Oxo-7-phenyl-3-((3-((trifluoromethyl)thio)phenyl)amino)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 147 by the method of Example 22. δ H (DMSO- d_6) 8.94 (1H, s), 7.61-7.53 (3H, m), 7.49-7.47 (2H, m), 7.35-7.25 (4H, m), 7.14-7.12 (2H, m), 7.01-6.99 (1H, m), 6.38 (1H, d, J 9.6Hz). LCMS (ES^+) RT 3.368 minutes, 461.9 (M+H) $^+$.

10

Example 176

15 **3-((3-Ethylphenyl)amino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 153 by the method of Example 22. δ H (DMSO- d_6) 9.07 (1H, s), 7.56-7.76 (5H, m), 7.36-7.43 (3H, m), 7.23 (1H, t, J 7.7Hz), 6.85-6.92 (2H, m), 6.80 (1H, d, J 1.7Hz), 6.48 (1H, d, J 9.7Hz), 2.61 (2H, q, J 7.6Hz), 1.21 (3H, t, J 7.6Hz). LCMS (ES^+) RT 3.27 minutes, 390 (M+H) $^+$.

20

Example 177**7-(2-Chlorophenyl)-3-((3-methylphenyl)amino)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

25 From Example 159 by the method of Example 22. Yellow solid. δ H (DMSO- d_6) δ H ($CDCl_3$) 8.95 (1H, s), 7.67-7.65 (1H, m), 7.56-7.50 (2H, m), 7.48-7.44 (1H, m), 7.24-7.20 (2H, m), 7.0-6.91 (3H, m), 6.38 (1H, d, J 9.8Hz), 5.27 (2H, s), 2.34 (3H, s). LCMS (ES^+) RT 3.196 minutes, 410 (M+H) $^+$.

30 **Example 178**

3-[(2-Cyano-3-methylphenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 131 by the method of Example 38. White solid. δ H (CDCl₃) 8.65 (1H, br s), 7.43-7.40 (2H, m), 7.39-7.25 (4H, m), 6.97 (1H, d, *J* 7.6Hz),
5 6.70 (1H, d, *J* 8.2Hz), 6.48 (1H, d, *J* 9.7Hz), 5.55 (1H, br s), 2.57 (3H, s).
LCMS (ES⁺) RT 3.079 minutes, 418.9 (M+H)⁺.

Example 179

3-[(4-Fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

10 From Example 132 by the method of Example 38. White solid. δ H (CDCl₃) 9.1 (1H, br s), 7.4-7.34 (2H, m), 7.31-7.23 (2H, m), 7.09 (1H, d, *J* 8.6Hz),
6.98-6.88 (3H, m), 6.33 (1H, d, *J* 9.8Hz), 5.34 (2H, br s), 2.25 (3H, s). LCMS (ES⁺) RT 3.208 minutes, 411.9 (M+H)⁺.

15

Example 180

3-[(2-Cyanophenyl)amino]-7-(4-fluorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 130 by the method of Example 38. Pale yellow solid. δ H (CDCl₃) 8.8 (1H, s), 7.66 (1H, d, *J* 7.8Hz), 7.52-7.41 (3H, m), 7.33-7.24 (3H, m), 7.12 (1H, t, *J* 7.6Hz), 7.01 (1H, d, *J* 8.3Hz), 6.49 (1H, d, *J* 9.7Hz), 5.51 (2H, br s). LCMS (ES⁺) RT 2.955 minutes, 405.0 (M+H)⁺.

Example 181

3-[(2-Hydroxyphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 160 by the method of Example 38. White solid. δ H (DMSO-d₆) 9.67 (1H, br s), 8.95 (1H, br s), 7.60-7.40 (5H, m), 7.18-7.14 (2H, m), 6.83-6.74 (3H, m), 6.57-6.50 (1H, m), 6.29 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT
30 2.787 minutes, 377 (M+H)⁺.

Example 182**3-[(3-Hydroxyphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- 5 From Example 161 by the method of Example 38. White solid. δ H (DMSO- d_6) 9.31 (1H, d), 8.76 (1H, s), 7.67-7.53 (3H, m), 7.50-7.47 (2H, m), 7.37-7.33 (2H, m), 6.70 (1H, t, J 7.9Hz), 6.40 (1H, d, J 9.6Hz), 6.34-6.28 (3H, m). LCMS (ES^+) RT 2.634 minutes, 377 (M+H) $^+$.

10 **Example 183**

3-[(2-Cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

- From Example 10 by the method of Example 38. White solid. δ H (DMSO- d_6) 9.49 (1H, s), 7.73 (1H, dd, J 1.2, 7.7Hz), 7.45-7.68 (8H, m), 7.34 (1H, d, J 9.6Hz), 7.08 (1H, t, J 6.5Hz), 6.95 (1H, d, J 8.3Hz), 6.44 (1H, d, J 9.6Hz).
15 LCMS (ES^+) RT 2.93 minutes, 387 (M+H) $^+$.

Example 184**3-[(2-Chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

- 20 From Example 2 by the method of Example 38. δ H ($CDCl_3$) 7.62-7.49 (2H, m), 7.36-7.32 (3H, m), 7.19 (1H, d, J 9.7Hz), 7.14-7.11 (1H, m), 6.98-6.88 (2H, m), 6.41 (1H, d, J 9.7Hz), 5.55 (2H, br s). LCMS (ES^+) RT 3.164 minutes, 397.9 (M+H) $^+$.

25

Example 185**3-[(3-Cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Example 9 by the method of Example 38. Off-white solid. δ H (DMSO- d_6) 8.89 (1H, s), 7.20-7.74 (12H, m), 6.53 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 2.92 minutes, 387 (M+H)⁺.

5 **Example 186**

3-[(2-Cyano-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Example 125 by the method of Example 38. δ H (DMSO- d_6) 9.57 (1H, s), 7.73-7.38 (9H, m), 7.06 (1H, d, J 7.5Hz), 6.82 (1H, d, J 8.8Hz), 6.50 (1H, d, J 9.6Hz), 3.34 (3H, s). LCMS (ES⁺) RT 3.052 minutes, 401 (M+H)⁺.

Example 187

3-[(2-Cyano-5-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

15 From Example 126 by the method of Example 38. δ H (DMSO- d_6) 9.56 (1H, s), 7.74-7.54 (8H, m), 7.39 (1H, dd, J 2.0, 9.6Hz), 6.98 (1H, d, J 7.9Hz), 6.86 (1H, s), 6.51 (1H, d, J 9.7Hz), 2.33 (3H, s). LCMS (ES⁺) RT 2.994 minutes, 400.9 (M+H)⁺.

20 **Example 188**

3-[(3-Chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

From Intermediate 75 by the method of Example 45. δ H (CDCl₃) 9.60 (1H, br s), 7.57-7.50 (3H, m), 7.36-7.34 (2H, m), 7.13-7.02 (3H, m), 6.94-6.90 (1H, m), 6.37 (1H, d, J 9.8Hz), 5.17 (2H, br s). LCMS (ES⁺) RT 3.158 minutes, 414 (M+H)⁺.

Example 189

30 **3-[(4-Fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 76 by the method of Example 45. δ H (DMSO- d_6) 9.00 (1H, s), 7.70-7.49 (5H, m), 7.37 (2H, s), 7.29 (1H, d, J 9.6Hz), 7.18-7.10 (2H, m), 6.95-7.03 (2H, m), 6.42 (1H, d, J 9.6Hz). LCMS (ES⁺) RT 3.05 minutes, 380 (M+H)⁺.

5

Example 190**3-[(3-Chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 77 by the method of Example 45. δ H (DMSO- d_6) 8.98 (1H, s), 7.80-7.70 (3H, m), 7.68-7.66 (1H, m), 7.55 (1H, d, J 9.6Hz), 7.39-7.35 (1H, m), 7.05-7.03 (2H, m), 6.95-6.92 (1H, m), 6.60 (1H, d, J 9.2Hz). LCMS (ES⁺) RT 3.174 minutes, 395.8 (M+H)⁺.

Example 191

15 **3-[(3-Methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbothioamide**

Hydrogen sulfide gas was bubbled through a solution of Example 139 (680mg) in pyridine (10mL) and triethylamine (0.27mL) at 0 °C. The mixture was stirred at r.t. overnight. Volatiles were removed *in vacuo* and purification
20 by column chromatography (silica, 50% EtOAc in DCM) gave the title compound as a yellow solid (750mg, 100%). δ H (DMSO- d_6) 9.40 (1H, br s), 7.85-7.70 (5H, m), 7.60 (1H, d, J 9.7Hz), 7.32 (1H, t, J 7.4Hz), 6.94-6.91 (2H, m), 6.83 (1H, d, J 8.1Hz), 6.61 (1H, d, J 9.7Hz), 2.42 (3H, s). LCMS (ES⁺) RT 3.445 minutes, 391 (M+H)⁺.

25

Example 192**N,N-Diethyl-3-[(3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboximidamide**

A solution of ethyl magnesium bromide (1M, 4.6mL, 4.6mmol) was added to
30 diethylamine (0.43mL, 4.62mmol) in ether (25mL) at 0 °C. The mixture was heated at reflux for 5min then Example 139 (300mg, 0.84mmol) was added

and the mixture heated at reflux for 4h. Water was added and the mixture was extracted with DCM. The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (reverse phase silica, 60% EtOH in water) gave the title compound. δ H (DMSO-d₆)

- 5 8.18 (1H, br s), 7.75-7.57 (6H, m), 7.08 (1H, t, *J* 7.8Hz), 6.87 (1H, br s), 6.71 (1H, s), 6.65 (2H, t, *J* 7.0Hz), 6.56 (1H, d, *J* 9.6Hz), 3.17 (4H, br m), 2.25 (3H, s), 0.87 (6H, br t, *J* 6.9Hz). LCMS (ES⁺) RT 2.338 minutes, 430 (M+H)⁺.

Example 193

- 10 **3-[(3-Methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboximidamide**

Trifluoroacetic acid (3mL) was added to a solution of Intermediate 78 (140mg) in DCM (10mL). After 2h at r.t., the volatiles were removed *in vacuo* and the residue was azeotroped with hexane. The residue was dissolved in

- 15 DCM and the solution washed with NaHCO₃ aq, dried (Na₂SO₄) and concentrated *in vacuo*. Purification by prep. HPLC gave the title compound (25mg). δ H (DMSO-d₆) 8.11 (1H, s), 7.48-7.33 (6H, m), 6.93 (1H, t, *J* 10.1Hz), 6.84-6.47 (3H, m), 6.27 (1H, d, *J* 12.8Hz), 3.75-3.72 (3H, v br), 2.04 (3H, s). LCMS (ES⁺) RT 2.244 minutes, 374 (M+H)⁺.

20

Example 194

3-[(2,4-Difluorophenyl)amino]-N-(2-hydroxy-2-methylpropyl)-6-oxo-7-phenyl-6,7-dihydrothienof[2,3-b]pyridine-2-carboxamide

2-Hydroxy-2-methylpropylamine (0.14g, 1.06mmol) was added to a solution of Intermediate 79 (0.200g, 0.35mmol) and diisopropylethylamine (0.220mL, 1.26mmol) in DCM (5mL) and the mixture stirred at r.t. overnight. The mixture was diluted with DCM and washed with 1M HCl aq. The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 70% EtOAc in hexane) gave the title compound as a

- 30 yellow solid (145mg, 88%). δ H (CDCl₃) 8.67 (1H, s), 7.51 (3H, m), 7.19 (2H, m), 7.12 (1H, d, *J* 9.7Hz), 7.00 (1H, m), 6.88 (1H, m), 6.75 (1H, m), 6.37 (1H,

d, *J* 9.8Hz), 5.93 (1H, t), 3.26 (2H, s), 1.13 (6H, s). LCMS (ES⁺) RT 3.184 minutes, 470 (M+H)⁺.

Example 195

5 **Methyl 2-({3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl}carbonyl)hydrazinecarboxylate**

A mixture of Intermediate 79 (200mg, 0.354mmol) and methyl hydrazinecarboxylate (96mg, 1.06mmol) in acetonitrile (5mL) was heated at 80 °C for 3 days. The mixture was concentrated *in vacuo* and the residue
10 purified by column chromatography (silica, 30% to 70% EtOAc in hexane). The title compound was obtained as a white solid (55mg, 32%). ¹H (DMSO-d₆) 9.71 (1H, br s), 9.13 (1H, br s), 7.67-7.60 (3H, m), 7.52 (2H, d), 7.36-7.42 (1H, m), 7.17-7.21 (2H, m), 7.04 (1H, t), 6.40 (1H, d), 3.56 (3H, br s). LCMS (ES⁺) RT 3.09 minutes, 472 (M+H)⁺.

15

Example 196

3-[(3-Chlorophenyl)amino]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

From Example 3 by the method of Example 15. ¹H (DMSO-d₆) 8.48 (1H, s), 7.95 (1H, d, *J* 9.5Hz), 7.64-7.55 (3H, m), 7.50-7.48 (2H, m), 7.24 (1H, t, *J*
20 8.0Hz), 7.09-7.03 (2H, m), 6.84-6.82 (1H, m), 6.65 (1H, s), 6.53 (1H, d, *J* 9.5Hz). LCMS (ES⁺) RT 3.724 minutes, 352.8 (M+H)⁺.

Example 197

Ethyl 3-anilino-7-[4-(1-hydroxy-1-methylethyl)phenyl]-6-oxo-6,7-

25 **dihydrothieno[2,3-b]pyridine-2-carboxylate**

From Intermediate 81 and aniline by the method of Example 1. White solid. ¹H (CDCl₃) 8.79 (1H, br s), 7.74 (2H, d, *J* 8.5Hz), 7.40-7.36 (4H, m), 7.21-7.18 (4H, m), 6.36 (1H, d, *J* 9.8Hz), 4.29 (2H, q, *J* 7.1Hz), 1.68 (6H, s), 1.33 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.72 minutes, 449 (M+H)⁺.

30

Example 198

**Ethyl 3-[(2,4-difluorophenyl)amino]-7-[4-
[(methylsulfonyl)amino]phenyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-
2-carboxylate**

A solution of sodium ethoxide in EtOH (1 eq.) was added to a suspension of
5 Intermediate 85 (50mg, 0.08mmol) in EtOH/Water (8:1, 2mL). The mixture
was stirred at r.t. for 2h. EtOAc (20mL) was added and the solution washed
with 2M HCl (20mL), water (2 x 20mL) and brine, dried (MgSO₄) and
concentrated *in vacuo*. Purification by column chromatography (silica,
20%EtOAc in hexane) gave the title compound (20mg). δ H (CDCl₃) 8.53 (1H,
10 br s), 7.30-7.27 (3H, m), 7.16-6.80 (5H, m), 6.32 (1H, d, *J* 9.8Hz), 4.21 (2H,
q, *J* 7.1Hz), 3.05 (3H, s), 1.19 (3H, t, *J* 7.1Hz). LCMS (ES⁺) RT 3.552
minutes, 520 (M+H)⁺.

Example 199

15 **3-[(4-Fluoro-3-methylphenyl)amino]-N-hydroxy-N-methyl-6-oxo-7-
phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

From Intermediate 88 and N-methylhydroxylamine hydrochloride by the
method of Example 194. δ H (DMSO-d₆) 9.83 (1H, br s), 7.54 (3H, m), 7.45
(2H, m), 7.08 (1H, d, *J* 9.7Hz), 7.04-6.96 (2H, m), 6.84 (1H, m), 6.27 (1H, d, *J*
20 9.7Hz), 3.22 (3H, s), 2.15 (3H, s). LCMS (ES⁺) RT 3.37 minutes, 423.9
(M+H)⁺.

Example 200

2-Acetyl-3-anilino-7-phenylthieno[2,3-b]pyridin-6(7H)-one

25 From Intermediate 90 and aniline by the method of Example 1. Yellow solid.
 δ H (CDCl₃) 10.33 (1H, br s), 7.57-7.47 (3H, m), 7.37-7.29 (4H, m), 7.19-7.14
(3H, m), 7.00 (1H, d, *J* 9.8Hz), 6.23 (1H, d, *J* 9.8Hz), 2.20 (3H, s). LCMS
(ES⁺) RT 3.611 minutes, 361 (M+H)⁺.

30 **Example 192**

N,N-Diethyl-3-[(3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboximidamide

From Example 139 by the method of Example 192 using diethylamine

instead of ethylamine. δ H (DMSO-d₆) 8.18 (1H, br s), 7.75-7.57 (6H, m), 7.08

- 5 (1H, t, *J* 7.8Hz), 6.87 (1H, br s), 6.71 (1H, s), 6.65 (2H, t, *J* 7.0Hz), 6.56 (1H, d, *J* 9.6Hz), 3.17 (4H, br m), 2.25 (3H, s), 0.87 (6H, br t, *J* 6.9Hz). LCMS (ES⁺) RT 2.338 minutes, 430 (M+H)⁺.

Example 201

- 10 **3-Anilino-6-oxo-7-pyridin-3-yl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile**

From Intermediate 92 by the method of Example 1. Yellow solid. δ H (CDCl₃)

8.77-8.75 (1H, m), 8.65 (1H, d, *J* 1.3Hz), 7.74-7.70 (1H, m), 7.54-7.46 (1H, m), 7.40-7.23 (3H, m), 7.10 (1H, t, *J* 7.4Hz), 7.03 (2H, d, *J* 7.6Hz), 6.43 (1H,

- 15 d, *J* 9.8Hz), 6.35 (1H, br s). LCMS (ES⁺) RT 3.019 minutes, 345 (M+H)⁺.

Example 202

3-Anilino-6-oxo-7-pyridin-3-yl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide

- 20 From Example 201 by the method of Example 22. Off-white solid. δ H (DMSO-d₆) 9.07 (2H, br s), 8.90-8.89 (2H, m), 8.22-8.19 (1H, m), 7.83-7.80 (1H, m), 7.49-7.35 (4H, m), 7.07-7.04 (3H, m), 6.54 (1H, d, *J* 9.7Hz). LCMS (ES⁺) RT 2.719 minutes, 363 (M+H)⁺.

- 25 **Example 203**

3-Anilino-7-phenyl-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one

From Example 14 and pyrrolidine by the method of Example 17. Pale yellow solid. δ H (CDCl₃) 7.56-7.46 (3H, m), 7.36-7.33 (2H, m), 7.29 (1H, d, *J* 9.7Hz),

7.22-7.17 (2H, m), 7.00-6.92 (3H, m), 6.34 (1H, d, J 9.7Hz), 3.53-3.50 (4H, m), 1.84-1.80 (4H, m). LCMS (ES⁺) RT 3.46 minutes, 416 (M+H)⁺.

Example 204

5 **3-Anilino-7-phenyl-2-(piperidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one**

From Example 14 and piperidine by the method of Example 17. Pale yellow solid. δ H (CDCl₃) 7.55-7.45 (3H, m), 7.36-7.30 (3H, m), 7.22-7.16 (2H, m), 6.94-6.90 (3H, m), 6.37 (1H, d, J 9.7Hz), 3.48-3.45 (4H, m), 1.53-1.46 (2H, 10 m), 1.45-1.40 (4H, m). LCMS (ES⁺) RT 3.53 minutes, 430 (M+H)⁺.

Example 205

3-Anilino-2-[(4-ethylpiperazin-1-yl)carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one

15 From Example 14 and N-ethylpiperazine by the method of Example 17. δ H (CDCl₃) 8.25 (1H, br s), 7.75-7.53 (3H, m), 7.44-7.39 (3H, m), 7.31-7.27 (2H, m), 7.04-6.98 (3H, m), 6.45 (1H, d, J 9.7Hz), 3.64-3.61 (4H, m), 2.43-2.35 (6H, m), 1.06 (3H, t, J 7.2Hz). LCMS (ES⁺) RT 2.18 minutes, 459 (M+H)⁺.

20 **Example 206**

3-Anilino-7-[4-(dimethylamino)phenyl]-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one

From Intermediate 66 and pyrrolidine by the method of Example 17. δ H (CDCl₃) 9.54 (1H, br s), 7.27-7.14 (6H, m), 6.98-6.93 (2H, m), 6.75 (2H, d, J 25 9.0Hz), 6.32 (1H, d, J 9.6Hz), 3.53 (4H, m), 2.96 (6H, s), 1.82 (4H, m). LCMS (ES⁺) RT 3.61 minutes, 459 (M+H)⁺.

Example 207

30 **3-[(2,4-Difluorophenyl)amino]-2-(morpholin-4-ylcarbonyl)-7-phenylthieno[2,3-b]pyridin-6(7H)-one**

From Intermediate 67 and morpholine by the method of Example 17. δ H (CDCl₃) 8.12 (1H, br s), 7.58-7.49 (3H, m), 7.34-7.31 (2H, m), 7.24 (1H, d, *J* 9.7Hz), 6.96-6.82 (2H, m), 6.77-6.70 (1H, m), 6.41 (1H, d, *J* 9.7Hz), 3.55 (8H, br s). LCMS (ES⁺) RT 3.20 minutes, 468 (M+H)⁺.

5

Example 208**3-[(6-Oxo-7-phenyl-2-(pyrrolidin-1-ylcarbonyl)-6,7-dihydrothieno[2,3-b]pyridin-3-yl)amino]benzonitrile**

A mixture of Example 9 (250mg) and pyrrolidine (7mL) was heated at 110°C in a sealed tube for 18h. The mixture was diluted with DCM and washed with dil. HCl aq. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound as an off-white solid (112mg). δ H (DMSO-d₆) 9.22 (1H, s), 7.28-7.86 (10H, m), 6.68 (1H, d, *J* 9.6Hz), 3.33 (4H, m), 1.75 (4H, m). LCMS (ES⁺) RT 3.29 minutes, 441 (M+H)⁺.

15

Example 209**3-[(3-Chlorophenyl)amino]-7-phenyl-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one**

From Example 3 and pyrrolidine by the method of Example 208. Pale yellow solid. δ H (DMSO-d₆) 8.96 (1H, s), 7.72-7.69 (1H, m), 7.66-7.57 (2H, m), 7.53-7.51 (2H, m), 7.21 (1H, t, *J* 8.1Hz), 6.90-6.81 (3H, m), 6.52 (1H, d, *J* 9.6Hz), 3.23 (4H, br s), 1.63 (4H, br s). LCMS (ES⁺) RT 3.635 minutes, 449.9 (M+H)⁺.

25

Example 210**3-[(2,4-Difluorophenyl)amino]-7-phenyl-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one**

From Example 12 and pyrrolidine by the method of Example 208. Off-white solid. δ H (CDCl₃) 9.52 (1H, s), 7.46-7.56 (3H, m), 7.37-7.31 (2H, m), 7.20-

30

7.12 (3H, m), 6.97 (1H, d, *J* 5.7, 9.0Hz), 6.83 (1H, ddd, *J* 2.8, 8.4, 10.8Hz), 6.72 (1H, tq, *J* 1.5, 9.0Hz), 6.36 (1H, d, *J* 9.7Hz), 3.52 (4H, m), 1.82 (4H, m). LCMS (ES⁺) RT 3.57 minutes, 452 (M+H)⁺.

5 **Example 211**

3-[(4-Fluorophenyl)amino]-7-phenyl-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one

From Intermediate 76 and pyrrolidine by the method of Example 17. Off-white solid. δ H (DMSO-d₆) 8.7 (1H, s), 7.3 (4H, m), 7.2 (2H, m), 6.8 (2H, m), 6.7 (2H, m), 6.28 (1H, d, *J* 9.6Hz), 3.0 (4H, m), 1.42 (4H, m). LCMS (ES⁺) RT 3.487 minutes, 434 (M+H)⁺.

Example 212

15 **3-[(2,4-Difluorophenyl)amino]-6-oxo-7-phenyl-N-pyrrolidin-3-yl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide**

To a solution of Intermediate 93 in methanol (20mL) was added Pd(OH)₂ (20% on carbon, 10mg) and the reaction stirred at r.t. under an atmosphere of hydrogen (balloon) for 4h. The reaction was filtered through a pad of celite and the filtrate concentrated *in vacuo* to give the product as a gum. The gum was re-dissolved in acetonitrile and water and freeze dried to give the title compound as an off-white solid (44mg). δ H (DMSO-d₆) 9.23 (1H, bs), 8.50 (1H, s), 8.20 (1H, m), 7.72 (2H, m), 7.68 (2H, m), 7.46 (2H, m), 7.17 (2H, m), 6.57 (1H, d, *J* 9.7Hz), 4.47 (1H, m), 3.25-2.75 (4H, m), 2.11 (1H, m), 1.80 (1H, m). LCMS (ES⁺) RT 2.31 minutes, 467 (M+H)⁺.

25

The following assays and animal models can be used to demonstrate the potency and selectivity of the compounds according to the invention. In each assay an IC₅₀ value was determined for each test compound and represents the concentration of compound necessary to achieve 50% inhibition.

30

Preparation of activated human p38 α for inhibitor assays.**Purification of human p38 α**

Human p38 α , incorporating an N-terminal (His)6 tag, was expressed in
5 baculovirus-infected High-Five™ cells (Invitrogen) according to the
manufacturers instructions. The cells were harvested 72h post-infection and
lysed in phosphate buffered saline (PBS) containing 1% (w/v) β -
octylglucoside and Complete, EDTA-free™ protease inhibitors (Roche
Molecular Biochemicals). The lysate was centrifuged at 35000xg for 30min at
10 4°C and the supernatant applied to a NiNTA™ column (Qiagen). Bound
protein was eluted by 150mM imidazole in PBS (after a wash with 15mM
imidazole in PBS) and directly applied to a HiTrap Q™ column (AP Biotech).
Bound protein was eluted using a 20 column volume, 0 to 1M NaCl gradient.
Fractions containing (His)6-p38 were aliquotted and stored at -70° prior to
15 their activation.

Preparation of GST-MKK6EE-containing lysates

E. coli (BL21 pLysS) expressing the constitutively activated form of human
MKK6 fused with an N-terminal glutathione-S-transferase tag (GST-
20 MKK6EE) were harvested by centrifugation and frozen at -70°. Cells were
lysed by resuspension in 1/10th the culture volume of PBS containing
Complete, EDTA-free™ protease inhibitors followed by sonication on ice for
4x15 sec. Cell debris was removed by centrifugation at 35,000xg and the
resultant supernatant stored in aliquots at -70°.

25

Activation of (His)6-p38

0.45mL of purified (His)6-p38 was incubated with 50 μ L of the GST-MKK6EE-
containing lysate for 30min at 23° in the presence of 1mM β -
glycerophosphate, 10mM MgCl₂ and 9mM ATP. The extent of activation was
30 monitored by mass spectrometric detection of the doubly-phosphorylated
form of (His)6-p38, which routinely comprised greater than 90% of the final

(His)6-p38 preparation. The activated (His)6-p38 was then diluted x10 in PBS and repurified using the method described above. The concentration of purified, activated (His)6-p38 was measured by UV absorbance at 280nm using $A_{280} \cdot 0.1\% = 1.2$ and the preparation stored in aliquots at -70° prior to
5 its use in inhibitor assays.

p38 Inhibition Assays

Inhibition of phosphorylation of biotinylated myelin basic protein (MBP)

The inhibition of p38 catalysed phosphorylation of biotinylated MBP is
10 measured using a DELFIA based format. The assay was performed in a buffer comprising, 20mM HEPES (pH 7.4), 5mM $MgCl_2$ and 3mM DTT. For a typical IC_{50} determination, biotinylated MBP ($2.5\mu M$) was incubated at room temperature in a streptavidin-coated microtitre plate together with activated
15 $gst-p38$ (10nM) and ATP ($1\mu M$) in the presence of a range of inhibitor concentrations (final concentration of DMSO is 2 percent). After fifteen minutes the reaction was terminated by the addition of EDTA (75mM). The microtitre plate was then washed with Tris buffered saline (TBS), prior to the addition of $100\mu l$ of anti-phospho MBP antibody (mouse) together with europium-labeled anti-mouse IgG antibody. After one hour at room
20 temperature the plate was again washed in TBS followed by the addition of Enhancement solution (PerkinElmer Wallac). Fluorescence measurements were performed after a further fifteen minutes at room temperature.
 IC_{50} values are determined from the plot of Log_{10} inhibitor concentration (x-axis) versus percentage inhibition of the fluorescence generated by a control
25 sample in the absence of inhibitor (y-axis).

Purification of human Peripheral Blood Mononuclear Cells

Peripheral blood mononuclear cells (PBMC) were isolated from normal healthy volunteers. Whole blood was taken by venous puncture using
30 heparinised vacutainers (Becton Dickinson), diluted 1 in 4 in RPMI 1640 (Gibco, UK) and centrifuged at 400g for 35 min over a Ficoll-paque gradient

(Amersham-Pharmacia Biotech, UK). Cells at the interface were removed and washed once followed by a low speed spin (250g) to remove platelets. Cells were then resuspended in DMEM containing 10% FCS, penicillin 100 units ml⁻¹, streptomycin 50µg ml⁻¹ and glutamine 2mM (Gibco, UK).

5

Inhibitor dilutions

Inhibitor stocks (20mM) were kept as a frozen solution (-20°C) in DMSO. Serial dilutions of inhibitors were performed in DMSO as 250-times concentrated stocks. Inhibitors were diluted 1 in 250 into tissue culture media, prewarmed to 37°C and transferred to plates containing PBMC. PBMC and inhibitors were incubated together for 30 mins prior to addition of LPS. Inhibitors used in whole blood assays were prepared according to a different regime. Using the same stock solution serial dilutions of inhibitors were performed in DMSO. Inhibitors were then diluted 1 in 500 straight into whole blood in a volume of 1µL. Inhibitor was incubated with whole blood for 30 mins prior to the addition of LPS.

10

15

LPS stimulation of PBMC

PBMC were resuspended at a density of 2x10⁵ cells/well in flat bottomed 96 well tissue culture treated plates. After the addition of inhibitor cells were stimulated with an optimal dose of LPS (*E coli* strain B5:055, Sigma, at a final concentration of 1µg ml⁻¹) and incubated at 37°C in 5%CO₂/95% air for 18 hours. TNF-α levels were measured from cell free supernatants by sandwich ELISA (BioSource #CHC1751).

20

25

LPS stimulation of whole blood

Whole blood was taken by venous puncture using heparinised vacutainers (Becton Dickinson), and 500µl of blood aliquoted into each well of a 24 well tissue culture treated plate. After the addition of inhibitor cells were stimulated with an optimal dose of LPS (*E coli* strain B5:055, Sigma, at a final

30

concentration of $1\mu\text{g ml}^{-1}$) and incubated at 37°C without CO_2 for 18 hours. TNF- α levels were measured from cell free supernatants by sandwich ELISA (BioSource #CHC1751).

5 **Rat LPS induced TNF release**

Male Lewis rats (180-200g) are anaesthetised with Isofluror and injected i.v. with LPS* in a volume of 0.5ml sterile saline. After 90minutes blood is collected into EDTA tubes for preparation of plasma samples. Plasma is stored at -70°C prior to assay for TNF α by commercial ELISA.

10


Rat CIA

Female Lewis rats (180-200g) are anaesthetised with Isofluror and immunised i.d. at the base of the tail with $2 \times 100\mu\text{l}$ of emulsion containing 4mg/ml bovine collagen II in 0.01M acetic acid and Freund's Incomplete Adjuvant at a ratio of 1:1. A polyarthritis develops with onset from about 13 days post sensitisation. The disease is mainly confined to the ankles and is quantified by plethysmometry. Results are expressed as change in paw volume over time.

20 In the p38 inhibitor assays described above compounds of the invention have IC_{50} values of around $1\mu\text{M}$ and below. The compounds of the invention are clearly potent inhibitors of p38 kinase, especially p38 α kinase.

CLAIMS:

1. A compound of formula (1):



5

wherein:

the dashed line joining A and C(R^a) is present and represents a bond and

A is a -N= atom or a -C(R^b)= group, or the dashed line is absent and A is a
 10 -N(R^b)-, or -C(R^b)(R^c)- group;

R^a, R^b and R^c is each independently a hydrogen atom or an optionally substituted C₁₋₆alkyl, -CN, -CO₂H, -CO₂R¹ (where R¹ is an optionally substituted alkyl group), -CONH₂, -CONHR¹ or -CONR¹R² group (where R² is an optionally substituted alkyl group);

15 R is a hydrogen atom or a straight or branched C₁₋₆ alkyl group;

X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O₂)- or -NH-group;

Y is a nitrogen or substituted carbon atom or a -CH= group;

n is zero or the integer 1;

20 Alk¹ is an optionally substituted aliphatic or heteroaliphatic chain

L¹ is a covalent bond or a linker atom or group;

Cy¹ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;

25 Ar is an optionally substituted aromatic or heteroaromatic group;
 and the salts, solvates, hydrates and N-oxides thereof.

2. A compound according to Claim 1 wherein R is a hydrogen atom.
3. A compound according to Claim 1 or Claim 2 wherein R^a is a hydrogen
5 atom.
4. A compound according to any one of Claims 1 to 3 wherein the dashed
line joining A and C(R^a) is present and A is a $-(CR^b)=$ group.
- 10 5. A compound according to Claim 4 wherein R^b is a hydrogen atom.
6. A compound according to any one of Claims 1 to 5 wherein X is an -O- or
-S- atom.
- 15 7. A compound according to Claim 6 wherein X is a -S- atom.
8. A compound according to any one of Claims 1 to 7 wherein L¹ is a
covalent bond.
- 20 9. A compound according to any one of Claims 1 to 8 wherein n is the
integer 1 and Alk¹ is an optionally substituted C₁₋₆alkylene chain.
10. A compound according to Claim 9 wherein Alk¹ is a -CH₂- or -CH₂CH₂-
chain.
- 25 11. A compound according to any one of Claims 1 to 8 wherein n is zero.
12. A compound according to any one of Claims 1 to 11 wherein Cy¹ is an
optionally substituted cycloaliphatic, aromatic or heteroaromatic group.
- 30

13. A compound according to Claim 12 wherein Cy^1 is an optionally substituted C_{3-7} cycloalkyl group.

14. A compound according to Claim 13 wherein Cy^1 is a cyclopropyl group.

5

15. A compound according to Claim 12 wherein Cy^1 is an optionally substituted phenyl group.

16. A compound according to Claim 15 wherein Cy^1 is a phenyl group.

10

17. A compound according to Claim 15 wherein Cy^1 is a phenyl group substituted by one, two or three atoms or groups R^{10a} or $-L^6Alk^5(R^{10a})_r$, where R^{10a} is a halogen atom, or an amino ($-NH_2$), substituted amino, nitro, cyano, hydroxyl ($-OH$), substituted hydroxyl, formyl, carboxyl ($-CO_2H$), esterified carboxyl, thiol ($-SH$), substituted thiol, $-COR^{11}$ [where R^{11} is an $-L^6Alk^3(R^{10a})_r$, aryl or heteroaryl group in which Alk^3 is a straight or branched C_{1-3} alkylene chain], $-CSR^{11}$, $-SO_3H$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-SO_2NH_2$, $-SO_2NHR^{11}$, $-SO_2N(R^{11})_2$, $-CONH_2$, $-CSNH_2$, $-CONHR^{11}$, $-CSNHR^{11}$, $-CON(R^{11})_2$, $-CSN(R^{11})_2$, $-N(R^{12})SO_2R^{11}$ [where R^{12} is a hydrogen atom or a straight or branched alkyl group], $-N(SO_2R^{11})_2$, $-N(R^{12})SO_2NH_2$, $-N(R^{12})SO_2NHR^{11}$, $-N(R^{12})SO_2N(R^{11})_2$, $-N(R^{12})COR^{11}$, $-N(R^{12})CONH_2$, $-N(R^{12})CONHR^{11}$, $-N(R^{12})CON(R^{11})_2$, $-N(R^{12})CSNH_2$, $-N(R^{12})CSNHR^{11}$, $-N(R^{12})CSN(R^{11})_2$, $-N(R^{12})CSR^{11}$, $-N(R^{12})C(O)OR^{11}$, $-C=NR^{12}(NR^{12})$, $-SO_2NHet^1$ [where $-NHet^1$ is an optionally substituted C_{3-7} cyclicamino group optionally containing one or more other $-O-$ or $-S-$ atoms or $-N(R^{12})-$, $-C(O)-$ or $-C(S)-$ groups], $-CONHet^1$, $-CSNHet^1$, $-N(R^{12})SO_2NHet^1$, $-N(R^{12})CONHet^1$, $-N(R^{12})CSNHet^1$, $-SO_2N(R^{12})Het$ [where $-Het$ is an optionally substituted monocyclic C_{3-7} carbocyclic group optionally containing one or more other $-O-$ or $-S-$ atoms or $-N(R^{12})-$, $-C(O)-$, $-S(O)-$ or $-S(O)_2-$ groups], $-Het$, $-CON(R^{12})Het$, $-CSN(R^{12})Het$, $-N(R^{12})CON(R^{12})Het$, $-N(R^{12})CSN(R^{12})Het$,

15

20

25

30

5 -N(R¹²)SO₂N(R¹²)Het, aryl or heteroaryl groups; L⁶ is a covalent bond or a linker atom or group; Alk⁵ is an optionally substituted straight or branched C₁₋₆alkylene, C₂₋₆alkenylene or C₂₋₆alkynylene chain, optionally interrupted by one, two or three -O- or -S- atoms or -S(O)_n- [where n is an integer 1 or 2] or -N(R¹²)- e.g. -N(CH₃)- groups; and r is zero or the integer 1, 2, or 3.

10 18. A compound as claimed in Claim 12 wherein Cy¹ is an optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazinyl or indolyl group.

19. A compound as claimed in Claim 18 wherein Cy¹ is a thienyl, pyridyl or indolyl group.

15 20. A compound according to Claim 18 wherein each of said Cy¹ groups is substituted by one, two or three atoms or groups R^{10a} or -L⁶Alk⁵(R^{10a}) as defined in Claim 17.

20 21. A compound according to any one of Claims 1 to 20 wherein Y is a group -CH= or -C(R¹⁰)= where R¹⁰ is an atom or group R^{10a} or -L⁶Alk⁵(R^{10a}) as defined in Claim 17.

25 22. A compound according to Claim 21 wherein R¹⁰ is a -CN, -X¹NH₂, (where X¹ is a -C(O)- or -S(O)₂- group), -X¹NHR¹¹, -X¹N(R¹¹)₂, -X¹NHet¹, -X¹N(R¹²)Het, -X¹N(R¹²)Alk⁵Het, -COR¹¹, -C=NR¹²(NR¹²) or esterified carboxyl group where R¹¹, R¹², -NHet¹, Het and Alk³ are as defined in Claim 17.

30 23. A compound according to Claim 22 wherein R¹⁰ is a -CN, -CONH₂, -CONHR¹¹, -CON(R¹¹)₂, -CONHet¹, -CON(R¹²)Het, -CON(R¹²)Alk⁵Het or esterified carboxyl group.

24. A compound according to any one of Claims 1 to 23 wherein Ar is an optionally substituted phenyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl or triazinyl group.
- 5
25. A compound according to Claim 24 wherein Ar is an optionally substituted phenyl group.
26. A compound according to Claim 25 wherein Ar is a phenyl group or a phenyl group substituted by one, two or three atoms or groups R^{10a} or $-L^6Alk^5(R^{10a})_r$, as defined in Claim 17.
- 10
27. A compound as described in each of the Examples herein and the salts, solvates, hydrates and N-oxides thereof.
- 15
28. A pharmaceutical composition comprising a compound of any one of Claims 1 to 27 together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- 20

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT, no 03/02667

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D495/04 A61K31/44 A61P29/00 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	WO 99 64400 A (BEMIS GUY ; VERTEX PHARMA (US); COCHRAN JOHN (US); SALITURO FRANCES) 16 December 1999 (1999-12-16)	1-5, 8, 11-28
Y	page 3, formulae III, IV	6, 7, 9, 10
A	HENRY J R ET AL: "Potent inhibitors of the map kinase p38" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 23, 1 December 1998 (1998-12-01), pages 3335-3340, XP004143754 ISSN: 0960-894X tables 1,2	1-28

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family.

Date of the actual completion of the international search

24 September 2003

Date of mailing of the international search report

09/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

Intern. Application No.
PCT/JP 03/02667

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 03 033502 A (DAVIS JEREMY MARTIN ;BROOKINGS DANIEL CHRISTOPHER (GB); CELLTECH R) 24 April 2003 (2003-04-24) claim 1 -----	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: Application No

PCT/JP 03/02667

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9964400	A	16-12-1999	AU 4429799 A	30-12-1999
			EP 1277740 A1	22-01-2003
			EP 1086085 A1	28-03-2001
			JP 2002517486 T	18-06-2002
			WO 9964400 A1	16-12-1999
			US 2003149037 A1	07-08-2003
			US 2001025044 A1	27-09-2001
WO 03033502	A	24-04-2003	WO 03033502 A1	24-04-2003